US20040220193A1 - Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound - Google Patents
Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound Download PDFInfo
- Publication number
- US20040220193A1 US20040220193A1 US10/855,357 US85535704A US2004220193A1 US 20040220193 A1 US20040220193 A1 US 20040220193A1 US 85535704 A US85535704 A US 85535704A US 2004220193 A1 US2004220193 A1 US 2004220193A1
- Authority
- US
- United States
- Prior art keywords
- group
- cyano
- methyl
- thienyl
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 294
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 13
- -1 Nitrogen-containing cyclic compound Chemical class 0.000 title description 314
- 150000003839 salts Chemical class 0.000 claims abstract description 64
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 62
- 210000002569 neuron Anatomy 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 94
- 230000002490 cerebral effect Effects 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 210000003061 neural cell Anatomy 0.000 claims description 22
- 230000001537 neural effect Effects 0.000 claims description 20
- 206010008118 cerebral infarction Diseases 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 208000006011 Stroke Diseases 0.000 claims description 13
- 206010019196 Head injury Diseases 0.000 claims description 11
- 208000019695 Migraine disease Diseases 0.000 claims description 11
- 230000030833 cell death Effects 0.000 claims description 11
- 206010015037 epilepsy Diseases 0.000 claims description 11
- 206010027599 migraine Diseases 0.000 claims description 11
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 10
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 10
- OEPQEIQIOLIMGF-UHFFFAOYSA-N 3-[2-[4-(4-cyano-5-methyl-4-thiophen-2-ylhexyl)piperazin-1-yl]ethoxy]benzonitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(C#N)=C1 OEPQEIQIOLIMGF-UHFFFAOYSA-N 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 9
- 206010030113 Oedema Diseases 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- RRNHPYTXOVXTEW-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(3-cyanophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(C#N)=C1 RRNHPYTXOVXTEW-UHFFFAOYSA-N 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 208000005392 Spasm Diseases 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 201000004810 Vascular dementia Diseases 0.000 claims description 6
- 208000028683 bipolar I disease Diseases 0.000 claims description 6
- 230000004087 circulation Effects 0.000 claims description 6
- 230000002633 protecting effect Effects 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- QYYAXJYTMMPTST-UHFFFAOYSA-N 2-[3-cyano-6-[4-[2-(3-cyanophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-3-carbonitrile Chemical compound S1C=CC(C#N)=C1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(C#N)=C1 QYYAXJYTMMPTST-UHFFFAOYSA-N 0.000 claims 7
- ATBCBKZNRWWWHI-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(3-cyanophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-3-carbonitrile Chemical compound C=1C(C#N)=CSC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(C#N)=C1 ATBCBKZNRWWWHI-UHFFFAOYSA-N 0.000 claims 7
- 150000002825 nitriles Chemical group 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract description 130
- 125000005843 halogen group Chemical group 0.000 abstract description 53
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 41
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract description 40
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract description 31
- 125000004430 oxygen atom Chemical group O* 0.000 abstract description 16
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 abstract description 7
- 125000003118 aryl group Chemical group 0.000 abstract description 6
- 230000008485 antagonism Effects 0.000 abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011575 calcium Substances 0.000 abstract description 4
- 229910052791 calcium Inorganic materials 0.000 abstract description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 550
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 318
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 293
- 239000000203 mixture Substances 0.000 description 208
- 229940093499 ethyl acetate Drugs 0.000 description 184
- 235000019439 ethyl acetate Nutrition 0.000 description 183
- 238000005160 1H NMR spectroscopy Methods 0.000 description 160
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 144
- 239000012267 brine Substances 0.000 description 133
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 133
- 239000012043 crude product Substances 0.000 description 126
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 113
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 110
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 109
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 108
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 104
- 239000000243 solution Substances 0.000 description 102
- 239000012044 organic layer Substances 0.000 description 101
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 96
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 93
- 239000003921 oil Substances 0.000 description 93
- 235000019198 oils Nutrition 0.000 description 93
- 238000006243 chemical reaction Methods 0.000 description 89
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 66
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 60
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 239000000741 silica gel Substances 0.000 description 51
- 229910002027 silica gel Inorganic materials 0.000 description 51
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 47
- 238000003756 stirring Methods 0.000 description 47
- 238000010898 silica gel chromatography Methods 0.000 description 46
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 45
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 125000002560 nitrile group Chemical group 0.000 description 40
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 38
- 235000019341 magnesium sulphate Nutrition 0.000 description 38
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 34
- 238000001914 filtration Methods 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 31
- 238000007796 conventional method Methods 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- 125000002252 acyl group Chemical group 0.000 description 26
- 238000010438 heat treatment Methods 0.000 description 26
- 239000000126 substance Substances 0.000 description 26
- 239000002274 desiccant Substances 0.000 description 25
- 229910052757 nitrogen Inorganic materials 0.000 description 25
- 239000013078 crystal Substances 0.000 description 24
- 239000006188 syrup Substances 0.000 description 24
- 235000020357 syrup Nutrition 0.000 description 24
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 23
- 239000012230 colorless oil Substances 0.000 description 23
- 238000010992 reflux Methods 0.000 description 23
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 21
- 238000001816 cooling Methods 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- 125000004193 piperazinyl group Chemical group 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 17
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 17
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 17
- 239000012299 nitrogen atmosphere Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 229910052731 fluorine Inorganic materials 0.000 description 14
- 125000001153 fluoro group Chemical group F* 0.000 description 14
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 235000009518 sodium iodide Nutrition 0.000 description 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 13
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 13
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 125000001309 chloro group Chemical group Cl* 0.000 description 13
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 229940127291 Calcium channel antagonist Drugs 0.000 description 11
- 239000000480 calcium channel blocker Substances 0.000 description 11
- 125000003386 piperidinyl group Chemical group 0.000 description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 10
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 10
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000001544 thienyl group Chemical group 0.000 description 10
- 108700012358 P/Q-type calcium channel Proteins 0.000 description 9
- 102000050761 P/Q-type calcium channel Human genes 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- QXFYKWOTQOJEDR-UHFFFAOYSA-N 4-cyano-5-methyl-4-thiophen-2-ylhexanoic acid Chemical compound OC(=O)CCC(C(C)C)(C#N)C1=CC=CS1 QXFYKWOTQOJEDR-UHFFFAOYSA-N 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 7
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 125000004434 sulfur atom Chemical group 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 6
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 6
- CWMIHLKMNANBDH-UHFFFAOYSA-N 4-cyano-5-methyl-4-thiophen-3-ylhexanoic acid Chemical class OC(=O)CCC(C(C)C)(C#N)C=1C=CSC=1 CWMIHLKMNANBDH-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 150000001924 cycloalkanes Chemical class 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 239000012280 lithium aluminium hydride Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 5
- 230000008033 biological extinction Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 150000001925 cycloalkenes Chemical class 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 5
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 4
- AVGHIQUXSVAJBC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.1]heptane Chemical group C1C2CCN1NC2 AVGHIQUXSVAJBC-UHFFFAOYSA-N 0.000 description 4
- 125000006017 1-propenyl group Chemical group 0.000 description 4
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 239000012448 Lithium borohydride Substances 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 4
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 3
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 3
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 3
- XVJXHOQHAAWBEU-UHFFFAOYSA-N 2-(2-oxo-4-phenyl-1,3-oxazolidin-3-yl)acetaldehyde Chemical compound C1OC(=O)N(CC=O)C1C1=CC=CC=C1 XVJXHOQHAAWBEU-UHFFFAOYSA-N 0.000 description 3
- ZDNIRVUEHFVUHU-UHFFFAOYSA-N 2-(3-fluorophenoxy)acetaldehyde Chemical compound FC1=CC=CC(OCC=O)=C1 ZDNIRVUEHFVUHU-UHFFFAOYSA-N 0.000 description 3
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 3
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 3
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 3
- 125000005916 2-methylpentyl group Chemical group 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- PTLAQPFTXGCFHO-UHFFFAOYSA-N 3-(2-oxoethoxy)benzonitrile Chemical compound O=CCOC1=CC=CC(C#N)=C1 PTLAQPFTXGCFHO-UHFFFAOYSA-N 0.000 description 3
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000005917 3-methylpentyl group Chemical group 0.000 description 3
- PZSXCGFMDLLQRD-UHFFFAOYSA-N 5-(3-cyano-6-hydroxy-2-methylhexan-3-yl)thiophene-2-carbonitrile Chemical compound OCCCC(C(C)C)(C#N)C1=CC=C(C#N)S1 PZSXCGFMDLLQRD-UHFFFAOYSA-N 0.000 description 3
- GVDUKPVDFXGFEM-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(3-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(F)=C1 GVDUKPVDFXGFEM-UHFFFAOYSA-N 0.000 description 3
- UZNNCHDSFCJLGM-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 UZNNCHDSFCJLGM-UHFFFAOYSA-N 0.000 description 3
- XCLNZZVJSMBOIO-UHFFFAOYSA-N 5-[4-[2-(3-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(F)=C1 XCLNZZVJSMBOIO-UHFFFAOYSA-N 0.000 description 3
- YHQVYLHHBVERBE-UHFFFAOYSA-N 5-hydroxy-2-propan-2-yl-2-thiophen-3-ylpentanenitrile Chemical compound OCCCC(C(C)C)(C#N)C=1C=CSC=1 YHQVYLHHBVERBE-UHFFFAOYSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Chemical group 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 3
- 229960003856 argatroban Drugs 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000003828 azulenyl group Chemical group 0.000 description 3
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 3
- ZZQJLOTZSABTOM-UHFFFAOYSA-N ethyl 4-cyano-5-methyl-4-thiophen-3-ylhexanoate Chemical compound CCOC(=O)CCC(C#N)(C(C)C)C=1C=CSC=1 ZZQJLOTZSABTOM-UHFFFAOYSA-N 0.000 description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 125000003838 furazanyl group Chemical group 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 3
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000006606 n-butoxy group Chemical group 0.000 description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 3
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 3
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- BRLMQGVPSLJRHW-UHFFFAOYSA-N tert-butyl 4-(3-thiophen-2-ylpropyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCCC1=CC=CS1 BRLMQGVPSLJRHW-UHFFFAOYSA-N 0.000 description 3
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- UZDDXUMOXKDXNE-MRVPVSSYSA-N (1r)-1-(4-methylphenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(C)C=C1 UZDDXUMOXKDXNE-MRVPVSSYSA-N 0.000 description 2
- UZDDXUMOXKDXNE-QMMMGPOBSA-N (1s)-1-(4-methylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(C)C=C1 UZDDXUMOXKDXNE-QMMMGPOBSA-N 0.000 description 2
- FSDBXQYHHCUEIE-UHFFFAOYSA-N (2-phenyl-1,3-oxazol-4-yl)methanol Chemical compound OCC1=COC(C=2C=CC=CC=2)=N1 FSDBXQYHHCUEIE-UHFFFAOYSA-N 0.000 description 2
- HNFDKPSDOQRBBX-UHFFFAOYSA-N (2-phenyl-1,3-thiazol-4-yl)methanol Chemical compound OCC1=CSC(C=2C=CC=CC=2)=N1 HNFDKPSDOQRBBX-UHFFFAOYSA-N 0.000 description 2
- BPAFLGGUEBMWRN-UHFFFAOYSA-N (5-phenyl-1,2-oxazol-3-yl)methanol Chemical compound O1N=C(CO)C=C1C1=CC=CC=C1 BPAFLGGUEBMWRN-UHFFFAOYSA-N 0.000 description 2
- RXXIVABOKBNIEI-UHFFFAOYSA-N (6-phenylpyridin-3-yl)methanol Chemical compound N1=CC(CO)=CC=C1C1=CC=CC=C1 RXXIVABOKBNIEI-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- 125000006150 1,1,2-trimethylpropyl sulfonyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 2
- 125000005923 1,2-dimethylpropyloxy group Chemical group 0.000 description 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- JXSPKRUNMHMICQ-UHFFFAOYSA-N 1-(2-bromoethoxy)-4-fluorobenzene Chemical compound FC1=CC=C(OCCBr)C=C1 JXSPKRUNMHMICQ-UHFFFAOYSA-N 0.000 description 2
- SGBYOMLTDAHOLJ-UHFFFAOYSA-N 1-(3-thiophen-2-ylpropyl)piperazine Chemical compound C=1C=CSC=1CCCN1CCNCC1 SGBYOMLTDAHOLJ-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- XVNCXOLDKUMQME-UHFFFAOYSA-N 1-[1-(4-cyano-5-methyl-4-phenylhexyl)piperidin-4-yl]-4-phenylpiperidine-4-carbonitrile Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(CC1)CCC1N(CC1)CCC1(C#N)C1=CC=CC=C1 XVNCXOLDKUMQME-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- VHUARYQWNKLLPQ-UHFFFAOYSA-N 1-benzyl-4-[3-[1-(4-fluorophenyl)cyclohexyl]propyl]piperazine Chemical compound C1=CC(F)=CC=C1C1(CCCN2CCN(CC=3C=CC=CC=3)CC2)CCCCC1 VHUARYQWNKLLPQ-UHFFFAOYSA-N 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- 125000006039 1-hexenyl group Chemical group 0.000 description 2
- 125000006023 1-pentenyl group Chemical group 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- WNRURFLRGWUTQN-UHFFFAOYSA-N 2-(1-cyanobutyl)thiophene-3-carbonitrile Chemical compound CCCC(C#N)C=1SC=CC=1C#N WNRURFLRGWUTQN-UHFFFAOYSA-N 0.000 description 2
- QHHXIRWPGSCGLJ-UHFFFAOYSA-N 2-(3-cyano-6-hydroxy-2-methylhexan-3-yl)thiophene-3-carbonitrile Chemical compound OCCCC(C(C)C)(C#N)C=1SC=CC=1C#N QHHXIRWPGSCGLJ-UHFFFAOYSA-N 0.000 description 2
- JOYXZHJCIIOCFH-UHFFFAOYSA-N 2-(3-formylthiophen-2-yl)pentanenitrile Chemical compound CCCC(C#N)C=1SC=CC=1C=O JOYXZHJCIIOCFH-UHFFFAOYSA-N 0.000 description 2
- ANRDUCQCZKLSGF-UHFFFAOYSA-N 2-(chloromethyl)-1,3-benzoxazole Chemical compound C1=CC=C2OC(CCl)=NC2=C1 ANRDUCQCZKLSGF-UHFFFAOYSA-N 0.000 description 2
- KGCIHDGHDIOSAG-UHFFFAOYSA-N 2-[3-(1,3-dioxolan-2-yl)thiophen-2-yl]acetonitrile Chemical compound S1C=CC(C2OCCO2)=C1CC#N KGCIHDGHDIOSAG-UHFFFAOYSA-N 0.000 description 2
- TXUSBKJRSQFCSS-UHFFFAOYSA-N 2-[3-(1,3-dioxolan-2-yl)thiophen-2-yl]pentanenitrile Chemical compound S1C=CC(C2OCCO2)=C1C(C#N)CCC TXUSBKJRSQFCSS-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- 125000003858 2-ethylbutoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])O*)C([H])([H])C([H])([H])[H] 0.000 description 2
- BSMGLVDZZMBWQB-UHFFFAOYSA-N 2-methyl-1-phenylpropan-1-one Chemical compound CC(C)C(=O)C1=CC=CC=C1 BSMGLVDZZMBWQB-UHFFFAOYSA-N 0.000 description 2
- 125000005924 2-methylpentyloxy group Chemical group 0.000 description 2
- SMANTNBDDJUWPC-UHFFFAOYSA-N 2-phenyl-5-[4-(4-phenylpiperidin-1-yl)piperidin-1-yl]-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(CC1)CCC1N(CC1)CCC1C1=CC=CC=C1 SMANTNBDDJUWPC-UHFFFAOYSA-N 0.000 description 2
- CLSHQIDDCJTHAJ-UHFFFAOYSA-N 2-thienylacetonitrile Chemical compound N#CCC1=CC=CS1 CLSHQIDDCJTHAJ-UHFFFAOYSA-N 0.000 description 2
- VOJKCZSSUHBMKS-UHFFFAOYSA-N 2-thiophen-3-yl-1,3-dioxolane Chemical compound O1CCOC1C1=CSC=C1 VOJKCZSSUHBMKS-UHFFFAOYSA-N 0.000 description 2
- GTVGDDQWOXDTOF-UHFFFAOYSA-N 3-(1,3-dioxolan-2-yl)thiophene-2-carbaldehyde Chemical compound S1C=CC(C2OCCO2)=C1C=O GTVGDDQWOXDTOF-UHFFFAOYSA-N 0.000 description 2
- CNEWDGGPSMFWQX-UHFFFAOYSA-N 3-(1-benzyl-3,6-dihydro-2h-pyridin-4-yl)propan-1-ol Chemical compound C1CC(CCCO)=CCN1CC1=CC=CC=C1 CNEWDGGPSMFWQX-UHFFFAOYSA-N 0.000 description 2
- IHRWMVVXSQATHL-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)propan-1-ol Chemical compound C1CC(CCCO)CCN1CC1=CC=CC=C1 IHRWMVVXSQATHL-UHFFFAOYSA-N 0.000 description 2
- USDGMHSZXRXSRW-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)propyl methanesulfonate Chemical compound C1CC(CCCOS(=O)(=O)C)CCN1CC1=CC=CC=C1 USDGMHSZXRXSRW-UHFFFAOYSA-N 0.000 description 2
- QKAOSFZXZWDNEU-UHFFFAOYSA-N 3-[2-[4-(4-cyano-5-methyl-4-thiophen-3-ylhexyl)piperazin-1-yl]ethoxy]benzonitrile Chemical compound C1=CSC=C1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(C#N)=C1 QKAOSFZXZWDNEU-UHFFFAOYSA-N 0.000 description 2
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
- WPJZGPLKRBIDGD-UHFFFAOYSA-N 3-fluoro-n'-hydroxybenzenecarboximidamide Chemical compound ON=C(N)C1=CC=CC(F)=C1 WPJZGPLKRBIDGD-UHFFFAOYSA-N 0.000 description 2
- LUJMEECXHPYQOF-UHFFFAOYSA-N 3-hydroxyacetophenone Chemical compound CC(=O)C1=CC=CC(O)=C1 LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 description 2
- XQFVVZAIRUZMEX-UHFFFAOYSA-N 3-methyl-2-naphthalen-2-ylbutanenitrile Chemical compound C1=CC=CC2=CC(C(C#N)C(C)C)=CC=C21 XQFVVZAIRUZMEX-UHFFFAOYSA-N 0.000 description 2
- WJIGPJQNSADFEI-UHFFFAOYSA-N 3-methyl-2-thiophen-2-ylbutanenitrile Chemical compound CC(C)C(C#N)C1=CC=CS1 WJIGPJQNSADFEI-UHFFFAOYSA-N 0.000 description 2
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 2
- BQFZLZCBCSKUPL-UHFFFAOYSA-N 3-thiophen-2-ylpropan-1-ol Chemical compound OCCCC1=CC=CS1 BQFZLZCBCSKUPL-UHFFFAOYSA-N 0.000 description 2
- PJLLRQNPQDWNMF-UHFFFAOYSA-N 4-bromo-2-(dimethoxymethyl)thiophene Chemical compound COC(OC)C1=CC(Br)=CS1 PJLLRQNPQDWNMF-UHFFFAOYSA-N 0.000 description 2
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- FKMBNPNJCVSKRA-UHFFFAOYSA-N 4-hydroxy-2-thiophen-2-ylbutanenitrile Chemical compound OCCC(C#N)C1=CC=CS1 FKMBNPNJCVSKRA-UHFFFAOYSA-N 0.000 description 2
- ORDFAEVHPVWWEE-UHFFFAOYSA-N 4-methyl-3-phenylpentanal Chemical compound O=CCC(C(C)C)C1=CC=CC=C1 ORDFAEVHPVWWEE-UHFFFAOYSA-N 0.000 description 2
- QTSNMZCWXXMRTK-UHFFFAOYSA-N 4-methyl-3-phenylpentanoic acid Chemical compound OC(=O)CC(C(C)C)C1=CC=CC=C1 QTSNMZCWXXMRTK-UHFFFAOYSA-N 0.000 description 2
- JKPVQWBZWCEGFF-UHFFFAOYSA-N 5-(1-cyano-2-methylpropyl)thiophene-3-carbonitrile Chemical compound CC(C)C(C#N)C1=CC(C#N)=CS1 JKPVQWBZWCEGFF-UHFFFAOYSA-N 0.000 description 2
- FGCCKDHDLFPQLD-UHFFFAOYSA-N 5-(1-hydroxy-2-methylpropyl)thiophene-3-carbonitrile Chemical compound CC(C)C(O)C1=CC(C#N)=CS1 FGCCKDHDLFPQLD-UHFFFAOYSA-N 0.000 description 2
- AVSVGANYFJIKKM-UHFFFAOYSA-N 5-(2-methylpropanoyl)thiophene-3-carbonitrile Chemical compound CC(C)C(=O)C1=CC(C#N)=CS1 AVSVGANYFJIKKM-UHFFFAOYSA-N 0.000 description 2
- DPWBEPHNBLXYBG-UHFFFAOYSA-N 5-(3-cyano-6-iodo-2-methylhexan-3-yl)thiophene-2-carbonitrile Chemical compound ICCCC(C(C)C)(C#N)C1=CC=C(C#N)S1 DPWBEPHNBLXYBG-UHFFFAOYSA-N 0.000 description 2
- WHXUEJAEOKJMAD-UHFFFAOYSA-N 5-(hydroxymethyl)-3-phenyl-1,3-oxazolidin-2-one Chemical compound O=C1OC(CO)CN1C1=CC=CC=C1 WHXUEJAEOKJMAD-UHFFFAOYSA-N 0.000 description 2
- IVQCKGULTRNTMC-UHFFFAOYSA-N 5-[3-[4-[4-cyano-4-(5-cyanothiophen-2-yl)-5-methylhexyl]piperazin-1-yl]propyl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCCC1=CC=C(C#N)S1 IVQCKGULTRNTMC-UHFFFAOYSA-N 0.000 description 2
- SNSVQLSICUJSNU-UHFFFAOYSA-N 5-[4-(1-ethylbenzimidazol-2-yl)-1,4-diazepan-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1N(CC1)CCCN1CCCC(C#N)(C(C)C)C1=CC=CC=C1 SNSVQLSICUJSNU-UHFFFAOYSA-N 0.000 description 2
- GYXYNOBAELFHPV-UHFFFAOYSA-N 5-[4-(1-methylbenzimidazol-2-yl)-1,4-diazepan-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound C1CCN(C=2N(C3=CC=CC=C3N=2)C)CCN1CCCC(C(C)C)(C#N)C1=CC=CC=C1 GYXYNOBAELFHPV-UHFFFAOYSA-N 0.000 description 2
- UVXYSYRGBVLXSK-UHFFFAOYSA-N 5-[4-(4-benzylpiperidin-1-yl)piperidin-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(CC1)CCC1N(CC1)CCC1CC1=CC=CC=C1 UVXYSYRGBVLXSK-UHFFFAOYSA-N 0.000 description 2
- GWOWLSFGWWZDOM-DXDQHDRFSA-N 5-[6-[(3r)-3-[benzyl(2-cyanoethyl)amino]pyrrolidin-1-yl]-3-cyano-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound N#CCCN([C@@H]1CCN(C1)CCCC(C(C)C)(C#N)C=1SC(=CC=1)C#N)CC1=CC=CC=C1 GWOWLSFGWWZDOM-DXDQHDRFSA-N 0.000 description 2
- GWOWLSFGWWZDOM-BXXZMZEQSA-N 5-[6-[(3s)-3-[benzyl(2-cyanoethyl)amino]pyrrolidin-1-yl]-3-cyano-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound N#CCCN([C@H]1CCN(C1)CCCC(C(C)C)(C#N)C=1SC(=CC=1)C#N)CC1=CC=CC=C1 GWOWLSFGWWZDOM-BXXZMZEQSA-N 0.000 description 2
- DLTDLUAJPULDBI-UHFFFAOYSA-N 5-formylthiophene-3-carbonitrile Chemical compound O=CC1=CC(C#N)=CS1 DLTDLUAJPULDBI-UHFFFAOYSA-N 0.000 description 2
- UMENJZNQHLXNOH-UHFFFAOYSA-N 5-hydroxy-2-(2-thiophen-2-ylpropan-2-yl)pentanenitrile Chemical compound OCCCC(C#N)C(C)(C)C1=CC=CS1 UMENJZNQHLXNOH-UHFFFAOYSA-N 0.000 description 2
- QGUAWPJBMBQBLF-UHFFFAOYSA-N 5-hydroxy-2-naphthalen-2-yl-2-propan-2-ylpentanenitrile Chemical compound C1=CC=CC2=CC(C(CCCO)(C#N)C(C)C)=CC=C21 QGUAWPJBMBQBLF-UHFFFAOYSA-N 0.000 description 2
- ZSQFADNSIQLOES-UHFFFAOYSA-N 5-iodo-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound ICCCC(C(C)C)(C#N)C1=CC=CC=C1 ZSQFADNSIQLOES-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- LHQSCZKCEHBZLI-UHFFFAOYSA-N benzyl 4-[2-(4-fluorophenoxy)ethyl]piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1OCCC1CCN(C(=O)OCC=2C=CC=CC=2)CC1 LHQSCZKCEHBZLI-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940125400 channel inhibitor Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 238000007333 cyanation reaction Methods 0.000 description 2
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 150000003946 cyclohexylamines Chemical class 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- GKPOOPJSMDBBND-UHFFFAOYSA-N ethyl 4-(4-cyano-5-methyl-4-phenylhexyl)-1-[2-(4-fluorophenoxy)ethyl]piperazine-2-carboxylate Chemical compound C1CN(CCOC=2C=CC(F)=CC=2)C(C(=O)OCC)CN1CCCC(C#N)(C(C)C)C1=CC=CC=C1 GKPOOPJSMDBBND-UHFFFAOYSA-N 0.000 description 2
- GBZQJVIONKWIEA-UHFFFAOYSA-N ethyl 4-cyano-4-(4-cyanothiophen-2-yl)-5-methylhexanoate Chemical compound CCOC(=O)CCC(C#N)(C(C)C)C1=CC(C#N)=CS1 GBZQJVIONKWIEA-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 2
- 125000005921 isopentoxy group Chemical group 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- PCHWACZEGUNGFY-UHFFFAOYSA-N n-methoxy-n,4-dimethyl-3-phenylpentanamide Chemical compound CON(C)C(=O)CC(C(C)C)C1=CC=CC=C1 PCHWACZEGUNGFY-UHFFFAOYSA-N 0.000 description 2
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229950003837 ozagrel Drugs 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- 125000004344 phenylpropyl group Chemical group 0.000 description 2
- 125000005542 phthalazyl group Chemical group 0.000 description 2
- 125000005543 phthalimide group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000005920 sec-butoxy group Chemical group 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- NCNYJCOBUTXCBR-IPZCTEOASA-M sodium;(e)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoate Chemical compound [Na+].C1=CC(/C=C/C(=O)[O-])=CC=C1CN1C=NC=C1 NCNYJCOBUTXCBR-IPZCTEOASA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- HDSRYTDSBUTXLW-PLEWWHCXSA-N tert-butyl n-[(3r)-1-[4-cyano-4-(5-cyanothiophen-2-yl)-5-methylhexyl]pyrrolidin-3-yl]carbamate Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN1CC[C@@H](NC(=O)OC(C)(C)C)C1 HDSRYTDSBUTXLW-PLEWWHCXSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 150000003527 tetrahydropyrans Chemical group 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- ZAIQBJPTOXDDKA-UHFFFAOYSA-N (1-benzylpyrrolidin-2-yl)methanol Chemical compound OCC1CCCN1CC1=CC=CC=C1 ZAIQBJPTOXDDKA-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- LSNYJLGMVHJXPD-FHFMTJEOSA-N (5z,7z,9z)-benzo[8]annulene Chemical group C/1=C/C=C\C=C/C2=CC=CC=C2\1 LSNYJLGMVHJXPD-FHFMTJEOSA-N 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004733 1,1,2-trimethylpropylthio group Chemical group CC(C(C)C)(S*)C 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- 125000006142 1,1-dimethylbutyl sulfonyl group Chemical group 0.000 description 1
- 125000004725 1,1-dimethylbutylthio group Chemical group CC(CCC)(S*)C 0.000 description 1
- 125000004719 1,1-dimethylpropylthio group Chemical group CC(CC)(S*)C 0.000 description 1
- 125000004726 1,2-dimethylbutylthio group Chemical group CC(C(CC)C)S* 0.000 description 1
- 125000006134 1,2-dimethylpropyl sulfonyl group Chemical group 0.000 description 1
- 125000004720 1,2-dimethylpropylthio group Chemical group CC(C(C)C)S* 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 125000006144 1,3-dimethylbutyl sulfonyl group Chemical group 0.000 description 1
- 125000004727 1,3-dimethylbutylthio group Chemical group CC(CC(C)C)S* 0.000 description 1
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- LKUAPSRIYZLAAO-UHFFFAOYSA-N 1-(2-phenylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=CC=C1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 1
- LOJCUYCKDGYLJH-UHFFFAOYSA-N 1-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN1CCNCC1 LOJCUYCKDGYLJH-UHFFFAOYSA-N 0.000 description 1
- PXHHWTPZLMBOKN-UHFFFAOYSA-N 1-(4-benzylpiperazin-1-yl)-3-[1-(4-fluorophenyl)cyclohexyl]propan-1-one Chemical compound C1=CC(F)=CC=C1C1(CCC(=O)N2CCN(CC=3C=CC=CC=3)CC2)CCCCC1 PXHHWTPZLMBOKN-UHFFFAOYSA-N 0.000 description 1
- YSEWGFKMFOKNHE-UHFFFAOYSA-N 1-(4-methylthiophen-2-yl)oxyethanol Chemical compound CC(O)OC1=CC(C)=CS1 YSEWGFKMFOKNHE-UHFFFAOYSA-N 0.000 description 1
- XDYFSUNPOXVQIA-UHFFFAOYSA-N 1-[1-[1-(3,4-dihydro-2h-quinolin-1-yl)ethenylsulfonyl]ethenyl]-3,4-dihydro-2h-quinoline Chemical compound C1CCC2=CC=CC=C2N1C(=C)S(=O)(=O)C(=C)N1C2=CC=CC=C2CCC1 XDYFSUNPOXVQIA-UHFFFAOYSA-N 0.000 description 1
- IHVXZESETSWDAC-UHFFFAOYSA-N 1-[2-(4-fluorophenoxy)ethyl]piperazine Chemical compound C1=CC(F)=CC=C1OCCN1CCNCC1 IHVXZESETSWDAC-UHFFFAOYSA-N 0.000 description 1
- UQCAZCHWXCCKGI-UHFFFAOYSA-N 1-[2-(4-methylsulfonylphenoxy)ethyl]piperazine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OCCN1CCNCC1 UQCAZCHWXCCKGI-UHFFFAOYSA-N 0.000 description 1
- SQNFJDNLWSCYRH-UHFFFAOYSA-N 1-[3-(1-hydroxyethoxy)phenyl]ethanone Chemical compound CC(O)OC1=CC=CC(C(C)=O)=C1 SQNFJDNLWSCYRH-UHFFFAOYSA-N 0.000 description 1
- IEGPOBQJJVVYRN-UHFFFAOYSA-N 1-[3-(2-piperazin-1-ylethoxy)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(OCCN2CCNCC2)=C1 IEGPOBQJJVVYRN-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- HBVNLKQGRZPGRP-UHFFFAOYSA-N 1-benzylpyrrolidin-3-amine Chemical compound C1C(N)CCN1CC1=CC=CC=C1 HBVNLKQGRZPGRP-UHFFFAOYSA-N 0.000 description 1
- OQMNWQODLIDJCA-UHFFFAOYSA-N 1-ethenylsulfonylpiperidine Chemical compound C=CS(=O)(=O)N1CCCCC1 OQMNWQODLIDJCA-UHFFFAOYSA-N 0.000 description 1
- 125000006153 1-ethyl-2-methylpropyl sulfonyl group Chemical group 0.000 description 1
- 125000004736 1-ethyl-2-methylpropylthio group Chemical group C(C)C(C(C)C)S* 0.000 description 1
- 125000004717 1-ethylpropylthio group Chemical group C(C)C(CC)S* 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000004713 1-methylbutylthio group Chemical group CC(CCC)S* 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HTQWGIHCFPWKAS-UHFFFAOYSA-N 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1CNCCC11C(=O)NCN1C1=CC=CC=C1 HTQWGIHCFPWKAS-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- 125000006145 2,2-dimethylbutyl sulfonyl group Chemical group 0.000 description 1
- 125000004728 2,2-dimethylbutylthio group Chemical group CC(CS*)(CC)C 0.000 description 1
- 125000004716 2,2-dimethylpropylthio group Chemical group CC(CS*)(C)C 0.000 description 1
- 125000004729 2,3-dimethylbutylthio group Chemical group CC(CS*)C(C)C 0.000 description 1
- OJTMHIMQUQOLJV-UHFFFAOYSA-N 2,5-difluorobenzonitrile Chemical compound FC1=CC=C(F)C(C#N)=C1 OJTMHIMQUQOLJV-UHFFFAOYSA-N 0.000 description 1
- GGZQLTVZPOGLCC-UHFFFAOYSA-N 2-(2-bromoethyl)-1,3-dioxolane Chemical compound BrCCC1OCCO1 GGZQLTVZPOGLCC-UHFFFAOYSA-N 0.000 description 1
- RCAYLJDGPITOMY-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-piperazin-1-yl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=C(Cl)C=1C(C(C)C)(C#N)CCCN1CCNCC1 RCAYLJDGPITOMY-UHFFFAOYSA-N 0.000 description 1
- RQAQUJLYXPZVKN-UHFFFAOYSA-N 2-(2-fluorophenyl)-5-piperazin-1-yl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=C(F)C=1C(C(C)C)(C#N)CCCN1CCNCC1 RQAQUJLYXPZVKN-UHFFFAOYSA-N 0.000 description 1
- RSPKTYHZYGAQMJ-UHFFFAOYSA-N 2-(2-methoxyphenyl)-5-piperazin-1-yl-2-propan-2-ylpentanenitrile Chemical compound COC1=CC=CC=C1C(C(C)C)(C#N)CCCN1CCNCC1 RSPKTYHZYGAQMJ-UHFFFAOYSA-N 0.000 description 1
- FHQBVRVZHVUZQJ-UHFFFAOYSA-N 2-(2-methylphenyl)-5-piperazin-1-yl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=C(C)C=1C(C(C)C)(C#N)CCCN1CCNCC1 FHQBVRVZHVUZQJ-UHFFFAOYSA-N 0.000 description 1
- KMPNVUXYGANMHA-UHFFFAOYSA-N 2-(3-cyano-6-iodo-2-methylhexan-3-yl)thiophene-3-carbonitrile Chemical compound ICCCC(C(C)C)(C#N)C=1SC=CC=1C#N KMPNVUXYGANMHA-UHFFFAOYSA-N 0.000 description 1
- UJPSMLABFBWEKF-UHFFFAOYSA-N 2-(3-fluorophenyl)-5-piperazin-1-yl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC(F)=CC=1C(C(C)C)(C#N)CCCN1CCNCC1 UJPSMLABFBWEKF-UHFFFAOYSA-N 0.000 description 1
- GJYOTFYYTINORH-UHFFFAOYSA-N 2-(3-oxocyclohexa-1,5-dien-1-yl)propanenitrile Chemical compound N#CC(C)C1=CC(=O)CC=C1 GJYOTFYYTINORH-UHFFFAOYSA-N 0.000 description 1
- XJGOZHFLRGNWSW-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-piperazin-1-yl-2-propan-2-ylpentanenitrile Chemical compound C=1C=C(F)C=CC=1C(C(C)C)(C#N)CCCN1CCNCC1 XJGOZHFLRGNWSW-UHFFFAOYSA-N 0.000 description 1
- NZZXMKUTTFVKKK-UHFFFAOYSA-N 2-(5-bromothiophen-2-yl)-5-hydroxy-2-propan-2-ylpentanenitrile Chemical compound OCCCC(C(C)C)(C#N)C1=CC=C(Br)S1 NZZXMKUTTFVKKK-UHFFFAOYSA-N 0.000 description 1
- DRJGTMOTYBEPCM-UHFFFAOYSA-N 2-(chloromethyl)-1,3-benzoxazole-5-carbonitrile Chemical compound N#CC1=CC=C2OC(CCl)=NC2=C1 DRJGTMOTYBEPCM-UHFFFAOYSA-N 0.000 description 1
- ADDZHRRCUWNSCS-UHFFFAOYSA-N 2-Benzofurancarboxaldehyde Chemical compound C1=CC=C2OC(C=O)=CC2=C1 ADDZHRRCUWNSCS-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical group C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000006149 2-ethylbutyl sulfonyl group Chemical group 0.000 description 1
- 125000004732 2-ethylbutylthio group Chemical group C(C)C(CS*)CC 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004714 2-methylbutylthio group Chemical group CC(CS*)CC 0.000 description 1
- 125000006139 2-methylpentyl sulfonyl group Chemical group 0.000 description 1
- 125000004722 2-methylpentylthio group Chemical group CC(CS*)CCC 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LPCWDVLDJVZIHA-UHFFFAOYSA-N 2-naphthalen-2-ylacetonitrile Chemical compound C1=CC=CC2=CC(CC#N)=CC=C21 LPCWDVLDJVZIHA-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- GWZCLMWEJWPFFA-UHFFFAOYSA-N 2-thiophen-3-ylacetonitrile Chemical compound N#CCC=1C=CSC=1 GWZCLMWEJWPFFA-UHFFFAOYSA-N 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical group C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- FZSPDHZYKANOQS-UHFFFAOYSA-N 3-(2,2-dimethoxyethyl)-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N(CC(OC)OC)C1C1=CC=CC=C1 FZSPDHZYKANOQS-UHFFFAOYSA-N 0.000 description 1
- VFDAZKUWPQLRAQ-UHFFFAOYSA-N 3-[(1-benzylpyrrolidin-3-yl)amino]propanenitrile Chemical compound C1C(NCCC#N)CCN1CC1=CC=CC=C1 VFDAZKUWPQLRAQ-UHFFFAOYSA-N 0.000 description 1
- WZJJWQVBLSPALW-UHFFFAOYSA-N 3-[n-(2-hydroxyethyl)anilino]propanenitrile Chemical compound N#CCCN(CCO)C1=CC=CC=C1 WZJJWQVBLSPALW-UHFFFAOYSA-N 0.000 description 1
- VDGHLSDHJXWQSL-UHFFFAOYSA-N 3-[n-(2-iodoethyl)anilino]propanenitrile Chemical compound N#CCCN(CCI)C1=CC=CC=C1 VDGHLSDHJXWQSL-UHFFFAOYSA-N 0.000 description 1
- MTPOMZIDHWJOKU-UHFFFAOYSA-N 3-[n-(2-piperazin-1-ylethyl)anilino]propanenitrile Chemical compound C=1C=CC=CC=1N(CCC#N)CCN1CCNCC1 MTPOMZIDHWJOKU-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical compound OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- ZRXHLJNBNWVNIM-UHFFFAOYSA-N 3-methyl-1-benzofuran Chemical compound C1=CC=C2C(C)=COC2=C1 ZRXHLJNBNWVNIM-UHFFFAOYSA-N 0.000 description 1
- IYFLGPFITRLWMQ-UHFFFAOYSA-N 3-methyl-2-(2-piperazin-1-ylethyl)-2-thiophen-2-ylbutanenitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCN1CCNCC1 IYFLGPFITRLWMQ-UHFFFAOYSA-N 0.000 description 1
- JYDUUSGXNRLWKH-UHFFFAOYSA-N 3-methyl-2-phenylpentanenitrile Chemical compound CCC(C)C(C#N)C1=CC=CC=C1 JYDUUSGXNRLWKH-UHFFFAOYSA-N 0.000 description 1
- ADQCKNNDFMFIIU-UHFFFAOYSA-N 3-methyl-2-thiophen-3-ylbutanenitrile Chemical compound CC(C)C(C#N)C=1C=CSC=1 ADQCKNNDFMFIIU-UHFFFAOYSA-N 0.000 description 1
- 125000006140 3-methylpentyl sulfonyl group Chemical group 0.000 description 1
- 125000004723 3-methylpentylthio group Chemical group CC(CCS*)CC 0.000 description 1
- ZUGAIMFLQLPTKB-UHFFFAOYSA-N 3-pyridin-3-ylpropan-1-ol Chemical compound OCCCC1=CC=CN=C1 ZUGAIMFLQLPTKB-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- XDJQFEPUJDCOIM-UHFFFAOYSA-N 4-(2-oxoethoxy)benzonitrile Chemical compound O=CCOC1=CC=C(C#N)C=C1 XDJQFEPUJDCOIM-UHFFFAOYSA-N 0.000 description 1
- HGIZGKJRUWKNMV-UHFFFAOYSA-N 4-(3-cyano-6-hydroxy-2-methylhexan-3-yl)thiophene-2-carbonitrile Chemical compound OCCCC(C(C)C)(C#N)C1=CSC(C#N)=C1 HGIZGKJRUWKNMV-UHFFFAOYSA-N 0.000 description 1
- QASBCTGZKABPKX-UHFFFAOYSA-N 4-(methylsulfanyl)phenol Chemical compound CSC1=CC=C(O)C=C1 QASBCTGZKABPKX-UHFFFAOYSA-N 0.000 description 1
- DFGHEYJILYQDTQ-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)ethyl]piperidine Chemical compound C1=CC(F)=CC=C1OCCC1CCNCC1 DFGHEYJILYQDTQ-UHFFFAOYSA-N 0.000 description 1
- HRUXWDXDOQSVOT-UHFFFAOYSA-N 4-[2-[(1-benzylpyrrolidin-3-yl)-(2-cyanoethyl)amino]ethoxy]benzonitrile Chemical compound C1CN(CC=2C=CC=CC=2)CC1N(CCC#N)CCOC1=CC=C(C#N)C=C1 HRUXWDXDOQSVOT-UHFFFAOYSA-N 0.000 description 1
- WQVNYVFQQKSJJQ-UHFFFAOYSA-N 4-[2-[2-cyanoethyl(pyrrolidin-3-yl)amino]ethoxy]benzonitrile Chemical compound C1CNCC1N(CCC#N)CCOC1=CC=C(C#N)C=C1 WQVNYVFQQKSJJQ-UHFFFAOYSA-N 0.000 description 1
- HXAOUYGZEOZTJO-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)butan-1-one Chemical compound FC1=CC=C(C(=O)CCCCl)C=C1 HXAOUYGZEOZTJO-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- MHJJSUXMSBDDDB-UHFFFAOYSA-N 4-methyl-3-phenylhexanal Chemical compound CCC(C)C(CC=O)C1=CC=CC=C1 MHJJSUXMSBDDDB-UHFFFAOYSA-N 0.000 description 1
- XOTOKOVCCBSUNT-UHFFFAOYSA-N 4-methyl-3-phenylpentan-1-ol Chemical compound OCCC(C(C)C)C1=CC=CC=C1 XOTOKOVCCBSUNT-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- NXBHBJIUDZPUGZ-UHFFFAOYSA-N 5-(1,4-diazepan-1-yl)-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN1CCCNCC1 NXBHBJIUDZPUGZ-UHFFFAOYSA-N 0.000 description 1
- DNWYBPJASKRIFR-UHFFFAOYSA-N 5-(2,5-dihydropyrrol-1-yl)-5-oxo-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCC(=O)N1CC=CC1 DNWYBPJASKRIFR-UHFFFAOYSA-N 0.000 description 1
- GGHCQAFEUONRDT-UHFFFAOYSA-N 5-(3-cyano-2-methyl-6-piperazin-1-ylhexan-3-yl)thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN1CCNCC1 GGHCQAFEUONRDT-UHFFFAOYSA-N 0.000 description 1
- TVOKXAZTTMRFCY-UHFFFAOYSA-N 5-(3-cyano-6-hydroxy-2-methylhexan-3-yl)thiophene-3-carbonitrile Chemical compound OCCCC(C(C)C)(C#N)C1=CC(C#N)=CS1 TVOKXAZTTMRFCY-UHFFFAOYSA-N 0.000 description 1
- DZRJUFPYNAGRDX-UHFFFAOYSA-N 5-(3-hydroxypropyl)thiophene-2-carbonitrile Chemical compound OCCCC1=CC=C(C#N)S1 DZRJUFPYNAGRDX-UHFFFAOYSA-N 0.000 description 1
- WTIAPRLXAWQZLN-UHFFFAOYSA-N 5-(3-piperazin-1-ylpropyl)thiophene-2-carbonitrile Chemical compound S1C(C#N)=CC=C1CCCN1CCNCC1 WTIAPRLXAWQZLN-UHFFFAOYSA-N 0.000 description 1
- AEXGXEVDOQOTEM-DIAVIDTQSA-N 5-[3-cyano-6-[(3r)-3-(2-cyanoethylamino)pyrrolidin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN1CC[C@@H](NCCC#N)C1 AEXGXEVDOQOTEM-DIAVIDTQSA-N 0.000 description 1
- PERZKXKXYZSGIC-UHFFFAOYSA-N 5-[4-[1-(2-methylpropyl)benzimidazol-2-yl]piperazin-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound N=1C2=CC=CC=C2N(CC(C)C)C=1N(CC1)CCN1CCCC(C#N)(C(C)C)C1=CC=CC=C1 PERZKXKXYZSGIC-UHFFFAOYSA-N 0.000 description 1
- OLKHNHZQILHHDC-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-naphthalen-1-yl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC2=CC=CC=C2C=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 OLKHNHZQILHHDC-UHFFFAOYSA-N 0.000 description 1
- WTJIVDRTFXHTDO-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-naphthalen-2-yl-2-propan-2-ylpentanenitrile Chemical compound C=1C=C2C=CC=CC2=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 WTJIVDRTFXHTDO-UHFFFAOYSA-N 0.000 description 1
- MTCZFFNDUJJLQF-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-yl-2-pyridin-2-ylpentanenitrile Chemical compound C=1C=CC=NC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 MTCZFFNDUJJLQF-UHFFFAOYSA-N 0.000 description 1
- DTAUHICPYDYGOJ-UHFFFAOYSA-N 5-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-yl-2-pyridin-4-ylpentanenitrile Chemical compound C=1C=NC=CC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 DTAUHICPYDYGOJ-UHFFFAOYSA-N 0.000 description 1
- IYHSRHYHOVOFKN-XPCCGILXSA-N 5-[6-[(3r)-3-aminopyrrolidin-1-yl]-3-cyano-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN1CC[C@@H](N)C1 IYHSRHYHOVOFKN-XPCCGILXSA-N 0.000 description 1
- OJPYHVGJRNUDJJ-UHFFFAOYSA-N 5-[tert-butyl(dimethyl)silyl]oxy-2-(2-naphthalen-2-ylpropan-2-yl)pentanenitrile Chemical compound C1=CC=CC2=CC(C(C)(C)C(C#N)CCCO[Si](C)(C)C(C)(C)C)=CC=C21 OJPYHVGJRNUDJJ-UHFFFAOYSA-N 0.000 description 1
- PLICPAVBPJZXLN-UHFFFAOYSA-N 5-fluoro-2-(2-piperazin-1-ylethoxy)benzonitrile Chemical compound N#CC1=CC(F)=CC=C1OCCN1CCNCC1 PLICPAVBPJZXLN-UHFFFAOYSA-N 0.000 description 1
- ONRWLQMTZBJKMQ-UHFFFAOYSA-N 5-hydroxy-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound OCCCC(C(C)C)(C#N)C1=CC=CC=C1 ONRWLQMTZBJKMQ-UHFFFAOYSA-N 0.000 description 1
- OWUPRCYXLJNXFU-UHFFFAOYSA-N 5-hydroxy-2-propan-2-yl-2-pyridin-2-ylpentanenitrile Chemical compound OCCCC(C(C)C)(C#N)C1=CC=CC=N1 OWUPRCYXLJNXFU-UHFFFAOYSA-N 0.000 description 1
- MDNPLYWYAPCZPB-UHFFFAOYSA-N 5-hydroxy-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound OCCCC(C(C)C)(C#N)C1=CC=CS1 MDNPLYWYAPCZPB-UHFFFAOYSA-N 0.000 description 1
- JENXHUVVMNHEDM-UHFFFAOYSA-N 5-iodo-2-(2-phenylpropan-2-yl)pentanenitrile Chemical compound ICCCC(C#N)C(C)(C)C1=CC=CC=C1 JENXHUVVMNHEDM-UHFFFAOYSA-N 0.000 description 1
- NWWSZWYPUCBSQR-UHFFFAOYSA-N 5-iodo-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound ICCCC(C(C)C)(C#N)C1=CC=CS1 NWWSZWYPUCBSQR-UHFFFAOYSA-N 0.000 description 1
- HDFHCNQQXPHSLE-UHFFFAOYSA-N 5-iodo-2-propan-2-yl-2-thiophen-3-ylpentanenitrile Chemical compound ICCCC(C(C)C)(C#N)C=1C=CSC=1 HDFHCNQQXPHSLE-UHFFFAOYSA-N 0.000 description 1
- WMFZXXVJUSKVLI-UHFFFAOYSA-N 5-piperazin-1-yl-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCCN1CCNCC1 WMFZXXVJUSKVLI-UHFFFAOYSA-N 0.000 description 1
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical group N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 description 1
- IXXAYKKRCMMEBY-UHFFFAOYSA-N 5h-pyrazolo[3,4-d][1,3]oxazole Chemical group N1=NC2=NCOC2=C1 IXXAYKKRCMMEBY-UHFFFAOYSA-N 0.000 description 1
- MFQSDQUBQWSNNA-UHFFFAOYSA-N 6-hydroxy-2-(2-phenylpropan-2-yl)undecanenitrile Chemical compound CCCCCC(O)CCCC(C#N)C(C)(C)C1=CC=CC=C1 MFQSDQUBQWSNNA-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- COVRRVWNNDYMAO-UHFFFAOYSA-N CC(=O)C1=CC=CC(OCCC2(N(CCNC2)C(O)=O)C(C)(C)C)=C1 Chemical compound CC(=O)C1=CC=CC(OCCC2(N(CCNC2)C(O)=O)C(C)(C)C)=C1 COVRRVWNNDYMAO-UHFFFAOYSA-N 0.000 description 1
- ILOGVPXSMRAKEK-UHFFFAOYSA-N CC1=CSC(OCCC2(N(CCNC2)C(O)=O)C(C)(C)C)=C1 Chemical compound CC1=CSC(OCCC2(N(CCNC2)C(O)=O)C(C)(C)C)=C1 ILOGVPXSMRAKEK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OFQRUTMGVBMTFQ-UHFFFAOYSA-N Ethyl 4-methylpentanoate Chemical compound CCOC(=O)CCC(C)C OFQRUTMGVBMTFQ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 108010027023 Q-Type Calcium Channels Proteins 0.000 description 1
- 239000008327 RUB A535 Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229940111979 Thromboxane synthase inhibitor Drugs 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- MXOQNVMDKHLYCZ-UHFFFAOYSA-N benzamidoxime Chemical compound ON=C(N)C1=CC=CC=C1 MXOQNVMDKHLYCZ-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WITCLTOOIPMTGJ-UHFFFAOYSA-N benzyl 4-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound C1CN(CCO)CCN1C(=O)OCC1=CC=CC=C1 WITCLTOOIPMTGJ-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- LYHIYZUYZIHTCV-UHFFFAOYSA-N cyclopenta[b]pyran Chemical group C1=COC2=CC=CC2=C1 LYHIYZUYZIHTCV-UHFFFAOYSA-N 0.000 description 1
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical group CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- JRIFLLHSMYBFHD-UHFFFAOYSA-N ethyl 1-benzyl-4-(4-cyano-5-methyl-4-phenylhexyl)piperazine-2-carboxylate Chemical compound C1CN(CC=2C=CC=CC=2)C(C(=O)OCC)CN1CCCC(C#N)(C(C)C)C1=CC=CC=C1 JRIFLLHSMYBFHD-UHFFFAOYSA-N 0.000 description 1
- MIVOXQPHLBDIGM-UHFFFAOYSA-N ethyl 1-benzyl-4-[2-(4-fluorophenoxy)ethyl]piperazine-2-carboxylate Chemical compound C1CN(CC=2C=CC=CC=2)C(C(=O)OCC)CN1CCOC1=CC=C(F)C=C1 MIVOXQPHLBDIGM-UHFFFAOYSA-N 0.000 description 1
- VGCZTSBSVMCHOT-UHFFFAOYSA-N ethyl 4-(4-cyano-5-methyl-4-phenylhexyl)piperazine-2-carboxylate Chemical compound C1CNC(C(=O)OCC)CN1CCCC(C#N)(C(C)C)C1=CC=CC=C1 VGCZTSBSVMCHOT-UHFFFAOYSA-N 0.000 description 1
- BQBNHXOWGCGJNH-UHFFFAOYSA-N ethyl 4-[2-(4-fluorophenoxy)ethyl]piperazine-2-carboxylate Chemical compound C1CNC(C(=O)OCC)CN1CCOC1=CC=C(F)C=C1 BQBNHXOWGCGJNH-UHFFFAOYSA-N 0.000 description 1
- HZXKNMFPTRERPG-UHFFFAOYSA-N ethyl 4-methyl-3-phenylpentanoate Chemical compound CCOC(=O)CC(C(C)C)C1=CC=CC=C1 HZXKNMFPTRERPG-UHFFFAOYSA-N 0.000 description 1
- ZTVKGEALJSBLKX-UHFFFAOYSA-N ethyl 4-trimethylsilylbutanoate Chemical compound CCOC(=O)CCC[Si](C)(C)C ZTVKGEALJSBLKX-UHFFFAOYSA-N 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 125000002425 furfuryl group Chemical group C(C1=CC=CO1)* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical group CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 1
- AJPPKGMEHMXPMC-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(F)C=C1 AJPPKGMEHMXPMC-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- OPRKFUUVSNFMFW-UHFFFAOYSA-N methyl 3-(5-cyanothiophen-2-yl)propanoate Chemical compound COC(=O)CCC1=CC=C(C#N)S1 OPRKFUUVSNFMFW-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- 125000004708 n-butylthio group Chemical group C(CCC)S* 0.000 description 1
- 125000006137 n-hexyl sulfonyl group Chemical group 0.000 description 1
- 125000004718 n-hexylthio group Chemical group C(CCCCC)S* 0.000 description 1
- 125000006129 n-pentyl sulfonyl group Chemical group 0.000 description 1
- 125000004712 n-pentylthio group Chemical group C(CCCC)S* 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- 125000004706 n-propylthio group Chemical group C(CC)S* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene group Chemical group C1=CC=C2C=CC=C12 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical group C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical group CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical group N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- OUFHXMSGJIYFPW-UHFFFAOYSA-N pyrazino[2,3-c]pyridazine Chemical group N1=NC=CC2=NC=CN=C21 OUFHXMSGJIYFPW-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JXHZRQHZVYDRGX-UHFFFAOYSA-M sodium;hydrogen sulfate;hydrate Chemical compound [OH-].[Na+].OS(O)(=O)=O JXHZRQHZVYDRGX-UHFFFAOYSA-M 0.000 description 1
- ZIQRIAYNHAKDDU-UHFFFAOYSA-N sodium;hydroiodide Chemical compound [Na].I ZIQRIAYNHAKDDU-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 108010003641 statine renin inhibitory peptide Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- NFEGNISFSSLEGU-UHFFFAOYSA-N tert-butyl 2-diethoxyphosphorylacetate Chemical compound CCOP(=O)(OCC)CC(=O)OC(C)(C)C NFEGNISFSSLEGU-UHFFFAOYSA-N 0.000 description 1
- DDMKUEMNCXXWNG-UHFFFAOYSA-N tert-butyl 4-[3-(5-cyanothiophen-2-yl)propyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCCC1=CC=C(C#N)S1 DDMKUEMNCXXWNG-UHFFFAOYSA-N 0.000 description 1
- QCHPTXSBLQYNHZ-UHFFFAOYSA-N tert-butyl 4-[4-cyano-4-(5-cyanothiophen-2-yl)-5-methylhexyl]piperazine-1-carboxylate Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN1CCN(C(=O)OC(C)(C)C)CC1 QCHPTXSBLQYNHZ-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-SSDOTTSWSA-N tert-butyl n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCNC1 DQQJBEAXSOOCPG-SSDOTTSWSA-N 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WAOWQLJJQBDGQC-UHFFFAOYSA-N tetraazanium;tetrafluoride Chemical compound [NH4+].[NH4+].[NH4+].[NH4+].[F-].[F-].[F-].[F-] WAOWQLJJQBDGQC-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 1
- ONCNIMLKGZSAJT-UHFFFAOYSA-N thieno[3,2-b]furan Chemical group S1C=CC2=C1C=CO2 ONCNIMLKGZSAJT-UHFFFAOYSA-N 0.000 description 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 239000003768 thromboxane synthase inhibitor Substances 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical group N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Definitions
- the present invention relates to a novel compound useful as a calcium antagonist, a salt thereof, a hydrate of them, a production process thereof, and a pharmaceutical composition thereof; and specifically relates to a neuron-selective calcium antagonist, in particular a novel compound having a P/Q-type calcium channel and/or an N-type calcium channel inhibiting activity, etc.
- Cerebral apoplexy is the second cause of death next to malignant tumor and is the biggest cause for bedridden man often suffering from severe secondary diseases.
- a key to the treatment of cerebral apoplexy is to deal with the acute stage, and the treatment at the acute stage influences the life and function prognosis of the patient and significantly influences secondary diseases.
- thrombolytic agent For the purpose of improving blood stream, several drugs such as ozagrel sodium (thromboxane synthase inhibitor), argatroban (anti-thrombin agent) as an agent for treatment of chronic arterial occlusion, t-PA (alteplase: tissue plasminogen activator which should be used within 3 hours after the onset) as thrombolytic agent etc. are now approved of, or in off lavel use.
- ozagrel sodium thromboxane synthase inhibitor
- argatroban anti-thrombin agent
- t-PA alteplase: tissue plasminogen activator which should be used within 3 hours after the onset
- N type or P/Q type calcium channels can serve as an agent for inhibiting the death of neural cells or for protecting cerebral neural cells, an agent for treating or improving nervous diseases, an agent for treating or improving acute ischemic stroke, head trauma, death of neural cells, Alzheimer disease, cerebral circulatory metabolism disturbance, cerebral function disturbance or pain, an anti-spasm agent, an agent for treating or improving schizophrenia and an agent for preventing, treating or improving migraine, epilepsy, maniac-depressive psychosis, neural degenerative diseases (Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease), cerebral ischemia, epilepsy, head trauma, AIDS dementia complications, edema, anxiety disorder (generalized anxiety disorder) and diabetic neuropathy, and as an agent for preventing, treating or improving edema, anxiety disorder, schizophrenia, diabetic neuropathy and migraine.
- an agent for treating or improving nervous diseases an agent for treating or improving acute ischemic stroke, head trauma, death of neural cells, Alzheimer disease, cerebral circulatory metabolism disturbance, cerebral function disturbance or pain
- Neural degenerative diseases (Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease), cerebral ischemia, epilepsy, head trauma, and AIDS dementia complications: Revista de Neurologia., 24(134), 1199-1209, 1996.
- Anxiety disorder (generalized anxiety disorder), schizophrenia: Jyunkanseigyo (Circulation Control),14(2),139-145,1993.
- Diabetic neuropathy Shinkeinaika (Neurological Medicine),50,423-428,1999.
- the present inventors have intensively studied for investigating a preparation which has a superior effect of treatment and amelioration for cerebral acute ischemic stroke for which no useful preparation is not found and has high safety which does not cause bloodshed tendency, focusing on a neuron-selective, potential-dependent calcium channel antagonist which directly effects on neural cell and inhibits the progression of infarction nidus.
- the present inventors have succeeded in synthesizing a novel nitrogen-containing compound which is represented by the formula (I), a salt thereof and a hydrate thereof, and further surprisingly have found that these compounds, a salt thereof or a hydrate thereof have the superior suppression action of neural cell death and protective action of cerebral neuron based on the P/Q type or N-type calcium channel antagonism, that cell infarction property and toxicity are remarkably reduced in comparison with a conventional calcium antagonist and that the compound and the like are superior in safety, and have completed the present invention.
- Ar is (1) a C 6-14 aromatic hydrocarbon cyclic group which may be substituted, (2) a 5- to 14-membered aromatic heterocyclic group which may be substituted, (3) a C 1-6 alkyl group substituted with a C 6-14 aromatic hydrocarbon cyclic group which may be substituted or (4) a C 1-6 alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group which may be substituted;
- the ring A indicates a piperazine ring, homopiperazine ring, piperidine ring, homopiperidine ring, pyrrolidine ring or diazabicyclo[2,2,1]heptane ring which may be substituted, respectively;
- the ring B indicates (1) a C 3-14 hydrocarbon ring which may be substituted or (2) a 5- to 14-membered heterocyclic ring which may be substituted;
- E indicates (1) a single bond, a group represented by the formula (2) —CO— or (3) —CH(OH)—;
- X indicates
- the first aspect of the present invention is 1) a compound represented by the above formula (I), a salt thereof or a hydrate of them, and further, 2) in the above-mentioned 1), Ar may be a C 6-14 aromatic hydrocarbon ring or 5- to 14-membered aromatic heterocyclic ring, which may be substituted, 3) in the above-mentioned 1), Ar may be a thiophene ring or benzene ring, which may be substituted, 4) in the above 1), Ar may be a C 6-14 aromatic hydrocarbon ring or 5- to 14-membered aromatic heterocyclic ring, which may be substituted with any one or more groups selected from nitrile group and a halogen atom, 5) in the above-mentioned 1), Ar may be a thiophene ring or a benzene ring which may be substituted with any one or more groups selected from nitrile group and a halogen atom, respectively, 6) in the above-
- R 1 has the same meaning as in the above definition;
- R 13 and R 14 are the same as or different from each other and each indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) mercapto group, (5) a C 1-6 alkyl group which may be substituted with any one or more groups selected from hydroxyl group and a halogen atom, (6) a C 1-6 alkoxy group which may be substituted with any one or more groups selected from hydroxyl group, a halogen atom and a C 1-6 alkoxycarbonyl group, (7) a nitro group, (8) an amino group which may be substituted, (9) cyano group, (10) carboxyl group, (11) a C 1-6 alkoxycarbonyl group, (12) a C 1-6 thioalkoxy group, (13) a C 1-6 alkylsulfonyl group, (14) a lower acyl group, (15) a C 6-14 aromatic hydrocarbon
- R 1 and R 2 have the same meanings as defined above;
- R 13 and R 14 are the same as or different from each other and each indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) mercapto group, (5) a C 1-6 alkyl group which may be substituted with any one or more groups selected from hydroxyl group and a halogen atom, (6) a C 1-6 alkoxy group which may be substituted with any one or more groups selected from hydroxyl group, a halogen atom and a C 1-6 alkoxycarbonyl group, (7) nitro group, (8) an amino group which may be substituted, (9) cyano group, (10) carboxyl group, (11) a C 1-6 alkoxycarbonyl group, (12) a C 1-6 thioalkoxy group, (13) a C 1-6 alkylsulfonyl group, (14) a lower acyl group, (15) a C 6-14 aromatic hydrocarbon
- the second characteristic of the present invention is 29) a pharmaceutical composition containing the compound represented by the formula:
- Ar is (1) a C 6-14 aromatic hydrocarbon cyclic group which may be substituted, (2) a 5- to 14-membered aromatic heterocyclic group which may be substituted, (3) a C 1-6 alkyl group substituted with a C 1-14 aromatic hydrocarbon cyclic group which may be substituted or (4) a C 1-6 alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group which may be substituted;
- the ring A indicates a piperazine ring, a homopiperazine ring, a piperidine ring, a homopiperidine ring, a pyrrolidine ring, a diazabicyclo[2, 2,1]heptane ring which may be substituted, respectively;
- the ring B indicates (1) a C 3-14 hydrocarbon ring which may be substituted or (2) a 5- to 14-membered heterocyclic ring which may be substituted;
- E indicates (1) a single bond, a group represented by (2) the formula —CO— or (3)
- composition in the above-mentioned 29) may be a calcium antagonist
- the composition in the above-mentioned 29) may be a neuron-selective calcium antagonist
- the composition in the above-mentioned 29) may be a P/Q-type calcium channel and/or an N-type calcium
- the present invention provides a method for preventing, treating or improving a disease against which a calcium antagonism is effective, a disease against which a neuron-selective calcium antagonism is effective or a disease against which a P/Q-type calcium channel inhibitory action and/or an N-type calcium channel inhibitory action is effective, by administering a pharmacologically effective amount of the compound represetend by the above formula (I), a salt thereof or a hydrate of them to a patient.
- the present invention provides a method for preventing, treating or improving neural disease or pain.
- the present invention provides use of the compound represented by the above formula (I), a salt thereof or a hydrate of them for producing a calcium antagonist, a neuron-selective calcium antagonist, a P/Q-type calcium channel and/or an N-type calcium channel inhibitor, an agent for treating, preventing or improving a disease against which a P/Q-type calcium channel and/or an N-type calcium channel inhibitory action is efficacious, an agent for inhibiting the death of neural cells or for protecting cerebral neural cells.
- the present invention provides use of the compound represented by the above formula (I), a salt thereof or a hydrate of them for producing an agent for treating, preventing or improving neural diseases or an analgesic.
- the neural disease is any one of disease selected from acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral circulation metabolic affection, cerebral dysfunction, pain, spasm, schizophrenia, migraine, epilepsy, manic-depression, neural degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia and multiple sclerosis.
- the structural formula of a compound happens to represent a fixed isomer for convenience in the specification of the present application, but the present invention includes all of geometrical isomers which occur in the structure of the compound, optical isomers based on an asymmetric carbon, stereo-isomers, the isomers of tautomers and the like, and a mixture of the isomer.
- the present invention is not limited to the indication of the formulae for convenience, and may be one of the isomers and a mixture thereof. Accordingly, in the compounds of the present invention, there may exist an optically active body and a racemic body which have an asymmetric carbon atom in the molecule, but they are not limited in the present invention, and both of them are included therein.
- crystal polymorphism happens to exist, but is not similarly limited, and the crystal form may be either single or a mixture of crystal forms and may be a hydrate in addition to an anhydride.
- a so-called metabolite which occurs due to decomposition of the compounds according to the present invention in vivo is also included in the scope of claim for patent of the present invention.
- the “neural disease” in the specification of the present application mainly indicates acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral circulation metabolic affection, cerebral dysfunction, pain, spasm, schizophrenia, migraine, epilepsy, manic-depression, neural degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia and multiple sclerosis.
- analgesic in the specification of the present application means a medicine which mitigates or removes pain by changing the perception of stimulation of a nociceptor without causing narcoticism and unconsciousness.
- halogen atom used in the specification of the present application means atoms such as fluorine atom, chlorine atom, bromine atom and iodine atom, preferably fluorine atom, chlorine atom and bromine atom, and more preferably fluorine atom and chlorine atom.
- the “C 1-6 alkyl group” used in the specification of the present application means an alkyl group having 1 to 6 carbon atoms, and the preferable examples thereof include linear or branched alkyl groups such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, n-hexyl group, 1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-propylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylbutyl group, 1,2-di
- C 2-6 alkenyl group used in the specification of the present application means an alkenyl group having 2 to 6 carbon atoms, and is preferably a linear or branched alkenyl group such as vinyl group, allyl group, 1-propenyl group, 2-propenyl group,isopropenyl group, 2-methyl-1-propenyl group, 3-methyl-1-propenyl group, 2-methyl-2-propenyl group, 3-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 1-hexenyl group, 1,3-hexanedienyl group and 1,6-hexanedienyl group.
- C 2-6 alkynyl group used in the specification of the present application means an alkynyl group having 2 to 6 carbon atoms, and is preferably a linear or branched alkynyl group such as ethynyl group, 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group, 3-methyl-1-propynyl group, 1-ethynyl-2-propynyl group, 2-methyl-3-propynyl group, 1-pentynyl group, 1-hexynyl group, 1,3-hexanediynyl group and 1,6-hexanediynyl group.
- the “C 1-6 alkoxy group” used in the specification of the present application means a “C 1-6 alkyloxy group” in which an oxygen atom is bonded with a group having the same meaning as the C 1-6 alkyl group in the fore-mentioned definition, and the preferable examples thereof include methoxy group, ethoxy group, n-propoxy group, isopropoxy group, sec-propoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, n-pentyloxy group, isopentyloxy group, sec-pentyloxy group, n-hexoxy group, isohexoxy group, 1,1-dimethylpropyloxy group, 1,2-dimethylpropoxy group, 2,2-dimethylpropyloxy group, 2-ethylpropoxy group, 1-methyl-2-ethylpropoxy group, 1-ethyl-2-methylpropoxy group, 1,1,2-trimethylpropoxy group, 1,1,2-
- C 1-6 alkenyloxy group used in the specification of the present application means a group in which oxygen atom is bound to a group having the same meaning as the C 1-6 alkenyl group defined above, and the preferable examples thereof include vinyloxy group, allyloxy group, 1-propenyloxy group, 2-propenyloxy group, isopropenyloxy group, 2-methyl-1-propenyloxy group, 3-methyl-1-propenyloxy group, 2-methyl-2-propenyloxy group, 3-methyl-2-propenyloxy group, 1-butenyloxy group, 2-butenyloxy group, 3-butenyloxy group, 1-pentenyloxy group, 1-hexenyloxy group, 1,3-hexanedienyloxy group, 1,6-hexanedienyloxy group etc.
- the “C 3-8 cycloalkyl group” used in the specification of the present application means a cycloalkyl group in which the ring is formed by 3 to 8 carbon atoms, and the preferable group includes cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group etc.
- the “C 3-8 cycloalkane” used in the specification of the present application means a ring corresponding to the above-mentioned C 3-8 cycloalkyl group.
- C 3-8 cycloalkenyl group used in the specification of the present application means a C 3-8 cycloalkenyl group in which a ring is formed by 3 to 8 carbon atoms, and the examples thereof include a group represented by the formula:
- aromatic cyclic group used in the specification of the present application is a term meaning a C 6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group.
- C 6-14 aromatic hydrocarbon cyclic group examples include mono-cyclic, di-cyclic or tri-cyclic C 6-14 aromatic hydrocarbon groups such as phenyl group, indenyl group, 1-naphthyl group, 2-naphthyl group, azulenyl group, hepthalenyl group, biphenyl group, indathenyl group, acenaphthyl group, fluorenyl group, phenalenyl group, phenanthrenyl group, anthracenyl group, cyclopentacyclooctenyl group, benzocyclooctenyl group, and the like.
- Examples of the “5- to 14-membered aromatic heterocyclic group” include a mono-cyclic, di-cyclic or tri-cyclic 5- to 14-membered aromatic heterocyclic ring which contains any one or more of hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom, and for example:
- aromatic heterocyclic rings containing nitrogen such as pyrrolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazolyl group, tetrazolyl group, benzotriazolyl group, pyrazolyl group, imidazolyl group, benzimidazolyl group, indolyl group, isoindolyl group, indolizinyl group, purinyl group, indazolyl group, quinolyl group, isoquinolyl group, quinolizyl group, phthalazyl group, naphthylidinyl group, quinoxalyl group, quinazolinyl group, cinnolinyl group, pteridinyl group, imidazotriazinyl group, pyrazinopyridazinyl group, acridinyl group, phenanthridinyl group, carb
- aromatic heterocyclic rings containing oxygen such as furyl group, pyranyl group, cyclopentapyranyl group, benzofuranyl group and isobenzofuranyl group;
- C 3-14 hydrocarbon ring used in the specification of the present application means a C 3-8 cycloalkane, a C 3-8 cycloalkene or a C 6-14 aromatic hydrocarbon ring, and the meanings of these rings refer to the same meaning as a C 3-8 cycloalkane, a C 3-8 cycloalkene and a C 6-14 aromatic hydrocarbon ring defined above.
- the “5- to 14-membered heterocyclic ring” used in the specification of the present application means a 5- to 14-membered heterocyclic ring containing any one or more of hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom, and an aromatic heterocyclic ring and a non-aromatic heterocyclic ring are included in the ring.
- the above-mentioned “5- to 14-membered aromatic heterocyclic ring” have the same meaning as a 5- to 14-membered aromatic heterocyclic ring defined above.
- the preferable ring as the “5- to 14-membered non-aromatic heterocyclic ring” includes 5- to 14-membered non-aromatic heterocyclic rings such as pyrrolidine ring, pyrroline ring, piperidine ring, piperazine ring, imidazoline ring, pyrazolidine ring, imidazolidine ring, morpholine ring, tetrahydrofuran ring, tetrahydropyran ring, aziridine ring, oxirane ring, oxathiorane ring, pyridone ring etc., and condensed rings such as phthalimide ring, succinimide ring etc.
- hydrocarbon group used in the specification of the present application specifically means a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 3-8 cycloalkyl, a C 3-8 cycloalkenyl group or a C 6-14 aromatic hydrocarbon cyclic group, and the respective meanings are the same as defined above.
- Ar indicates (1) a C 6-14 aromatic hydrocarbon cyclic group which may be substituted, (2) a 5- to 14-membered aromatic heterocyclic group which may be substituted, (3) a C 1-6 alkyl group substituted with a C 6-14 aromatic hydrocarbon cyclic group which may be substituted or (4) a C 1-6 alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group which may be substituted.
- C 6-14 aromatic hydrocarbon cyclic group preferably include phenyl group, pentalenyl group, indenyl group, naphthyl group, 1,2,3,4-tetrahydronaphthyl group, azulenyl group, hepthalenyl group, benzocyclooctenyl group, tetranyl group, phenanthrenyl group etc., and more preferably phenyl group, naphthyl group etc.
- the preferable examples of the “5- to 14-membered aromatic heterocyclic group” include pyrrolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazolyl group, tetrazolyl group, benzotriazolyl group, pyrazolyl group, imidazolyl group, benzimidazolyl group, indolyl group, isoindolyl group, indolizinyl group, purinyl group, indazolyl group, quinolyl group, isoquinolyl group, quinolizyl group, phthalazyl group, naphthylidinyl group, quinoxalyl group, quinazolinyl group, cinnolinyl group, pteridinyl group, imidazotriazinyl group, pyrazinopyridazinyl group, acridinyl group,
- examples of the “substituent” include (i) hydroxyl group, (ii) a halogen atom (for example, fluorine atom, chlorine atom, bromine atom and an iodine atom), (iii) nitrile group, (iv) a C 1-6 alkyl group (preferably, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, n-hexyl group
- examples of the more preferable “C 6-14 aromatic hydrocarbon cyclic group which may be substituted” or “5- to 14-membered aromatic heterocyclic group which may be substituted” in the definition of Ar include a thiophene, a pyridine, a benzene or a naphthalene ring which may be substituted with any one or more groups selected from a halogen atom and cyano group.
- the most preferable example includes a thiophene ring which may be substituted with any one or more groups selected from a halogen atom and cyano group, and namely, a ring represented by the formula:
- R 13a , R 13b and R 13c are the same as or different from each other, and each indicates a hydrogen atom, a halogen atom or cyano group.
- the C 1-6 alkyl group substituted with those groups means a C 1-6 alkyl group substituted with such groups.
- preferable examples of the “C 1-6 alkyl group” include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, n-hexyl group, 1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-propylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-
- C 1-6 alkyl group substituted with an aromatic group which may be substituted include a benzyl group, a phenethyl group, a phenylpropyl group, a naphthylmethyl group, a naphthylethyl group, a naphthylpropyl group, a pyridylmethyl group, a pyrazinylmethyl group, a pyrimidinylmethyl group, a pyrrolylmethyl group, an imidazolylmethyl group, a pyrazolylmethyl group, aquinolylmethyl group, an isoquinolylmethyl group, furfuryl group, thienylmethyl group, thiazolylmethyl group etc., which maybe optionally substituted respectively with one ore more groups selected from nitrile group, ahalogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.) etc.
- ahalogen atom for example,
- preferable examples of the “C 1-6 alkoxycarbonyl group” in the definition of Ar include methoxycarbonyl group, ethoxycarbonyl group, n-propoxycarbonyl group, isopropoxycarbonyl group, sec-propoxycarbonyl group, n-butoxycarbonyl group, isobutoxycarbonyl group, sec-butoxycarbonylcarbonyl group, tert-butoxycarbonylcarbonyl group, n-pentoxycarbonyl group, isopentoxycarbonyl group, sec-pentoxycarbonyl group, tert-pentoxycarbonyl group, n-hexoxycarbonyl group, isohexoxycarbonyl group, 1,2-dimethylpropoxycarbonyl group, 2-ethylpropoxycarbonyl group, a 1-methyl-2-ethylpropoxycarbonyl group, 1-ethyl-2-ethylpropoxycarbonyl group, 1,1,2-trimethylpropoxycarbonyl group, 1,1
- hydroxy C 1-6 alkyl group include linear or branched C 1-6 alkyl groups such as hydroxymethyl group, 1-hydroxyethyl group, 2-hydroxyethyl group, 3-hydroxy-n-propyl group, hydroxy-isopropyl group, hydroxy-sec-propyl group, hydroxy-n-butyl group, hydroxy-isobutyl group, hydroxy-sec-butyl group, hydroxy-tert-butyl group, hydroxy-n-pentyl group, hydroxy-iso-pentyl group, hydroxy-n-hexyl group and hydroxy-iso-hexyl group.
- halogenated C 1-6 alkyl group means a group in which one or more of the same or different halogen atoms are bound to the “C 1-6 alkyl group” having the same meaning as the C 1-6 alkyl group defined above, and preferable examples thereof include fluoromethyl group, difluoromethyl group, trifluoromethyl group, chloromethyl group, 1-fluoroethyl group, 2-fluoroethyl group, 1,1-difluoroethyl group, 1,2-difluoroethyl group, 2,2-difluoroethyl group, 2,2,2-trifluoroethyl group etc.
- hydroxyimino C 1-6 alkyl group means a group in which hydroxyimino group is bound to a group having the same meaning as the C 1-6 alkyl group defined above.
- the “amino group in which a nitrogen atom may be optionally substituted” means an amino group which is represented by the formula —N(R 15 )R 16 — (wherein R 15 and R 16 are the same as or different from each other and each indicates (1) a hydrogen atom, (2) a C 1-6 alkyl group, a C 1-6 alkenyl group or a C 1-6 alkynyl group which may be substituted respectively with one or more groups selected from a halogen atom, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group and a C 1-6 alkoxy group, (3) a C 3-8 cycloalkyl group or a C 3-8 cycloalkenyl group which may be substituted with a halogen atom, (4) a carbonyl group substituted with any one of groups selected from a C 1-6 alkyl group, a C 1-6 alkenyl group, a C 1-6 alkynyl group,
- Examples of the preferable amino group include unsubstituted amino group, methylamino group, dimethylamino group, ethylamino group, diethylamino group, methylethylamino group, acetamide (CH 3 CONH—) group, propionamide group, methanesulfonamide group, ethanesulfonamide group, pyrrolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, 4-morpholinyl group, 4-thiomorpholinyl etc.
- amino group which may be substituted include an amino group which may be substituted with one or two groups selected from a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 3-8 cycloalkyl group and a C 3-8 cycloalkenyl group.
- the above-mentioned “carbamoyl group in which the nitrogen atom may be substituted” means a carbamoyl group in which the nitrogen atom may be substituted with a group selected from a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 3-8 cycloalkyl group and a C 3-8 cycloalkenyl group.
- the carbamoyl group naturally includes a case in which the nitrogen atom of the carbamoyl group is a portion of a cyclic amine.
- the preferable examples of the “carbamoyl group in which the nitrogen atom may be substituted” includes unsubstituted carbamoyl group, N-methylcarbamoyl group, N,N-dimethylcarbamoyl group, N-ethylcarbamoyl group, N,N-diethylcarbamoyl group, N-methyl-N-ethylcarbamoyl group, 1-pyrrolidinylcarbonyl group, 1-pyrazolinylcarbonyl group, 1-piperidylcarbonyl group, 1-piperazinylcarbonyl group, 4-morpholinylcarbonyl group, 4-thiomorpholinylcarbonyl group etc.
- sulfamoyl group in which the nitrogen atom may be substituted means a sulfamoyl group in which the nitrogen atom may be optionally substituted with a group selected from a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group etc.
- the sulfamoyl group naturally includes a case in which the nitrogen atom of the sulfamoyl group is a portion of a cyclic amine.
- the preferable examples of the “sulfamoyl group in which the nitrogen atom may be substituted” include unsubstituted sulfamoyl group (—SO 2 NH 2 ), N-methylsulfamoyl group (—SO 2 NHCH 2 ), N,N-dimethylsulfamoyl group (—SO 2 NH(CH 3 ) 2 ), N-ethylsulfamoyl group (—SO 2 NHC 2 H 5 ), N,N-diethylsulfamoyl group (—SO 2 NH(C 2 H 5 ) 2 ), N-methyl-N-ethylsulfamoyl group (—SO 2 N(CH 3 )C 2 H 5 ), 1-pyrrolidinylsulfonyl group, 1-pyrazolinylsulfonyl group, 1-piperidylsulfonyl group, 1-piperazinylsulfonyl group, 4-morpholinyl
- lower acyl group means a linear or molecular chain acyl group derived from a fatty acid having 1 to 6 carbons, and the preferable examples of the group include formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group etc.
- the ring A indicates any one ring selected from piperazine ring, homopiperazine ring, piperidine ring, homopiperidine ring, pyrrolidine ring and diazabicyclo[2,2,1]heptane ring.
- the ring A preferably include a piperazine ring, a homopiperazine ring, a piperidine ring, a homopiperidine ring, a pyrrolidine ring, more preferably a piperidine ring, a piperazine ring, and further more preferably a piperazine ring.
- the ring B indicates (1) a C 3-14 hydrocarbon ring which may be substituted, or (2) a 5- to 14-memberedheterocyclic ring which may be substituted.
- the “C 3-14 hydrocarbon ring” in the definition of the ring B means a C 3-8 cycloalkane, a C 3-8 cycloalkene or a C 6-14 aromatic hydrocarbon ring.
- examples of the ring preferably include 3- to 8-membered cycloalkanes such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane etc., and more preferably cyclopropane, cyclobutane, cyclopentane, cyclohexane etc.
- examples of the ring preferable include 3- to 8-membered cycloalkenes such as cyclopropene, cyclobutene, cyclopentene, cyclohexene and cycloheptene, and further, a non-aromatic unsaturated hydrocarbon ring in which a carbon-carbon double bond in an aromatic hydrocarbon ring is partially saturated. Cyclopropene, cyclobutene, cyclopentene, cyclohexene etc. are more preferred.
- the ring B is a “C 6-14 aromatic hydrocarbon ring”
- the ring preferably includes benzene ring, pentalene ring, indene ring, naphthalene ring, 1,2,3,4-tetrahydronaphthalene ring, azulene ring, heptalene ring, benzocyclooctene ring, phenanthrene ring etc., and the condensed ring of a C 3-8 cycloalkane with an aromatic hydrocarbon ring and the condensed ring of a C 3-8 cycloalkene with an aromatic hydrocarbon ring are also included in the “C 6-14 aromatic hydrocarbon ring”.
- the “5- to 14-membered heterocyclic ring” in the definition of the ring B indicates a 5- to 14-membered non-aromatic heterocyclic ring or a 5- to 14-membered aromatic heterocyclic ring.
- the ring B is the “5- to 14-membered non-aromatic heterocyclic ring”
- the ring preferably includes pyrrolidine ring, pyrroline ring, piperazine ring, imidazoline ring, pyrazolidine ring, imidazolidine ring, morpholine ring, tetrahydropyran ring, aziridine ring, oxirane ring, phthalimide ring, succinimide ring etc.
- the preferable ring includes pyrrole ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, pyrazole ring, imidazole ring, indole ring, isoindolyl ring, indolizine ring, purine ring, indazole ring, quinoline ring, isoquinoline ring, quinolizine ring, phthalazine ring, naphthylidine ring, quinoxaline ring, quinazoline ring, benzimidazole ring, cinnoline ring, pteridine ring, imidazotriazine ring, pyrazinopyridazine ring, acridine ring, phenanthridine ring, carbazole ring, carbazoline ring, perimidine ring,
- Examples of the “substituent” in the “C 3-14 hydrocarbon ring which may be substituted” or the “5- to 14-membered heterocyclic ring which may be substituted” in the ring B include one or more groups selscted from (1) hydroxyl group, (2) a halogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.), (3) nitrile group, (4) a C 1-6 alkyl group which may be substituted (for example, a C 1-6 alkyl group which may be substituted with one or moregroupsselected from hydroxyl group, a halogen atom, nitrile group, hydroxyimino group etc.), (5) a C 2-6 alkenyl group which may be substituted (for example, a C 2-6 alkenyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom, nitrile group, hydroxyimin
- the most preferable aspect of the ring B is a C 6-14 aromatic hydrocarbon ring or a 5- to 14-membered aromatic heterocyclic ring which may be substituted, respectively.
- Specific examples include a benzene ring, a thiophene ring, a pyridine ring, a 1,4-benzodioxane ring, an indole ring, a benzothiazole ring, a benzoxazole ring, a benzimidazole ring, a 2-keto-1-imidazole ring, a thiazole ring, a oxazole ring, an isoxazole ring, a 1,2,4-oxadiazole ring, an indanone ring, a benzofurane ring, a quinoline ring, a l,2,3,4-tetrahydroquinoline ring, a naphthalene ring, a 1,2,3,4-tetra
- the bonding chain E indicates a single bond, a group represented by the formula —CO— or —CH(OH)—.
- the most preferable aspect in E is a single bond.
- the bonding chain X indicates (1) a single bond, (2) oxygen atom, (3) sulfur atom, (4) a C 1-6 alkylene chain which may be substituted, a group represented by (5) the formula —NR 2 — (wherein R 2 indicates a hydrogen atom, or a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a lower acyl group or a C 1-6 alkylsulfonyl group which may be substituted), (6) —CO—, (7) —COO—, (8) —OOC—, (9) —CONR 3 — 0 (wherein R 3 indicates a hydrogen atom or a C 1-6 alkyl group which may be substituted), (10) —NR 4 CO— (wherein R 4 indicates a hydrogen atom, or a C 1-6 alkyl group which may be optionally substituted), (11) —SO—, (12) —SO 2 —
- the “C 1-6 alkylene chain” indicates a chain derived from a linear or branched C 1-6 alkane, and the examples thereof include methylene, ethylene, ethylidene, trimethylene, isopropylidene, propylene, tetramethylene, 1,2-butylene, 1,3-butylene, 2,3-butylene, isobutylene etc.
- C 1-6 alkyl group which may be substituted include a C 1-6 alkyl group (for example, methyl group, ethyl group, n-propyl group, isopropyl group etc.) which may be substituted with one or more groups selected from hydroxyl group, a halogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.), nitrile group, nitro group, a C 1-6 alkoxy group (for example, methoxy group, ethoxy group, n-propoxy group, isopropoxy group etc.), etc.
- a C 1-6 alkyl group for example, methyl group, ethyl group, n-propyl group, isopropyl group etc.
- a halogen atom for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.
- nitrile group for example, nitro group
- the preferable examples of the “C 3-8 cycloalkyl group” indicated by R 2 and R 10 includes cyclopropanyl group, cyclobutanyl group, cyclopentanyl group, cyclohexanyl group, cycloheptanyl group etc., and the group is more preferably cyclopropanyl group, cyclobutanyl group, cyclopentanyl group, cyclohexanyl group etc.
- the preferable examples of the “lower acyl group” indicated by R 2 and R 10 include formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group etc.
- the preferable examples of the “C 1-6 alkylsulfonyl group” indicated by R 2 and R 10 include methylsulfonyl group, ethylsulfonyl group, n-propylsulfonyl group, isopropylsulfonyl group, sec-propylsulfonyl group, n-butylsulfonyl group, isobutylsulfonyl group, sec-butylsulfonyl group, tert-butylsulfonyl group, n-pentylsulfonyl group, isopentylsulfonyl group, sec-pentylsulfonyl group, tert-pentylsulfonyl group, n-hexylsulfonyl group, isohexylsulfonyl group, 1,2-dimethylpropylsul
- R 15 and R 16 are the same as or different from each other and each indicates a hydrogen atom, nitrile group, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 3-8 cycloalkyl group or a C 3-8 cycloalkylene group.
- the preferable groups of both of them are the same as or different from each other and each means a hydrogen atom, nitrile group, methyl group, ethyl group, n-propyl group, isopropyl group, cyclopropyl group, cyclopentyl group, cyclohexyl group etc.
- R 15 is nitrile group, ethyl group, n-propyl group, isopropyl group or cyclohexyl group
- R 16 is a hydrogen atom.
- the most preferable aspect of the formula —C( ⁇ NR 15 )NR 16 — is a chain represented by the formula —C( ⁇ NCN)NH—.
- the preferable aspect of X is a single bond, oxygen atom, sulfur atom, a C 1-6 alkylene chain which may be substituted, a group represented by the formula —NR 2 — (wherein R 2 indicates a hydrogen atom, or a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a lower acyl group or a C 1-6 alkylsulfonyl group which may be substituted), —CO—, —NR 10 —W 3 —O— (wherein R 10 indicates a hydrogen atom, or a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a lower acyl group or a C 1-6 alkylsulfonyl group which may be substituted; and W 3 indicates a C 1-6 alkylene group which may be substituted) and —NH—SO 2 —.
- the more preferable aspect is oxygen atom, a C 1-6 alkylene chain which may be substituted, a group represented by the formula —NR 2 — (wherein R 2 indicates a hydrogen atom, or a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a lower acyl group or a C 1-6 alkylsulfonyl group which may be substituted), —CO—, —NR 10 —W 3 —O— (wherein R 10 indicates a hydrogen atom, or a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a lower acyl group or a C 1-6 alkylsulfonyl group which may be substituted; and W 3 indicates a C 1-6 alkylene group which may be substituted) and —NH—SO 2 —.
- the further more preferable aspect is oxygen atom, a C 1-6 alkylene chain which may be substituted, a group represented by the formula —NR 2 — (wherein R 2 indicates a hydrogen atom, or a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a lower acyl group or a C 1-6 alkylsulfonyl group which may be substituted), —CO—, and —NH—SO 2 —.
- the most preferable aspect is oxygen atom or a group represented by the formula —NR 2 — (wherein R 2 indicates a hydrogen atom, or a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a lower acyl group or a C 1-6 alkylsulfonyl group which may be substituted).
- the group represented by R 1 in the above formula (I) indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) a C 1-6 alkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (5) a C 2-6 alkenyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (6) a C 2-6 alkynyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (7) a C 3-8 cycloalkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (9) a C 1-6 alkoxy-C 1-6 alkyl group, (10) an amino-C 1-6 alkyl group in which the nitrogen atom may be substituted
- the preferable atom as the above-mentioned “halogen atom” includes fluorine atom, chlorine atom and bromine atom, and more preferably includes fluorine atom and chlorine atom.
- the “C 1-6 alkyl group” in R 1 preferably includes methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group tert-butyl group etc., more preferably methyl group, ethyl group, n-propyl group and isopropyl group, further preferably n-propyl group and isopropyl group, and most preferably isopropyl group.
- the “C 2-6 alkenyl group” in R 1 preferably includes vinyl group, allyl group, 1-propenyl group, isopropenyl group, 1-buten-1-yl group, 1-buten-2-yl group, 1-buten-3-yl group, 2-buten-1-yl group, 2-buten-2-yl group etc., and more preferably vinyl group, allyl group, isopropenyl group etc.
- the preferable examples of the “C 2-6 alkynyl group” in R 1 include ethynyl group, 1-propynyl group, 2-propynyl group, butynyl group, pentynyl group, hexynyl group etc.
- the preferable examples of the “C 3-8 cycloalkyl group” in R 1 include cyclopropanyl group, cyclobutanyl group, cyclopentanyl group, cyclohexanyl group etc.
- the preferable examples of the “C 1-6 alkoxy-C 1-6 alkyl group” in R 1 indicate a C 1-6 alkyl group substituted with a group having the same meaning as the C 1-6 alkoxy group defined above, and the preferable group includes methoxymethyl group, ethoxymethyl group, 1-methoxyethyl group, 2-methoxyethyl group, 1-ethoxyethyl group, 2-methoxy-n-propyl group, 3-methoxy-n-propyl group, 2-(n-propoxy)ethyl group etc.
- the preferable examples as the “C 1-6 alkyl group substituted with nitrile group” in R 1 includes cyanomethyl group, 2-cyanoethyl group, 3-cyano-n-propyl group, 2-cyano-isopropyl group, 2-cyano-n-butyl group, 2-cyano-sec-butyl group, 2-cyano-tert-butyl group, 2-cyano-n-pentyl group, 3-cyano-n-hexyl group etc.
- the preferable examples as the “amino-C 1-6 alkyl group in which the nitrogen atom may be substituted” in R 1 includes aminomethyl group, methylaminomethyl group, dimethylaminomethyl group, ethylaminomethyl group, diethylaminomethyl group, methylethylaminomethyl group, acetamidomethyl group, pyrrolidinylmethyl group, 2-pyrazolinylethyl group, 1-piperidylethyl group, piperazinylmethyl group etc.
- the preferable examples as the “aralkyl group” in R 1 includes benzyl group, phenethyl group, phenylpropyl group, naphthylmethyl group, naphthylethyl group, naphthylpropyl group etc.
- R 1 includes a hydrogen atom, a halogen atom, hydroxyl group, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 3-8 cycloalkyl group, a hydroxyl C 1-6 alkyl group, a C 1-6 alkoxy-C 1-6 alkyl group, a cyano-C 1-6 alkyl group and a C 1-6 alkyl group substituted with a halogen atom.
- the more preferable aspect thereof includes a halogen atom, hydroxyl group, a C 1-6 alkyl group, a C 2-6 alkenyl group and a C 2-6 alkynyl group, and the further preferable aspect includes a C 1-6 alkyl group (particularly, methyl group, ethyl group, n-propyl group, isopropyl group).
- D 1 , D 2 , W 1 and W 2 are the same as or different from each other and each respectively indicates (1) a single bond or (2) an optionally substituted C 1-6 alkylene chain.
- C 1-6 alkylene chain in the above-mentioned “C 1-6 alkylene chain which may be substituted” includes methylene chain, ethylene chain, ethylidene chain, trimethylene chain, isoproylidene chain, propylene chain, tetramethylene chain, 1,2-butylene chain, 1,3-butylene chain, 2,3-butylene chain, isobutylene chain etc.
- a chain being asymmetric in left and right is included in these C 1-6 alkylene chains, but in this case, the binding direction is not limited, and both of the binding directions are also included in the “C 1-6 alkylene chain”.
- the preferable aspect of the “substituent” in the above-mentioned “C 1-6 alkylene chain which may be substituted” includes (i) a hydroxy group, (ii) a halogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.), (iii) nitrile group, (iv) a C 1-6 alkyl group (for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, tert-butyl group etc.), (v) a C 2-6 alkenyl group (for example, vinyl group, allyl group, 1-propenyl group, 2-propenyl group, isopropenyl group, 2-methyl-1-propenyl group, 3-methyl-1-propenyl group, 2-methyl-2-propenyl group etc.), (vi) a C 1-6 alkoxy group (for
- substituents when the “substituent” is a c 1-6 alkyl group and/or a C 2-6 alkenyl group, these substituents can be bound together to form a 5- to 14-membered ring, and in the case of W 1 and W 2 , these substituents can be bonded with the ring B or X to form a 5- to 14-membered ring.
- D 1 , D 2 , W 1 and W 2 are the same as or different from each other and each include (1) a single bond or (2) a methylene chain, ethylene chain, ethylidene chain, trimethylene chain, isopropylidene chain, propylene chain, tetramethylene chain, 1,2-butylene chain, 1,3-butylene chain, 2,3-butylene chain, isobutylene chain etc., which may be substituted respectively with one or more groups selected from hydroxyl group, a halogen atom and nitrile group.
- the preferable aspect of the partial sturucture -D 1 -E-D 2 - includes ethylene chain (—CH 2 —CH 2 —), ethylidene chain (—CH(CH 3 )—), trimethylene chain (—(CH 2 ) 3 —), isopropylidene chain (—CH(CH 3 ) 2 —), propylene chain (—CH(CH 3 )CH 2 —), tetramethylene chain (—(CH 2 ) 4 —), 1,2-butylene chain (—CH(C 2 H 5 )CH 2 —), 1,3-butylene chain (—CH(CH 3 )CH 2 CH 2 —), 2,3-butylene chain (—CH(CH 3 )CH(CH 3 )—), isobutylene chain (—CH(CH 3 ) 2 CH 2 —) etc.
- the more preferable aspect includes trimethylene chain (—(CH 2 ) 3 —), isopropylidene chain (—CH(CH 3 ) 2 —), propylene chain (—CH(CH 3 )CH 2 —), tetramethylene chain (—(CH 2 ) 4 —), 1,2-butylene chain (—CH(C 2 H 5 )CH 2 —) etc., and the further preferable aspect includes tetramethylene chain (—(CH 2 ) 3 —) etc.
- the preferable aspect of the partial structure —W 1—X—W 2 — includes a single bond, a chain represented by the formula —CH 2 —CH 2 —O—, —CH 2 —CH 2 —NR 2 —, —(CH 2 ) 3 —O— or —(CH 2 ) 3 —NR 2 —.
- Ar is an optionally substituted 5- to 14-membered aromatic heterocyclic group
- the ring A is piperazine ring, piperidine ring or pyrrolidine ring
- the ring B is a C 6-14 aromatic hydrocarbon group or 5- to 14-membered aromatic heterocyclic group which may be substituted
- E is a single bond
- X is a single bond, oxygen atom, an optionally substituted C 1-6 alkylene group or a group represented by the formula —NR 2 — (wherein R 2 has the same meaning as defined above).
- the compound represented by the above formula (I) according to the present invention, a salt thereof or a hydrate of them can be produced by known production processes or processess according to the processes.
- known production processes for example, a production process described in JP-A 2000-169462 (a production process described in paragraphs “0054” to “0065” in the Publication), and production processes described in JP-A 2000-12207, 2000-12208 and 2000-12209 are listed.
- the raw material compound in the production of the compound (I) may form a salt or a hydrate, and is not specifically limited so far as it does not inhibit the reaction.
- the compound (I) according to the present invention When the compound (I) according to the present invention is obtained as a free body, it can be converted to a salt which the above compound (I) may form, according to a conventional process.
- the compound according to the present invention When the compound according to the present invention is prepared as a free body, it can be converted to a salt according to a conventional process.
- the “salt” in the specification of the present application is not specifically limited so far as it forms a salt with the compound according to the present invention and is pharmacologically accepted, and is preferably a salt of hydrogen halide acid (for example, hydrofluorate, hydrochloride, hydrobromate, hydroiodate and the like), a salt of an inorganic acid (for example, sulfate, nitrate, perchlorate, phosphate, carbonate, bicarbonate and the like), a salt of an organocarboxylic acid (for example, a salt of acetic acid, a salt of trifluoroacetic acid, a salt of oxalic acid, a salt of maleic acid, a salt of tartaric acid, a salt of fumaric acid, a salt of citric acid, and the like), a salt of an organosulfonic acid (for example, methanesulfonate, trifluoromethanesulfonate, ethanes
- the compound represented by the fore-mentioned formula (I) or a salt thereof, or a hydrate thereof can be formulated by an ordinary method, and preferable preparations include tablets, powders, granules, parvules, coated tablets, capsules, syrups, troches, inhalants, suppositorium, injections, paste medicines, eye ointments, eye drops, nasal drops, eardrops, poultices, lotions and the like.
- excipients for preparations, excipients, binders, disintegrants, lubricants, colorants, and flavoring agents which are conventionally used, if necessary, stabilizers, emulsifiers, absorption accelerators, surfactants, pH regulators, antiseptics, antioxidants and the like can be used.
- Ingredients which are conventionally used for the raw materials of pharmaceutical preparations can be formulated by a normal method.
- animal and vegetable oils such as soy bean flexure, tallow and synthetic glyceride; hydrocarbons such as liquid paraffin, squalane and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenic alcohol; silicone resins; silicone oils; surfactants such as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene-hardened castor oil and polyoxyethylene-polyoxypropylene block copolymer; water-soluble polymers such as hydroxy ethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, poly(vinyl pyrrolidone) and methyl cellulose; lower alcohol such as ethanol and isopropanol; polyvalent alcohols such as
- excipients used are: lactose, corn starch, white sugar, dextrose, mannitol, sorbit, crystal cellulose, silicon dioxide and the like;
- binders used are: polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, gum arabic, gum tragacanth, gelatin, shellac, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, polypropylene glycol-polyoxyethylene block copolymer, meglumine, calcium citrate, dextrin, pectin and the like;
- disintegrants used are: starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, carboxymethyl cellulose calcium and the like;
- lubricants used are: magnesium stearate, talc, polyethylene glycol, silica, hardened vegetable oil and the like
- oral preparations are made as powders, fine granules, granules, tablets, coated tablets, capsules etc. according to a conventional method after adding the compound according to the present invention, a salt thereof or a hydrate of them, fillers, and further, if necessary, binders, disintegrants, lubricants, colorants, flavoring agents etc.
- a salt thereof or a hydrate of them fillers, and further, if necessary, binders, disintegrants, lubricants, colorants, flavoring agents etc.
- sugar coating and gelatin coating and additionally, if necessary, appropriate coating are allowed to be carried out.
- the suspending agent include methyl cellulose, polysorbate 80, hydroxyethyl cellulose, gum arabic, tragacanth powder, carboxymethyl cellulose sodium, polyoxyethylene sorbitan monolaurate and the like;
- preferable examples of the resolving aids include polyoxyethylene hardened castor oil, polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate and the like;
- preferable examples of the stabilizer include sodium sulfite, meta sodium sulfite, diethyl ether and the like;
- Preferable examples in the preservative include methyl p-oxybenzoate, ethyl p-oxybenzoate, sorbic acid, phenol, cresol, chlorocresol and the like.
- the preparation process is not specifically limited, and the external preparations can be produced by a conventional method.
- the raw material of a base drug used various raw materials which are conventionally used for pharmaceuticals, quasi drug, cosmetics and the like can be used.
- raw materials such as animal and vegetable oils, a mineral oil, an ester oil, waxes, higher alcohols, fatty acids, a silicone oil, a surfactant, phosphatides, alcohols, polyvalent alcohols, water-soluble polymers, clay minerals, purified water and the like are listed.
- a pH regulator, an antioxidant, a chelating agent, antiseptic and fungicide, a coloring agent, flavors and the like can be added.
- ingredients having differential derivation action can be formulated.
- the dose of the pharmaceuticals according to the present invention is different depending on the extent of symptom, age, sexuality, body weight, administration form, modality of salt, the difference of sensitiveness for medicine, the specific modality of affection, but in the case of an adult, for oral administration, approximately 30 ⁇ g to 1000 mg per day in general, preferably 100 ⁇ g to 500 mg, and more preferably 100 ⁇ g to 100 mg of the pharmaceutical is administered at one time or several times.
- For injection administration approximately 1 to 3000 ⁇ g/kg in general, and preferably 3 to 1000 ⁇ g/kg of the pharmaceutical is administered at one time or several times.
- the compound represented by the above formula (I) according to the present invention, a salt thereof or a hydrate of them is useful as a calcium antagonist and specifically, a neuron-selective calcium antagonist.
- the compound according to the present invention has a novel compound having a P/Q-type calcium channel and an N-type calcium channel inhibiting activity, and is useful as an agent for treating or preventing a disease against which a P/Q-type calcium channel inhibitory action and an N-type calcium channel inhibitory action are effective.
- the compound represented by the above formula (I) according to the present invention, a salt thereof or a hydrate of them has a remarkably low extent of cell affection in comparison with a conventional antagonist, and is a safe calcium antagonist whose toxicity is reduced.
- the compound according to the present invention is useful as a neural cell death depressor, a cerebral neural cell demulcent, an agent for treating or preventing neural disease and an analgesic.
- it is useful as an agent for treating, preventing or improving acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral circulation metabolic affection, cerebral dysfunction, pain, spasm, schizophrenia, migraine, epilepsy, manic-depression, neural degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia, multiple sclerosis etc.
- FIG. 1 shows a HPLC chart in Reference Example 97.
- FIG. 2 shows a HPLC chart in Reference Examples 100 and 101, the spectrum of No. 1 in the drawing shows a spectrum in Reference Example 100 and the spectrum of No. 2 shows a spectrum in Reference Example 101, respectively.
- FIG. 3 shows a HPLC chart in Reference Example 103.
- the mixture was used for the following reaction without purification. Namely, 1.40 g of the abve-mentioned crude 4-cyano-5-methyl-5-(2-naphthyl)hexanoxy-tert-butyldimethylsilane was dissolved in 20 ml of tetrahydrofuran, and 5 ml (5 mmol) of tetraammonium fluoride was added thereto.
- the physico-chemical data of the target compound was as indicated below.
- the resulting residue was dissolved in acetonitrile (20 mL), a 1 M tetrabutylammonium fluoride/tetrahydrofuran solution (9.7 ml) was added thereto, and the mixture was stirred at a room temperature. After 18 hours, the organic layer was separated by adding water and ethyl acetate. The resulting organic layer was rinsed with water and brine, and dried over magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a red oil (637 mg, 43%).
- the organic layer was separated by adding a 0.2N hydrochloric acid solution (250 mL) and ethyl acetate (200 mL) thereto.
- the resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated.
- 756 Mg among the resulting crude product (7.9 g) was dissolved in methanol (5 mL), a catalytic amount of 10% palladium carbon (9.5 mg) was added, and the mixture was stirred under hydrogen atmosphere. After 4 hours, the catalyst was filtered off, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a colorless oil (350 mg).
- N-methyl-N-methoxy-4-methyl-3-phenyl-pentaneamide (215 mg) was dissolved in tetrahydrofuran (9.1 mL) at ⁇ 78° C., and a diisobutylaluminum hydride/toluene solution (1.5 M, 1.2 mL) was added. After one hour, methanol (3 mL) was added to the reaction system, the temperature of the mixture was returned to room temperature after termination of foaming, and the mixture was continuously stirred. The organic layer was separated by adding diethyl ether, water and a 1N aqueous hydrochloric acid thereto.
- the organic layer was separated by adding diethyl ether and an aqueous saturated ammonium chloride thereto.
- the resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated, to give the title compound as a colorless oil (200 mg).
- the resulting compound was dissolved in isopropanol(2 mL)/water(2 mL), p-toluenesulfonic acid (6 mg) was added thereto, and then the reaction was carried out for 8.5 hours under refluxing.
- the organic layer was separated by adding diethyl ether and an aqueous saturated ammonium chloride thereto.
- Oxalyl chloride (0.70 ml) was dissolved in methylene chloride (10 ml), and then the mixture was cooled to ⁇ 60 to ⁇ 50° C. Dimethyl sulfoxide (0.57 ml) was added thereto, and the mixture was stirred for 2 minutes. Further, a methylene chloride solution (6 ml) of 3-cyano-5-(1-hydroxy-2-methylpropyl)thiophene (1.21 g) was added thereto at ⁇ 60 to ⁇ 50° C., and the mixture was stirred for 15 minutes. Then, triethylamine (4.65 ml) was added, and the temperature of the mixture was raised to a room temperature.
- the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound pale as a yellow oil (1.25 g, 47%). Further, the catalyst was filtered off, and the filtrate was evaporated. The resulting residue was purified by preparative thin layer silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (0.39 g, 83%).
- the crude product was dissolved in acetone, and 12.0 g (80.1 mmol) of sodium iodide was added. After completion of the reaction, brine was added thereto, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product.
- the crude product was dissolved in 40 ml of methanol, and 30 ml of a 4N hydrogen chloride-ethyl acetate solution was added. After completion of the reaction, water and 10 ml of 5N HCl were added, and the mixture was washed with ethyl acetate. Then the aqueous layer was adjusted to pH 11 with a 5N aqueous sodium hydroxide, and then the objective product was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate andthe solventwas evaporated, to give 1.81 g (7.01 mmol, 75.7%) of the title compound as a yellow syrup, as a crude product.
- tert-butyl-2-(4-methylthiophenoxy)ethyl-1-piperazinecarboxylate (1.15 g) as white crystals.
- the product (1.15 g) was dissolved in methanol (10 ml), and the solution was added to a 4N hydrochloric acid-ethyl acetate solution (30 ml) in an ice bath. After stirring at room temperature overnight, the resulting white crystals were collected by filtration and washed with diethyl ether. A 1N aqueous sodium hydroxide and dichloromethane were added to the crystals, to separate the organic layer. The resulting organic layer was evaporated, to give the title compound as a yellow oil (820 mg, 53%; 3 steps).
- the product (1.33 g) was dissolved in methanol (10 ml), and the solution was added to a 4N hydrochloric acid-ethyl acetate solution (30 ml). The mixture was stirred at a room temperature overnight, the resulting white crystals were collected by filtration and washed with diethyl ether. The organic layer was separated by adding a 1N aqueous sodium hydroxide and dichloromethane to the crystals. The resulting organic layer was evaporated, to give the title compound (830 mg, 62%; 2 steps) as a yellow oil.
- tert-Butyl-1-piperazinecarboxylate (540 mg) was added to an acetonitrile solution (11 ml) of 1-iodo-4-cyano-5-methyl-4-(2-thienyl)hexane (744 mg) and triethylamine (0.93 ml) synthesized according to Example 84, and the mixture was stirred at 50° C. for 5 hours under nitrogen atmosphere. The reaction solution was evaporated, and then the resulting crude product was purified by silica gel column chromatography (hexane/ethyl acetate system), to give a colorless oil (705 mg, 81%).
- the resulting product (705 mg) was dissolved in methanol (5 ml), a 4N hydrochloric acid-ethyl acetate solution (15 ml) was added, and the mixture was stirred for 10 hours. Diethyl ether and ethyl acetate were added, and the mixture was stirred in an ice bath. The resulting hydrochloride of the title compound was collected by filtration (white crystals, 490 mg, 75%). The hydrochloride of the title compound obtained was extracted with dichloromethane and an aqueous saturated sodium bicarbonate, to be converted into a free body, and it was used for the next reaction.
- diethyl cyanophosphonate (618 mg) was added to a tetrahydrofuran solution (15 ml) of 3-pyrroline (262 mg) and 4-cyano-4-(2-thienyl)-5-methylhexanoic acid (692 mg) at room temperature, and the mixture was stirred overnight. After the reaction solution was evaporated, the crude product was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a yellow oil (440 mg).
- the physico-chemical data of the compound was as below.
- Oxalyl chloride (1.05 ml) was dissolved in methylene chloride (25 ml), and a methylene chloride solution (5 ml) of dimethyl sulfoxide (0.85 ml) was added dropwise at -60 to ⁇ 50° C. After stirring for 2 minutes, a methylene chloride solution (10 ml) of the above-mentioned oil (2.08 g) was added dropwise therinto within 5 minutes. After stirring for 15 minutes at this temperature, triethylamine (6.96 ml) was added. After stirring for 5 minutes, the temperature was raised to room temperature. The mixture was washed with water and brine, dried over anhydrous magnesium sulfate and evaporated, to give 1.91 g (93%) of an oil.
- optically active intermediates can be produced in accordance with known production methods or methods according to them, and additionally, for example, can be produced according to the following methods.
- the crude product was subjected to distillation under a reduced pressure (2 to 3 mmHg: 132 to 137 deg), to give 46.4 g (0.28 mol, 72.7%) of the title compound as a colorless oil.
- the physico-chemical data of the compound was as below.
- Free Body 4-Cyano-4-(3-thienyl)-5-methylhexanoic acid
- the free body of the title compound (3.94 g) was obtained by treating 4-cyano-4-(3-thienyl)-5-methylhexanoic acid•(S)-1-(4-methylphenyl)ethylamine salt (5.6 g) with an aqueous hydrochloric acid, in accordance with the method of Reference Example 97, to produce the title free compound (3.94 g).
- the physico-chemical data of the compound was as below. Further, the condition of HPLC analysis are shown below, and the analysis data (HPLC chart) are shown in FIG. 2.
- N,N-dimethylformamide (3 ml) was dissolved the residue, followed by adding a N,N-dimethylformamide solution (2 ml) of triethylamine (0.027 ml) and 2-(4-fluorophenoxy) ethyl bromide (25 mg). After stirring at 50° C. overnight, the solution was left to be cooled to room temperature. Ethyl acetate was added thereto, and the mixture was washed with water and further brine. After drying over anhydrous magnesium sulfate, it was evaporated. The resulting residue was purified by preparative thin layer silica gel column chromatography (methylene chloride/methanol), to give the title compound as a pale yellow oil (20 mg, 48%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
Abstract
The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.
In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula —CO—, etc.; X indicates a single bond, an oxygen atom etc.; R1 indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D1, D2, W1 and W2 are the same as or different from each other and each represents a single bond or an optionally substituted C1-6 alkylene chain.
Description
- The present invention relates to a novel compound useful as a calcium antagonist, a salt thereof, a hydrate of them, a production process thereof, and a pharmaceutical composition thereof; and specifically relates to a neuron-selective calcium antagonist, in particular a novel compound having a P/Q-type calcium channel and/or an N-type calcium channel inhibiting activity, etc.
- In Japan, the number of patients with cerebral apoplexy is about 1.4 million or more per year, and the medical expenses therefor are estimated to be about two billion yen. Cerebral apoplexy is the second cause of death next to malignant tumor and is the biggest cause for bedridden man often suffering from severe secondary diseases. A key to the treatment of cerebral apoplexy is to deal with the acute stage, and the treatment at the acute stage influences the life and function prognosis of the patient and significantly influences secondary diseases.
- For the purpose of improving blood stream, several drugs such as ozagrel sodium (thromboxane synthase inhibitor), argatroban (anti-thrombin agent) as an agent for treatment of chronic arterial occlusion, t-PA (alteplase: tissue plasminogen activator which should be used within 3 hours after the onset) as thrombolytic agent etc. are now approved of, or in off lavel use. However, the therapy according to a conventional medicine is the complicate procedures as described in (1) to (6), and cautious judgment by a specialist on the basis of enough knowledge and experience has been required. Namely, (1) in the case of thrombus-type cerebral infarction, respiratory control, blood pressure control and blood transfusion control are first conducted. (2) Blood gas and blood pressure are periodically measured. (3) At the acute stage, reactive high blood pressure is observed, but if complications in the heart and kidney are not observed, treatment for decreasing blood pressure is not conducted. (4) Then, in the early-acute stage case with no low absorption range observed in CT, the thrombus-lytic agent “urokinase” is used. (5) In the case where these agents are not applicable or in the case where 24 hours or more has elapsed after the onset, “ozagrel sodium” is administered. Or “argatroban” is administered. However, argatroban is not applicable to lacuna infarction. (6) To prevent the development of cerebral edema, “glycerin” or “mannitol” is administered at a suitable dosage.
- Further, the therapeutic effects of the drugs used heretofore are not satisfactory and further there is the danger that bleeding is often accompanied by their pharmacological effect. Accordingly, there is the problem that it is difficult for those except of skilled medical specialists to use these drugs.
- On the other hand, the following literatures describe that compounds having an inhibitory action on N type or P/Q type calcium channels can serve as an agent for inhibiting the death of neural cells or for protecting cerebral neural cells, an agent for treating or improving nervous diseases, an agent for treating or improving acute ischemic stroke, head trauma, death of neural cells, Alzheimer disease, cerebral circulatory metabolism disturbance, cerebral function disturbance or pain, an anti-spasm agent, an agent for treating or improving schizophrenia and an agent for preventing, treating or improving migraine, epilepsy, maniac-depressive psychosis, neural degenerative diseases (Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease), cerebral ischemia, epilepsy, head trauma, AIDS dementia complications, edema, anxiety disorder (generalized anxiety disorder) and diabetic neuropathy, and as an agent for preventing, treating or improving edema, anxiety disorder, schizophrenia, diabetic neuropathy and migraine.
- (1) Acute ischemia stroke: Annj. Rev. Physiol., 52 543-559, 1990.
- (2) Head trauma: SCRIP, No. 2203, 24, 1997.
- (3) Ischemia—death of cerebral neural cells: Advances in Pharmacology, 22, 271-297, 1991.
- (4) Alzheimer disease: Trends in Neuroscience, 16, 409, 1993.
- (5) Cerebral circulatory metabolism disturbance: Nichiyakurishi, 85, 323-328, 1985.
- (6) Cerebral function disturbance: Acta Neurol. Scand., 78:2, 14-200, 1998.
- (7) Analgesic: Drug of the Future, 23(2), 152-160, 1998.
- (8) Cerebral ischemia, migraine, epilepsy, maniac-depressive psychosis: Casopis Lekau Ceskych., 130(22-23), 625-630, 1991.
- (9) Neural degenerative diseases (Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease), cerebral ischemia, epilepsy, head trauma, and AIDS dementia complications: Revista de Neurologia., 24(134), 1199-1209, 1996.
- (10) Edema: Brain Research, 776,140-145,1997.
- (11) Anxiety disorder (generalized anxiety disorder), schizophrenia: Jyunkanseigyo (Circulation Control),14(2),139-145,1993.
- (12) Diabetic neuropathy: Shinkeinaika (Neurological Medicine),50,423-428,1999.
- (13) Migraine: Neurology,50(4),1105-1110,1998.
- In light of this, the present inventors have intensively studied for investigating a preparation which has a superior effect of treatment and amelioration for cerebral acute ischemic stroke for which no useful preparation is not found and has high safety which does not cause bloodshed tendency, focusing on a neuron-selective, potential-dependent calcium channel antagonist which directly effects on neural cell and inhibits the progression of infarction nidus. As a result, the present inventors have succeeded in synthesizing a novel nitrogen-containing compound which is represented by the formula (I), a salt thereof and a hydrate thereof, and further surprisingly have found that these compounds, a salt thereof or a hydrate thereof have the superior suppression action of neural cell death and protective action of cerebral neuron based on the P/Q type or N-type calcium channel antagonism, that cell infarction property and toxicity are remarkably reduced in comparison with a conventional calcium antagonist and that the compound and the like are superior in safety, and have completed the present invention.
- In the formula, Ar is (1) a C6-14 aromatic hydrocarbon cyclic group which may be substituted, (2) a 5- to 14-membered aromatic heterocyclic group which may be substituted, (3) a C1-6 alkyl group substituted with a C6-14 aromatic hydrocarbon cyclic group which may be substituted or (4) a C1-6 alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group which may be substituted; the ring A indicates a piperazine ring, homopiperazine ring, piperidine ring, homopiperidine ring, pyrrolidine ring or diazabicyclo[2,2,1]heptane ring which may be substituted, respectively; the ring B indicates (1) a C3-14 hydrocarbon ring which may be substituted or (2) a 5- to 14-membered heterocyclic ring which may be substituted; E indicates (1) a single bond, a group represented by the formula (2) —CO— or (3) —CH(OH)—; X indicates (1) a single bond, (2) an oxygen atom, (3) a sulfur atom, (4) a C1-6 alkylene chain which may be substituted, a group represented by (5) the formula —NR2— (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted), (6) —CO—, (7) —COO—, (8) —OOC—, (9) —CONR3— (wherein R3 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (10) —NR4CO— (wherein R4 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (11) —SO—, (12) —SO2—, (13) —SONR5— (wherein R5 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (14) —NR6SO— (wherein R6 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (15) —SO2NR7— (wherein R7 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (16) —NR8SO2— (wherein R8 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (17) >C═N—OR9 (wherein R9 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (18) —NR10—W3—O— (wherein R10 indicates a hydrogen atom or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted; and W3 indicates a C1-6 alkylene group which may be substituted), (19) —NH—CO—NH—, (20) —NH—CS—NH—, (21) —C(═NR15)NR16— (wherein R15 and R16 are the same as or different from each other and each indicates a hydrogen atom, nitrile group, a C1-6 alkyl group, a C2-6 alkenyl group, a C3-8 cycloalkyl group or a C3-8 cycloalkenyl group), (22) —NHC(═NH)—, (23) —O—CO—S—, (24) —S—CO—O—, (25) —OCOO—, (26) —NHCOO—, (27) —OCONH—, (28) —CO(CH2)mO— (wherein m indicates 0 or an integer of 1 to 6), (29) —CHOH— or (30) —CHOH(CH2)nO— (wherein n indicates 0 or an integer of 1 to 6); R1 indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) a C1-6 alkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (5) a C2-6 alkenyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (6) a C2-6 alkynyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (7) a C3-8 cycloalkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (9) a C1-6 alkoxy-C1-6 alkyl group, (10) an amino-C1-6 alkyl group in which the nitrogen may be substituted, (11) a group represented by the formula —N(R11)R12— (wherein R11 and R12 are the same as or different from each other and each indicates a hydrogen atom or a C1-6 alkyl group), (12) an aralkyl group, (13) morpholinyl group, (14) thiomorpholinyl group, (15) piperidyl group, (16) a pyrrolidinyl group or (17) a piperazinyl group; and D1, D2, W1 and W2 are the same as or different from each other and each indicates (1) a single bond or (2) a C1-6 alkylene chain which may be substituted,
- provided that, in the above definition, 1-[4-cyano-5-methyl-4-(2-cyano-5-thienyl)hexyl]-4-[2-(4-fluorophenoxy)ethyl]piperazine; 1-[4-cyano-5-methyl-4-(2-cyano-5-thienyl)hexyl]-4-[2-(3-fluorophenoxy)ethyl]piperazine; and 1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-fluorophenoxy)ethyl]piperazine are excluded.
-
- in the formula, R1 has the same meaning as in the above definition; R13 and R14 are the same as or different from each other and each indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) mercapto group, (5) a C1-6 alkyl group which may be substituted with any one or more groups selected from hydroxyl group and a halogen atom, (6) a C1-6 alkoxy group which may be substituted with any one or more groups selected from hydroxyl group, a halogen atom and a C1-6 alkoxycarbonyl group, (7) a nitro group, (8) an amino group which may be substituted, (9) cyano group, (10) carboxyl group, (11) a C1-6 alkoxycarbonyl group, (12) a C1-6 thioalkoxy group, (13) a C1-6 alkylsulfonyl group, (14) a lower acyl group, (15) a C6-14 aromatic hydrocarbon cyclic group which may be substituted, (16) a 5- to 14-membered aromatic heterocyclic group which may be optionally substituted, (17) an aryloxy group or (18) an aralkyloxy group, or (19) R13s themselves or R14s themselves may be bound together to form (i) an aliphatic ring which may be substituted, (ii) a heterocyclic ring which may be substituted or (iii) an alkylenedioxy group; n indicates 0 or an integer of 1 to 3; p indicates an integer of 1 to 6; q indicates an integer of 1 to 6; and r indicates 0 or an integer of 1 to 5,
- provided that, in the above definition, 1-[4-cyano-5-methyl-4-(2-cyano-5-thienyl)hexyl]-4-[2-(4-fluorophenoxy)ethyl]piperazine; 1-[4-cyano-5-methyl-4-(2-cyano-5-thienyl)hexyl]-4-[2-(3-fluorophenoxy)ethyl]piperazine; and 1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-fluorophenoxy)ethyl]piperazine are excluded and 27) the compound in the above-mentioned 1) may be a compound represented by the formula:
- in the formula, R1 and R2have the same meanings as defined above; R13 and R14 are the same as or different from each other and each indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) mercapto group, (5) a C1-6 alkyl group which may be substituted with any one or more groups selected from hydroxyl group and a halogen atom, (6) a C1-6 alkoxy group which may be substituted with any one or more groups selected from hydroxyl group, a halogen atom and a C1-6 alkoxycarbonyl group, (7) nitro group, (8) an amino group which may be substituted, (9) cyano group, (10) carboxyl group, (11) a C1-6 alkoxycarbonyl group, (12) a C1-6 thioalkoxy group, (13) a C1-6 alkylsulfonyl group, (14) a lower acyl group, (15) a C6-14 aromatic hydrocarbon cyclic group which may be substituted, (16) a 5- to 14-membered aromatic heterocyclic group which may be substituted, (17) an aryloxy group or (18) an aralkyloxy group, or (19) R13s themselves or R14s themselves may be bound together to form (i) an aliphatic ring which may be substituted, (ii) a heterocyclic ring which may be substituted or (iii) an alkylenedioxy group; n indicates 0 or an integer of 1 to 3; p indicates an integer of 1 to 6; q indicates an integer of 1 to 6; r indicates 0 or an integer of 1 to 5, and 28) in the above-mentioned 1), the compound may be any one selected from 4-[(4-cyano-5-methyl-4-phenyl)hexyl]-N-(4-fluorophenyl)-N′-(2-methylpropyl)-1(2H)-pyrazinecarboxyimidamide; 1-isopropyl-4-[4-(1-isobutyl-1H-benzo[d]imidazol-2-yl)piperazino]-1-phenylbutyl cyanide; 1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; 1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; 1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[3-(5-cyano-2-thienyl)propyl]piperazine; 1-[4-cyano-5-methyl-4-(3-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; 1-{4-cyano-5-methyl-4-[4-(2-cyano)-thienyl]hexyl}-4-[2-(3-cyanophenoxy)ethyl]piperazine; 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[(2-benzoxazolyl)amino]piperidine; 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3S)-3-[N-(2-cyanoethyl)-N-benzylamino]pyrrolidine; 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3R)-3-[N-(2-cyanoethyl)-N-benzylamino]pyrrolidine; 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-(benzothiazolyl]piperazine; 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[2-(6-methoxy)benzothiazolyl]piperazine; 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-(2-benzoxazolyl]piperazine; 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-(2-quinolinyl]piperazine; 4-[4-(1-methyl-1H-benzo[d]imidazol-2-yl)-1,4-diazepan-1-yl]-1-isopropyl-1-phenylbutyl cyanide; 4-[4-(1-ethyl-1H-benzo[d]imidazol-2-yl)-1,4-diazepan-1-yl]-1-isopropyl-1-phenylbutyl cyanide; ethyl 4-(4-cyano-5-methyl-4-phenylhexyl)-1-[2-(4-fluorophenoxy)ethyl]-2-piperazinecarboxylate; 1-[(2-oxo-1,2-dihydro-3-quinolyl)methyl]-4-[(4-cyano-5-methyl-4-phenyl)hexyl]piperidine; 4-[(4-cyano-5-methyl-4-phenyl)hexyl]-1-{[2-(methanesulfonylamino)phenyl]methyl}piperazine; 4-[(4-cyano-5-methyl-4-phenyl)hexyl]-1-{[2-(methanesulfonylamino)phenyl]methyl}piperidine; (S)-3-phenyl-2-amino-propanoic acid {1-[4-cyano-5-methyl-5-(2-thionyl)hexyl]piperazinyl}amide; 4-[4-(4-phenylpiperidinyl)piperidinyl]-1-isopropyl-1-phenylbutyl cyanide; 4-[4-(4-cyano-4-phenylpiperidinyl)piperidinyl]-1-isopropyl-1-phenylbutyl cyanide; and 4-[4-(4-benzylpiperidinyl)piperidinyl]-1-isopropyl-1-phenylbutyl cyanide.
-
- (in the formula, Ar is (1) a C6-14 aromatic hydrocarbon cyclic group which may be substituted, (2) a 5- to 14-membered aromatic heterocyclic group which may be substituted, (3) a C1-6 alkyl group substituted with a C1-14 aromatic hydrocarbon cyclic group which may be substituted or (4) a C1-6 alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group which may be substituted; the ring A indicates a piperazine ring, a homopiperazine ring, a piperidine ring, a homopiperidine ring, a pyrrolidine ring, a diazabicyclo[2, 2,1]heptane ring which may be substituted, respectively; the ring B indicates (1) a C3-14 hydrocarbon ring which may be substituted or (2) a 5- to 14-membered heterocyclic ring which may be substituted; E indicates (1) a single bond, a group represented by (2) the formula —CO— or (3) —CH(OH)—; X indicates (1) a single bond, (2) oxygen atom, (3) sulfur atom, (4) a C1-6 alkylene chain which may be substituted, a group represented by (5) the formula —NR2— (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted.), (6) —CO—, (7) —COO—, (8) —OOC—, (9) —CONR3— (wherein R3 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (10) —NR4CO— (wherein R4 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (11) —SO—, (12) —SO2—, (13) —SONR5— (wherein R5 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (14) —NR6SO— (wherein R6 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (15) —SO2NR7— (wherein R7 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (16) —NR8SO2— (wherein R8 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (17) >C═N—CR9 (wherein R9 indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (18) —NR10—W3—O— (wherein R10 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted; and W3 indicates a C1-6 alkylene group which may be substituted), (19) —NH—CO—NH—, (20) —NH—CS—NH—, (21) —C(═NR15)NR16— (wherein R15 and R16 are the same as or different from each other and each indicates a hydrogen atom, nitrile group, a C1-6 alkyl group, a C2-6 alkenyl group, a C3-8 cycloalkyl group or a C3-8 cycloalkenyl group), (22) —NHC(═NH)—, (23) —O—CO—S—, (24) —S—CO—O—, (25) —OCOO—, (26) —NHCOO—, (27) —OCONH—, (28) —CO(CH2)mO— (wherein m indicates 0 or an integer of 1 to 6), (29) —CHOH— or (30) —CHOH(CH2)nO— (wherein n indicates 0 or an integer of 1 to 6.); R1 indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) a C1-6 alkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (5) a C2-6 alkenyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (6) a C2-6 alkynyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (7) a C3-8 cycloalkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (9) a C1-6 alkoxy-C1-6 alkyl group, (10) an amino-C1-6 alkyl group in which the nitrogen atom may be substituted, (11) a group represented by the formula —N(R11)R12— (wherein R11 and R12 are the same as or different from each other and each indicates a hydrogen atom or a C1-6 alkyl group), (12) an aralkyl group, (13) morpholinyl group, (14) thiomorpholinyl group, (15) piperidyl group, (16) pyrrolidinyl group or (17) piperazinyl group; and D1, D2, W1 and W2 are the same as or different from each other and each indicates (1) a single bond or (2) a C1-6 alkylene chain which may be substituted,
- provided that, in the above definition, 1-[4-cyano-5-methyl-4-(2-cyano-5-thienyl)hexyl]-4-[2-(4-fluorophenoxy)ethyl]piperazine; 1-[4-cyano-5-methyl-4-(2-cyano-5-thienyl)hexyl]-4-[2-(3-fluorophenoxy)ethyl]piperazine; and 1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-fluorophenoxy)ethyl]piperazine are excluded), a salt thereof or a hydrate of them, and further, 30) the composition in the above-mentioned 29) may be a calcium antagonist, 31) the composition in the above-mentioned 29) may be a neuron-selective calcium antagonist, 32) the composition in the above-mentioned 29) may be a P/Q-type calcium channel and/or an N-type calcium channel inhibitor, 33) the composition in the above-mentioned 29) may be an agent for treating, preventing or improving a disease against which the inhibitory action of at least one of P/Q-type calcium channel and N-type calcium channel is efficacious, 34) the composition in the above-mentioned 29) may be an agent for inhibiting the death of neural cell or for protecting cerebral neural cells, 35) the composition in the above-mentioned 29) may be an agent for treating, preventing or improving neural disease, 36) the neural disease in the above-mentioned 35) may be acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, Huntington disease, cerebral circulatory metabolism disturbance, cerebral function disturbance, pain, spasm, schizophrenia, migraine, epilepsy, manic-depression, neural degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia and multiple sclerosis and 37) the composition in the above-mentioned 29) may be an analgesic.
- The present invention provides a method for preventing, treating or improving a disease against which a calcium antagonism is effective, a disease against which a neuron-selective calcium antagonism is effective or a disease against which a P/Q-type calcium channel inhibitory action and/or an N-type calcium channel inhibitory action is effective, by administering a pharmacologically effective amount of the compound represetend by the above formula (I), a salt thereof or a hydrate of them to a patient.
- The present invention provides a method for preventing, treating or improving neural disease or pain.
- Further, the present invention provides use of the compound represented by the above formula (I), a salt thereof or a hydrate of them for producing a calcium antagonist, a neuron-selective calcium antagonist, a P/Q-type calcium channel and/or an N-type calcium channel inhibitor, an agent for treating, preventing or improving a disease against which a P/Q-type calcium channel and/or an N-type calcium channel inhibitory action is efficacious, an agent for inhibiting the death of neural cells or for protecting cerebral neural cells.
- Additionally, the present invention provides use of the compound represented by the above formula (I), a salt thereof or a hydrate of them for producing an agent for treating, preventing or improving neural diseases or an analgesic.
- The neural disease is any one of disease selected from acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral circulation metabolic affection, cerebral dysfunction, pain, spasm, schizophrenia, migraine, epilepsy, manic-depression, neural degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia and multiple sclerosis.
- The meanings of the symbols, terms and the like described in the specification of the present application are illustrated below, and the present invention is illustrated in detail.
- The structural formula of a compound happens to represent a fixed isomer for convenience in the specification of the present application, but the present invention includes all of geometrical isomers which occur in the structure of the compound, optical isomers based on an asymmetric carbon, stereo-isomers, the isomers of tautomers and the like, and a mixture of the isomer. The present invention is not limited to the indication of the formulae for convenience, and may be one of the isomers and a mixture thereof. Accordingly, in the compounds of the present invention, there may exist an optically active body and a racemic body which have an asymmetric carbon atom in the molecule, but they are not limited in the present invention, and both of them are included therein. Further, crystal polymorphism happens to exist, but is not similarly limited, and the crystal form may be either single or a mixture of crystal forms and may be a hydrate in addition to an anhydride. A so-called metabolite which occurs due to decomposition of the compounds according to the present invention in vivo is also included in the scope of claim for patent of the present invention.
- The term “and/or” in the specification of the present application is used for the meanings which contain both the case of “and” and the case of “or”. Accordingly, for example, “A and/or B” includes both the case of “A and B” and the case of “A or B”, and indicates that it may be either of the cases.
- The “neural disease” in the specification of the present application mainly indicates acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral circulation metabolic affection, cerebral dysfunction, pain, spasm, schizophrenia, migraine, epilepsy, manic-depression, neural degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia and multiple sclerosis.
- The “analgesic” in the specification of the present application means a medicine which mitigates or removes pain by changing the perception of stimulation of a nociceptor without causing narcoticism and unconsciousness.
- The “halogen atom” used in the specification of the present application means atoms such as fluorine atom, chlorine atom, bromine atom and iodine atom, preferably fluorine atom, chlorine atom and bromine atom, and more preferably fluorine atom and chlorine atom.
- The “C1-6 alkyl group” used in the specification of the present application means an alkyl group having 1 to 6 carbon atoms, and the preferable examples thereof include linear or branched alkyl groups such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, n-hexyl group, 1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-propylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, 2-methylpentyl group and 3-methylpentyl group.
- The “C2-6 alkenyl group” used in the specification of the present application means an alkenyl group having 2 to 6 carbon atoms, and is preferably a linear or branched alkenyl group such as vinyl group, allyl group, 1-propenyl group, 2-propenyl group,isopropenyl group, 2-methyl-1-propenyl group, 3-methyl-1-propenyl group, 2-methyl-2-propenyl group, 3-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 1-hexenyl group, 1,3-hexanedienyl group and 1,6-hexanedienyl group.
- The “C2-6alkynyl group” used in the specification of the present application means an alkynyl group having 2 to 6 carbon atoms, and is preferably a linear or branched alkynyl group such as ethynyl group, 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group, 3-methyl-1-propynyl group, 1-ethynyl-2-propynyl group, 2-methyl-3-propynyl group, 1-pentynyl group, 1-hexynyl group, 1,3-hexanediynyl group and 1,6-hexanediynyl group.
- The “C1-6 alkoxy group” used in the specification of the present application means a “C1-6 alkyloxy group” in which an oxygen atom is bonded with a group having the same meaning as the C1-6 alkyl group in the fore-mentioned definition, and the preferable examples thereof include methoxy group, ethoxy group, n-propoxy group, isopropoxy group, sec-propoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, n-pentyloxy group, isopentyloxy group, sec-pentyloxy group, n-hexoxy group, isohexoxy group, 1,1-dimethylpropyloxy group, 1,2-dimethylpropoxy group, 2,2-dimethylpropyloxy group, 2-ethylpropoxy group, 1-methyl-2-ethylpropoxy group, 1-ethyl-2-methylpropoxy group, 1,1,2-trimethylpropoxy group, 1,1,2-trimethylpropoxy group, 1,1-dimethylbutoxy group, 1,2-dimethylbutoxy group, 2,2-dimethylbutoxy group, 2,3-dimethylbutyloxy group, 1,3-dimethylbutyloxy group, 2-ethylbutoxy group, 1,3-dimethylbutoxy group, 2-methylpentoxy group, 3-methylpentoxy group, hexyloxy group etc.
- The “C1-6 alkenyloxy group” used in the specification of the present application means a group in which oxygen atom is bound to a group having the same meaning as the C1-6 alkenyl group defined above, and the preferable examples thereof include vinyloxy group, allyloxy group, 1-propenyloxy group, 2-propenyloxy group, isopropenyloxy group, 2-methyl-1-propenyloxy group, 3-methyl-1-propenyloxy group, 2-methyl-2-propenyloxy group, 3-methyl-2-propenyloxy group, 1-butenyloxy group, 2-butenyloxy group, 3-butenyloxy group, 1-pentenyloxy group, 1-hexenyloxy group, 1,3-hexanedienyloxy group, 1,6-hexanedienyloxy group etc.
- The “C3-8 cycloalkyl group” used in the specification of the present application means a cycloalkyl group in which the ring is formed by 3 to 8 carbon atoms, and the preferable group includes cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group etc. Further, the “C3-8cycloalkane” used in the specification of the present application means a ring corresponding to the above-mentioned C3-8 cycloalkyl group.
-
- The “aromatic cyclic group” used in the specification of the present application is a term meaning a C6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group.
- (1) Examples of the above-mentioned “C6-14 aromatic hydrocarbon cyclic group” include mono-cyclic, di-cyclic or tri-cyclic C6-14 aromatic hydrocarbon groups such as phenyl group, indenyl group, 1-naphthyl group, 2-naphthyl group, azulenyl group, hepthalenyl group, biphenyl group, indathenyl group, acenaphthyl group, fluorenyl group, phenalenyl group, phenanthrenyl group, anthracenyl group, cyclopentacyclooctenyl group, benzocyclooctenyl group, and the like.
- (2) Examples of the “5- to 14-membered aromatic heterocyclic group” include a mono-cyclic, di-cyclic or tri-cyclic 5- to 14-membered aromatic heterocyclic ring which contains any one or more of hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom, and for example:
- (i) aromatic heterocyclic rings containing nitrogen such as pyrrolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazolyl group, tetrazolyl group, benzotriazolyl group, pyrazolyl group, imidazolyl group, benzimidazolyl group, indolyl group, isoindolyl group, indolizinyl group, purinyl group, indazolyl group, quinolyl group, isoquinolyl group, quinolizyl group, phthalazyl group, naphthylidinyl group, quinoxalyl group, quinazolinyl group, cinnolinyl group, pteridinyl group, imidazotriazinyl group, pyrazinopyridazinyl group, acridinyl group, phenanthridinyl group, carbazolyl group, carbazolinyl group, perimidinyl group, phenanthrolinyl group, phenacinyl group, imidazopyridinyl group, imidazopyrimidinyl group and pyrazolopyridinyl group;
- (ii) aromatic heterocyclic rings containing sulfur such as thienyl group and benzothienyl group;
- (iii) aromatic heterocyclic rings containing oxygen such as furyl group, pyranyl group, cyclopentapyranyl group, benzofuranyl group and isobenzofuranyl group; and
- (iv) aromatic heterocyclic rings containing 2 or more different kinds of hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom, such as thiazolyl group, isothiazolyl group, benzothiazolyl group, benzthiazolyl group, phenothiazinyl group, isoxazolyl group, furazanyl group, phenoxazinyl group, oxazolyl group, benzoxazolyl group, oxadiazolyl group, pyrazolooxazolyl group, imidazothiazolyl group, thienofuranyl group, furopyrrolyl group, pyridoxazinyl group may be proposed.
- The “C3-14hydrocarbon ring” used in the specification of the present application means a C3-8 cycloalkane, a C3-8 cycloalkene or a C6-14 aromatic hydrocarbon ring, and the meanings of these rings refer to the same meaning as a C3-8 cycloalkane, a C3-8 cycloalkene and a C6-14 aromatic hydrocarbon ring defined above.
- The “5- to 14-membered heterocyclic ring” used in the specification of the present application means a 5- to 14-membered heterocyclic ring containing any one or more of hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom, and an aromatic heterocyclic ring and a non-aromatic heterocyclic ring are included in the ring. Here, (1) the above-mentioned “5- to 14-membered aromatic heterocyclic ring” have the same meaning as a 5- to 14-membered aromatic heterocyclic ring defined above. Further, (2) the preferable ring as the “5- to 14-membered non-aromatic heterocyclic ring” includes 5- to 14-membered non-aromatic heterocyclic rings such as pyrrolidine ring, pyrroline ring, piperidine ring, piperazine ring, imidazoline ring, pyrazolidine ring, imidazolidine ring, morpholine ring, tetrahydrofuran ring, tetrahydropyran ring, aziridine ring, oxirane ring, oxathiorane ring, pyridone ring etc., and condensed rings such as phthalimide ring, succinimide ring etc.
- The “hydrocarbon group” used in the specification of the present application specifically means a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-8 cycloalkyl, a C3-8 cycloalkenyl group or a C6-14 aromatic hydrocarbon cyclic group, and the respective meanings are the same as defined above.
- Meaning of Ar
- In the compound represented by the above formula (I) according to the present invention, Ar indicates (1) a C6-14 aromatic hydrocarbon cyclic group which may be substituted, (2) a 5- to 14-membered aromatic heterocyclic group which may be substituted, (3) a C1-6 alkyl group substituted with a C6-14 aromatic hydrocarbon cyclic group which may be substituted or (4) a C1-6 alkyl group substituted with a 5- to 14-membered aromatic heterocyclic group which may be substituted.
- Examples of the above-mentioned “C6-14 aromatic hydrocarbon cyclic group” preferably include phenyl group, pentalenyl group, indenyl group, naphthyl group, 1,2,3,4-tetrahydronaphthyl group, azulenyl group, hepthalenyl group, benzocyclooctenyl group, tetranyl group, phenanthrenyl group etc., and more preferably phenyl group, naphthyl group etc.
- Further, the preferable examples of the “5- to 14-membered aromatic heterocyclic group” include pyrrolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazolyl group, tetrazolyl group, benzotriazolyl group, pyrazolyl group, imidazolyl group, benzimidazolyl group, indolyl group, isoindolyl group, indolizinyl group, purinyl group, indazolyl group, quinolyl group, isoquinolyl group, quinolizyl group, phthalazyl group, naphthylidinyl group, quinoxalyl group, quinazolinyl group, cinnolinyl group, pteridinyl group, imidazotriazinyl group, pyrazinopyridazinyl group, acridinyl group, phenanthridinyl group, carbazolyl group, carbazolinyl group, perimidinyl group, phenanthrolinyl group, phenacinyl group, imidazopyridinyl group, imidazopyrimidinyl group, pyrazolopyridinyl group, thienyl group, benzothienyl group, furyl group, pyranyl group, cyclopentapyranyl group, benzofuranyl group, isobenzofuranyl group, thiazolyl group, isothiazolyl group, benzothiazolyl group, benzthiazolyl group, phenothiazinyl group, isoxazolyl group, furazanyl group, phenoxazinyl group, oxazolyl group, benzoxazolyl group, oxadiazolyl group, pyrazolooxazolyl group, imidazothiazolyl group, thienofuranyl group, phlopyrrolyl group, pyridoxazinyl group etc., more preferably thienyl group, pyridyl group etc., and further preferably thienyl group.
- When Ar is the “C6-14 aromatic hydrocarbon cyclic group optionally substituted” or the “5- to 14-membered aromatic heterocyclic group optionally substituted”, examples of the “substituent” include (i) hydroxyl group, (ii) a halogen atom (for example, fluorine atom, chlorine atom, bromine atom and an iodine atom), (iii) nitrile group, (iv) a C1-6 alkyl group (preferably, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, n-hexyl group, 1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-propylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, 2-methylpentyl group, 3-methylpentyl group etc.), (v) a C2-6alkenyl group (preferably, vinyl group, allyl group, 1-propenyl group, 2-propenyl group, isopropenyl group, 2-methyl-1-propenyl group, 3-methyl-1-propenyl group, 2-methyl-2-propenyl group, 3-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 1-hexenyl group, 1,3-hexanedienyl group, 1,6-hexanedienyl group etc.), (vi) a C2-6alkynyl group (preferably, ethynyl group, 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group, 3-methyl-1-propynyl group, 1-ethynyl-2-propynyl group, 2-methyl-3-propynyl group, 1-pentynyl group, 1-hexynyl group, 1,3-hexanediynyl group, 1,6-hexanediynyl group etc.), (vii) a C1-6alkoxy group (preferably, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, sec-propoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, n-pentyloxy group, isopentyloxy group, sec-pentyloxy group, n-hexoxy group, isohexoxy group, 1,1-dimethylpropyloxy group, 1,2-dimethylpropoxy group, 2,2-dimethylpropyloxy group, 2-ethylpropoxy group, 1-methyl-2-ethylpropoxy group, 1-ethyl-2-methylpropoxy group, 1,1,2-trimethylpropoxy group, 1,1,2-trimethylpropoxy group, 1,1-dimethylbutoxy group, 1,2-dimethylbutoxy group, 2,2-dimethylbutoxy group, 2,3-dimethylbutyloxy group, 1,3-dimethylbutyloxy group, 2-ethylbutoxy group, 1,3-dimethylbutoxy group, 2-methylpentoxy group, 3-methylpentoxy group, hexyloxy group etc.), (viii) C1-6 alkylthio group (preferably, methylthio group, ethylthio group, n-propylthio group, isopropylthio group, n-butylthio group, isobutylthio group, sec-butylthio group, tert-butylthio group, n-pentylthio group, 1,1-dimethylpropylthio group, 1,2-dimethylpropylthio group, 2,2-dimethylpropylthio group, 1-ethylpropylthio group, 2-ethylpropylthio group, n-hexylthio group, 1-methyl-2-ethylpropylthio group, 1-ethyl-2-methylpropylthio group, 1,1,2-trimethylpropylthio group, 1-propylpropylthio group, 1-methylbutylthio group, 2-methylbutylthio group, 1,1-dimethylbutylthio group, 1,2-dimethylbutylthio group, 2,2-dimethylbutylthio group, 1,3-dimethylbutylthio group, 2,3-dimethylbutylthio group, 2-ethylbutylthio group, 2-methylpentylthio group, 3-methylpentylthio group etc.), (ix) a C1-6 alkoxycarbonyl group, (x) a hydroxyl C1-6alkyl group, (xi) a halogenated C1-6alkyl group, (xii) a hydroxyimino C1-6alkyl group, (xiii) nitro group, (xiv) an amino group in which the nitrogen atom may be substituted, (xv) a carbamoyl group in which the nitrogen atom may be substituted, (xvi) a sulfamoyl group in which the nitrogen atom may be substituted, (xvii) a lower acyl group, (xviii) an aromatic acyl group, (xix) a C1-6 alkylsulfonyl group such as methylsulfonyl group, etc., and the “substitutent” is preferably (a) hydroxyl group, (b) a halogen atom, (c) nitrile group, (d) a C1-6alkyl group, (e) a C1-6alkylsulfonyl group, (f) a C1-6 alkoxy group, (g) a C1-6 alkylthio group etc., and, more preferably, nitrile group or a halogen atom (for example, fluorine atom etc.).
-
- wherein R13a, R13b and R13c are the same as or different from each other, and each indicates a hydrogen atom, a halogen atom or cyano group.
- In the compound represented by the above formula (I) according to the present invention, when Ar is the “C1-6 alkyl group substituted with a C6-14 aromatic hydrocarbon cyclic group which may be substituted” or the “C1-6 alkyl group substituted with 5- to 14-membered aromatic heterocyclic group which may be substituted”, the “C6-14 aromatic hydrocarbon cyclic group which may be substituted” or the “5- to 14-membered aromatic heterocyclic group which may be substituted” has the same meaning as the C6-14 aromatic hydrocarbon cyclic group which may be substituted or the 5- to 14-membered aromatic heterocyclic group which may be substituted in the above-mentioned definition, respectively. The C1-6alkyl group substituted with those groups means a C1-6alkyl group substituted with such groups. Here, preferable examples of the “C1-6alkyl group” include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, n-hexyl group, 1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-propylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 2-ethylbutyl group, 2-methylpentyl group, 3-methylpentyl group etc. Preferable examples of the “C1-6 alkyl group substituted with an aromatic group which may be substituted” include a benzyl group, a phenethyl group, a phenylpropyl group, a naphthylmethyl group, a naphthylethyl group, a naphthylpropyl group, a pyridylmethyl group, a pyrazinylmethyl group, a pyrimidinylmethyl group, a pyrrolylmethyl group, an imidazolylmethyl group, a pyrazolylmethyl group, aquinolylmethyl group, an isoquinolylmethyl group, furfuryl group, thienylmethyl group, thiazolylmethyl group etc., which maybe optionally substituted respectively with one ore more groups selected from nitrile group, ahalogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.) etc.
- Further, preferable examples of the “C1-6 alkoxycarbonyl group” in the definition of Ar include methoxycarbonyl group, ethoxycarbonyl group, n-propoxycarbonyl group, isopropoxycarbonyl group, sec-propoxycarbonyl group, n-butoxycarbonyl group, isobutoxycarbonyl group, sec-butoxycarbonylcarbonyl group, tert-butoxycarbonylcarbonyl group, n-pentoxycarbonyl group, isopentoxycarbonyl group, sec-pentoxycarbonyl group, tert-pentoxycarbonyl group, n-hexoxycarbonyl group, isohexoxycarbonyl group, 1,2-dimethylpropoxycarbonyl group, 2-ethylpropoxycarbonyl group, a 1-methyl-2-ethylpropoxycarbonyl group, 1-ethyl-2-ethylpropoxycarbonyl group, 1,1,2-trimethylpropoxycarbonyl group, 1,1-dimethylbutoxycarbonyl group, 2,2-dimethylbutoxycarbonyl group, 2-ethylbutoxycarbonyl group, 1,3-dimethylbutoxycarbonyl group, 2-methylpentoxycarbonyl group, 3-methylpentoxycarbonyl group etc.
- Preferable examples of the above-mentioned “hydroxy C1-6 alkyl group” include linear or branched C1-6 alkyl groups such as hydroxymethyl group, 1-hydroxyethyl group, 2-hydroxyethyl group, 3-hydroxy-n-propyl group, hydroxy-isopropyl group, hydroxy-sec-propyl group, hydroxy-n-butyl group, hydroxy-isobutyl group, hydroxy-sec-butyl group, hydroxy-tert-butyl group, hydroxy-n-pentyl group, hydroxy-iso-pentyl group, hydroxy-n-hexyl group and hydroxy-iso-hexyl group.
- The above-mentioned “halogenated C1-6 alkyl group” means a group in which one or more of the same or different halogen atoms are bound to the “C1-6 alkyl group” having the same meaning as the C1-6 alkyl group defined above, and preferable examples thereof include fluoromethyl group, difluoromethyl group, trifluoromethyl group, chloromethyl group, 1-fluoroethyl group, 2-fluoroethyl group, 1,1-difluoroethyl group, 1,2-difluoroethyl group, 2,2-difluoroethyl group, 2,2,2-trifluoroethyl group etc.
- The above-mentioned “hydroxyimino C1-6 alkyl group” means a group in which hydroxyimino group is bound to a group having the same meaning as the C1-6 alkyl group defined above.
- The “amino group in which a nitrogen atom may be optionally substituted” means an amino group which is represented by the formula —N(R15)R16— (wherein R15and R16 are the same as or different from each other and each indicates (1) a hydrogen atom, (2) a C1-6alkyl group, a C1-6alkenyl group or a C1-6 alkynyl group which may be substituted respectively with one or more groups selected from a halogen atom, a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group and a C1-6 alkoxy group, (3) a C3-8 cycloalkyl group or a C3-8 cycloalkenyl group which may be substituted with a halogen atom, (4) a carbonyl group substituted with any one of groups selected from a C1-6alkyl group, a C1-6alkenyl group, a C1-6alkynyl group, a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a C1-6 alkoxy group, a C6-14 aromatic hydrocarbon cyclic group, a 5- to 14-membered aromatic heterocyclic group and a 5- to 14-membered non-aromatic heterocyclic group which may be substituted with a halogen atom, respectively, (5) a carbamoyl group substituted with any one of groups selected from a C1-6 alkyl group, a C1-6 alkenyl group, a C1-6 alkynyl group, a C6-14 aromatic hydrocarbon cyclic group and a 5- to 14-membered aromatic heterocyclic group or (6) a sulfonyl group substituted with any one of groups selected from a C1-6 alkyl group, a C1-6 alkenyl group and a C1-6 alkynyl group, or (7) R15 and R16 may be bound together to form a 3- to 10-membered non-aromatic heterocyclic group containing the nitrogen atom to which they are bound, and the heterocyclic group may be substituted with one or more of groups selected from hydroxyl group, a halogen atom, a C1-6 alkoxy group etc.).
- Examples of the preferable amino group include unsubstituted amino group, methylamino group, dimethylamino group, ethylamino group, diethylamino group, methylethylamino group, acetamide (CH3CONH—) group, propionamide group, methanesulfonamide group, ethanesulfonamide group, pyrrolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, 4-morpholinyl group, 4-thiomorpholinyl etc. The more preferable examples of the “amino group which may be substituted” include an amino group which may be substituted with one or two groups selected from a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-8 cycloalkyl group and a C3-8 cycloalkenyl group.
- The above-mentioned “carbamoyl group in which the nitrogen atom may be substituted” means a carbamoyl group in which the nitrogen atom may be substituted with a group selected from a C1-6alkyl group, a C2-6alkenyl group, a C2-6 alkynyl group, a C3-8 cycloalkyl group and a C3-8 cycloalkenyl group. Further, the carbamoyl group naturally includes a case in which the nitrogen atom of the carbamoyl group is a portion of a cyclic amine. The preferable examples of the “carbamoyl group in which the nitrogen atom may be substituted” includes unsubstituted carbamoyl group, N-methylcarbamoyl group, N,N-dimethylcarbamoyl group, N-ethylcarbamoyl group, N,N-diethylcarbamoyl group, N-methyl-N-ethylcarbamoyl group, 1-pyrrolidinylcarbonyl group, 1-pyrazolinylcarbonyl group, 1-piperidylcarbonyl group, 1-piperazinylcarbonyl group, 4-morpholinylcarbonyl group, 4-thiomorpholinylcarbonyl group etc.
- The above-mentioned “sulfamoyl group in which the nitrogen atom may be substituted” means a sulfamoyl group in which the nitrogen atom may be optionally substituted with a group selected from a C1-6alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group etc. Further, the sulfamoyl group naturally includes a case in which the nitrogen atom of the sulfamoyl group is a portion of a cyclic amine. The preferable examples of the “sulfamoyl group in which the nitrogen atom may be substituted” include unsubstituted sulfamoyl group (—SO2NH2), N-methylsulfamoyl group (—SO2NHCH2), N,N-dimethylsulfamoyl group (—SO2NH(CH3)2), N-ethylsulfamoyl group (—SO2NHC2H5), N,N-diethylsulfamoyl group (—SO2NH(C2H5)2), N-methyl-N-ethylsulfamoyl group (—SO2N(CH3)C2H5), 1-pyrrolidinylsulfonyl group, 1-pyrazolinylsulfonyl group, 1-piperidylsulfonyl group, 1-piperazinylsulfonyl group, 4-morpholinylsulfonyl group, 4-thiomorpholinylsulfonyl group etc.
- The above-mentioned “lower acyl group” means a linear or molecular chain acyl group derived from a fatty acid having 1 to 6 carbons, and the preferable examples of the group include formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group etc.
- Meaning of the Ring A
- In the compound represented by the above formula (I) according to the present invention, the ring A indicates any one ring selected from piperazine ring, homopiperazine ring, piperidine ring, homopiperidine ring, pyrrolidine ring and diazabicyclo[2,2,1]heptane ring. Examples of the ring A preferably include a piperazine ring, a homopiperazine ring, a piperidine ring, a homopiperidine ring, a pyrrolidine ring, more preferably a piperidine ring, a piperazine ring, and further more preferably a piperazine ring. When the ring A is piperazine ring, piperidine ring, pyrrolidine ring or diazabicyclo[2,2,1]heptane ring, an aspect represented by the formula:
-
- Meaning of Ring B
- In the compound represented by the above formula (I) according to the present invention, the ring B indicates (1) a C3-14 hydrocarbon ring which may be substituted, or (2) a 5- to 14-memberedheterocyclic ring which may be substituted.
- (1) The “C3-14 hydrocarbon ring” in the definition of the ring B means a C3-8 cycloalkane, a C3-8 cycloalkene or a C6-14 aromatic hydrocarbon ring. When the ring B is “a C3-8 cycloalkane”, examples of the ring preferably include 3- to 8-membered cycloalkanes such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane etc., and more preferably cyclopropane, cyclobutane, cyclopentane, cyclohexane etc. When the ring B is “a C3-8 cycloalkene”, examples of the ring preferable include 3- to 8-membered cycloalkenes such as cyclopropene, cyclobutene, cyclopentene, cyclohexene and cycloheptene, and further, a non-aromatic unsaturated hydrocarbon ring in which a carbon-carbon double bond in an aromatic hydrocarbon ring is partially saturated. Cyclopropene, cyclobutene, cyclopentene, cyclohexene etc. are more preferred. When the ring B is a “C6-14 aromatic hydrocarbon ring”, the ring preferably includes benzene ring, pentalene ring, indene ring, naphthalene ring, 1,2,3,4-tetrahydronaphthalene ring, azulene ring, heptalene ring, benzocyclooctene ring, phenanthrene ring etc., and the condensed ring of a C3-8 cycloalkane with an aromatic hydrocarbon ring and the condensed ring of a C3-8cycloalkene with an aromatic hydrocarbon ring are also included in the “C6-14 aromatic hydrocarbon ring”.
- (2) The “5- to 14-membered heterocyclic ring” in the definition of the ring B indicates a 5- to 14-membered non-aromatic heterocyclic ring or a 5- to 14-membered aromatic heterocyclic ring. When the ring B is the “5- to 14-membered non-aromatic heterocyclic ring”, the ring preferably includes pyrrolidine ring, pyrroline ring, piperazine ring, imidazoline ring, pyrazolidine ring, imidazolidine ring, morpholine ring, tetrahydropyran ring, aziridine ring, oxirane ring, phthalimide ring, succinimide ring etc. When the ring B is a “5- to 14-membered aromatic heterocyclic ring”, the preferable ring includes pyrrole ring, pyridine ring, pyridazine ring, pyrimidine ring, pyrazine ring, pyrazole ring, imidazole ring, indole ring, isoindolyl ring, indolizine ring, purine ring, indazole ring, quinoline ring, isoquinoline ring, quinolizine ring, phthalazine ring, naphthylidine ring, quinoxaline ring, quinazoline ring, benzimidazole ring, cinnoline ring, pteridine ring, imidazotriazine ring, pyrazinopyridazine ring, acridine ring, phenanthridine ring, carbazole ring, carbazoline ring, perimidine ring, phenanthroline ring, phenacine ring, thiophene ring, benzothiophene ring, furan ring, pyran ring, cyclopentapyran ring, benzofuran ring, isobenzofuran ring, thiazole ring, isothiazole ring, benzthiazole ring, benzothiazole ring, phenothiazine ring, isoxazole ring, furazane ring, phenoxazine ring, pyrazolooxazole ring, imidazothiazole ring, thienofuran ring, furopyrrole ring, pyridoxazine ring, 1,4-benzodioxane ring, benzoxazole ring, 2-keto-1-imidazole ring, oxazole ring, 1,2,4-oxadiazole ring, indanone ring, 1,2,3,4-tetrahydroquinoline ring etc.
- Examples of the “substituent” in the “C3-14 hydrocarbon ring which may be substituted” or the “5- to 14-membered heterocyclic ring which may be substituted” in the ring B include one or more groups selscted from (1) hydroxyl group, (2) a halogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.), (3) nitrile group, (4) a C1-6alkyl group which may be substituted (for example, a C1-6 alkyl group which may be substituted with one or moregroupsselected from hydroxyl group, a halogen atom, nitrile group, hydroxyimino group etc.), (5) a C2-6 alkenyl group which may be substituted (for example, a C2-6alkenyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom, nitrile group, hydroxyimino group etc.), (6) a C1-6alkoxy group which may be substituted (for example, a C1-6 alkenyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom, nitrile group, hydroxyimino group etc.), (7) a C1-6 alkylthio group which may be substituted, (8) a C1-6 alkoxycarbonyl group, (9) nitro group, (10) an amino group in which the nitrogen atom may be substituted, (11) a carbamoyl group in which the nitrogen atom may be substituted, (12) a sulfamoyl group in which the nitrogen atom may be substituted, (13) a lower acyl group, (14) an aromatic acyl group, (15) a C1-6 alkylsulfonyl group (for example, methylsulfonyl group, ethylsulfonyl group etc.), (16) a C6-14 aromatic hydrocarbon cyclic group, (17) a 5- to 14-membered aromatic heterocyclic group, and (18) an aralkyl group (for example, benzyl group, phenethyl group etc.), and it is preferably (i) hydroxyl group, (ii) a halogen atom (for example, fluorine atom, chlorine atom, bromine atom etc.), (iii) nitrile group, (iv) a C1-6 alkyl group (for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group etc.), (v) a C6-14 aromatic hydrocarbon cyclic group, (vi) a 5- to 14-membered aromatic heterocyclic group, etc., and more preferably, nitrile group, fluorine atom, chlorine atom etc.
- The most preferable aspect of the ring B is a C6-14 aromatic hydrocarbon ring or a 5- to 14-membered aromatic heterocyclic ring which may be substituted, respectively. Specific examples include a benzene ring, a thiophene ring, a pyridine ring, a 1,4-benzodioxane ring, an indole ring, a benzothiazole ring, a benzoxazole ring, a benzimidazole ring, a 2-keto-1-imidazole ring, a thiazole ring, a oxazole ring, an isoxazole ring, a 1,2,4-oxadiazole ring, an indanone ring, a benzofurane ring, a quinoline ring, a l,2,3,4-tetrahydroquinoline ring, a naphthalene ring, a 1,2,3,4-tetrahydronaphthalene ring etc., which may be substituted with one or more groups selected from nitrile group, a halogen atom (for example, fluorine atom, chlorine atom, bromine atom etc.), a C6-14 aromatic hydrocarbon cyclic group (for example, phenyl group, naphthyl group etc.), a 5- to 14-membered aromatic heterocyclic group (for example, pyridyl group, thienyl group, furyl group etc.), a C1-6 alkyl group (for example, methyl group, ethyl group, n-propyl group, isopropyl group, isobutyl group etc.), a lower acyl group and a C1-6alkylsulfonyl group (for example, methylsulfonyl group, ethylsulfonyl group etc.), respectively.
- Meaning of E
- In the compound represented by the above formula (I) according to the present invention, the bonding chain E indicates a single bond, a group represented by the formula —CO— or —CH(OH)—. The most preferable aspect in E is a single bond.
- Meaning of X
- In the compound represented by the above formula (I) according to the present invention, the bonding chain X indicates (1) a single bond, (2) oxygen atom, (3) sulfur atom, (4) a C1-6 alkylene chain which may be substituted, a group represented by (5) the formula —NR2— (wherein R2 indicates a hydrogen atom, or a C1-6alkyl group, a C3-8cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted), (6) —CO—, (7) —COO—, (8) —OOC—, (9) —CONR3—0 (wherein R3indicates a hydrogen atom or a C1-6 alkyl group which may be substituted), (10) —NR4CO— (wherein R4 indicates a hydrogen atom, or a C1-6 alkyl group which may be optionally substituted), (11) —SO—, (12) —SO2—, (13) —SONR5— (wherein R5 indicates a hydrogen atom, or a C1-6 alkyl group which may be substituted), (14) —NR6SO— (wherein R6 indicates a hydrogen atom, or a C1-6 alkyl group which may be substituted), (15) —SO2NR7— (wherein R7indicates a hydrogen atom, or a C1-6 alkyl group which may be substituted), (16) —NR8SO2— (wherein R8 indicates a hydrogen atom, or a C1-6 alkyl group which may be substituted), (17) >C═N—OR9 (wherein R9 indicates a hydrogen atom, or a C1-6 alkyl group which maybe substituted), (18) —NR10—W3—O— (wherein R10 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted; and W3 indicates a C1-6 alkylene group which may be substituted), (19) —NH—CO—NH—, (20) —NH—CS—NH—, (21) —C(═NR15)NR16— (wherein R15and R16 are the same as or different from each other and indicates a hydrogen atom, nitrile group, a C1-6 alkyl group, a C2-6 alkenyl group, a C3-8 cycloalkyl group or a C3-8 cycloalkenyl group), (22) —NHC(═NH)—, (23) —O—CO—S—, (24) —S—CO—O—, (25) —OCOO—, (26) —NHCOO—, (27) —OCONH—, (28) —CO(CH2)mO— (wherein m indicates 0 or an integer of 1 to 6), (29) —CHOH—, or (30) —CHOH(CH2)nO— (wherein n indicates 0 or an integer of 1 to 6).
- When X is the “C1-6 alkylene chain which may be substituted”, the “C1-6 alkylene chain” indicates a chain derived from a linear or branched C1-6 alkane, and the examples thereof include methylene, ethylene, ethylidene, trimethylene, isopropylidene, propylene, tetramethylene, 1,2-butylene, 1,3-butylene, 2,3-butylene, isobutylene etc.
- In the definition of X, the most preferable examples of the “C1-6 alkyl group which may be substituted” indicated by R2 to R10 include a C1-6alkyl group (for example, methyl group, ethyl group, n-propyl group, isopropyl group etc.) which may be substituted with one or more groups selected from hydroxyl group, a halogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.), nitrile group, nitro group, a C1-6 alkoxy group (for example, methoxy group, ethoxy group, n-propoxy group, isopropoxy group etc.), etc.
- In the definition of X, the preferable examples of the “C3-8 cycloalkyl group” indicated by R2 and R10 includes cyclopropanyl group, cyclobutanyl group, cyclopentanyl group, cyclohexanyl group, cycloheptanyl group etc., and the group is more preferably cyclopropanyl group, cyclobutanyl group, cyclopentanyl group, cyclohexanyl group etc.
- In the definition of X, the preferable examples of the “lower acyl group” indicated by R2 and R10 include formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group etc.
- In the definition of X, the preferable examples of the “C1-6 alkylsulfonyl group” indicated by R2 and R10 include methylsulfonyl group, ethylsulfonyl group, n-propylsulfonyl group, isopropylsulfonyl group, sec-propylsulfonyl group, n-butylsulfonyl group, isobutylsulfonyl group, sec-butylsulfonyl group, tert-butylsulfonyl group, n-pentylsulfonyl group, isopentylsulfonyl group, sec-pentylsulfonyl group, tert-pentylsulfonyl group, n-hexylsulfonyl group, isohexylsulfonyl group, 1,2-dimethylpropylsulfonyl group, 2-ethylpropylsulfonyl group, 1-methyl-2-ethylpropylsulfonyl group, 1-ethyl-2-methylpropylsulfonyl group, 1,1,2-trimethylpropylsulfonyl group, 1,1,2-trimethylpropylsulfonyl group, 1,1-dimethylbutylsulfonyl group, 2,2-dimethylbutylsulfonyl group, 2-ethylbutylsulfonyl group, 1,3-dimethylbutylsulfonyl group, 2-methylpentylsulfonyl group, 3-methylpentylsulfonyl group etc.
- In the definition of X, R15 and R16 are the same as or different from each other and each indicates a hydrogen atom, nitrile group, a C1-6 alkyl group, a C2-6 alkenyl group, a C3-8 cycloalkyl group or a C3-8 cycloalkylene group. The preferable groups of both of them are the same as or different from each other and each means a hydrogen atom, nitrile group, methyl group, ethyl group, n-propyl group, isopropyl group, cyclopropyl group, cyclopentyl group, cyclohexyl group etc. It is more preferable that R15 is nitrile group, ethyl group, n-propyl group, isopropyl group or cyclohexyl group, and R16 is a hydrogen atom. Further, the most preferable aspect of the formula —C(═NR15)NR16— is a chain represented by the formula —C(═NCN)NH—.
- The meanings of the respective groups listed in the definition of X are described above. (1) The preferable aspect of X is a single bond, oxygen atom, sulfur atom, a C1-6 alkylene chain which may be substituted, a group represented by the formula —NR2— (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted), —CO—, —NR10—W3—O— (wherein R10 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted; and W3 indicates a C1-6alkylene group which may be substituted) and —NH—SO2—. (2) The more preferable aspect is oxygen atom, a C1-6 alkylene chain which may be substituted, a group represented by the formula —NR2— (wherein R2 indicates a hydrogen atom, or a C1-6alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6alkylsulfonyl group which may be substituted), —CO—, —NR10—W3—O— (wherein R10 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted; and W3 indicates a C1-6 alkylene group which may be substituted) and —NH—SO2—. (3) The further more preferable aspect is oxygen atom, a C1-6 alkylene chain which may be substituted, a group represented by the formula —NR2— (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted), —CO—, and —NH—SO2—. (4) The most preferable aspect is oxygen atom or a group represented by the formula —NR2— (wherein R2 indicates a hydrogen atom, or a C1-6 alkyl group, a C3-8 cycloalkyl group, a lower acyl group or a C1-6 alkylsulfonyl group which may be substituted).
- Meaning of R1
- The group represented by R1 in the above formula (I) indicates (1) a hydrogen atom, (2) a halogen atom, (3) hydroxyl group, (4) a C1-6 alkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (5) a C2-6 alkenyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (6) a C2-6 alkynyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (7) a C3-8 cycloalkyl group which may be substituted with one or more groups selected from hydroxyl group, a halogen atom and nitrile group, (9) a C1-6 alkoxy-C1-6 alkyl group, (10) an amino-C1-6 alkyl group in which the nitrogen atom may be substituted, (11) the formula —N(R11)R12— (wherein R11 and R12 are the same as or different from each other and each indicates a hydrogen atom or a C1-6 alkyl group), (12) an aralkyl group, (13) morpholinyl group, (14) thiomorpholinyl group, (15) piperidyl group, (16) pyrrolidinyl group or (17) piperazinyl group.
- The preferable atom as the above-mentioned “halogen atom” includes fluorine atom, chlorine atom and bromine atom, and more preferably includes fluorine atom and chlorine atom.
- The “C1-6 alkyl group” in R1 preferably includes methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group tert-butyl group etc., more preferably methyl group, ethyl group, n-propyl group and isopropyl group, further preferably n-propyl group and isopropyl group, and most preferably isopropyl group.
- The “C2-6alkenyl group” in R1 preferably includes vinyl group, allyl group, 1-propenyl group, isopropenyl group, 1-buten-1-yl group, 1-buten-2-yl group, 1-buten-3-yl group, 2-buten-1-yl group, 2-buten-2-yl group etc., and more preferably vinyl group, allyl group, isopropenyl group etc.
- The preferable examples of the “C2-6 alkynyl group” in R1 include ethynyl group, 1-propynyl group, 2-propynyl group, butynyl group, pentynyl group, hexynyl group etc.
- The preferable examples of the “C3-8 cycloalkyl group” in R1 include cyclopropanyl group, cyclobutanyl group, cyclopentanyl group, cyclohexanyl group etc.
- The preferable examples of the “C1-6 alkoxy-C1-6 alkyl group” in R1 indicate a C1-6 alkyl group substituted with a group having the same meaning as the C1-6 alkoxy group defined above, and the preferable group includes methoxymethyl group, ethoxymethyl group, 1-methoxyethyl group, 2-methoxyethyl group, 1-ethoxyethyl group, 2-methoxy-n-propyl group, 3-methoxy-n-propyl group, 2-(n-propoxy)ethyl group etc.
- The preferable examples as the “C1-6alkyl group substituted with nitrile group” in R1 includes cyanomethyl group, 2-cyanoethyl group, 3-cyano-n-propyl group, 2-cyano-isopropyl group, 2-cyano-n-butyl group, 2-cyano-sec-butyl group, 2-cyano-tert-butyl group, 2-cyano-n-pentyl group, 3-cyano-n-hexyl group etc.
- The preferable examples as the “amino-C1-6 alkyl group in which the nitrogen atom may be substituted” in R1 includes aminomethyl group, methylaminomethyl group, dimethylaminomethyl group, ethylaminomethyl group, diethylaminomethyl group, methylethylaminomethyl group, acetamidomethyl group, pyrrolidinylmethyl group, 2-pyrazolinylethyl group, 1-piperidylethyl group, piperazinylmethyl group etc.
- The preferable examples as the “aralkyl group” in R1 includes benzyl group, phenethyl group, phenylpropyl group, naphthylmethyl group, naphthylethyl group, naphthylpropyl group etc.
- The meanings of the respective groups listed in the definition of R1 are described above, and the preferable aspect of R1 includes a hydrogen atom, a halogen atom, hydroxyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-8cycloalkyl group, a hydroxyl C1-6alkyl group, a C1-6 alkoxy-C1-6 alkyl group, a cyano-C1-6 alkyl group and a C1-6 alkyl group substituted with a halogen atom. The more preferable aspect thereof includes a halogen atom, hydroxyl group, a C1-6 alkyl group, a C2-6 alkenyl group and a C2-6 alkynyl group, and the further preferable aspect includes a C1-6 alkyl group (particularly, methyl group, ethyl group, n-propyl group, isopropyl group).
- Meanings of D1, D2 , W1 and W2
- In the compound represented by the above formula (I) according to the present invention, D1, D2, W1 and W2 are the same as or different from each other and each respectively indicates (1) a single bond or (2) an optionally substituted C1-6 alkylene chain.
- The preferable aspect of the “C1-6 alkylene chain” in the above-mentioned “C1-6 alkylene chain which may be substituted” includes methylene chain, ethylene chain, ethylidene chain, trimethylene chain, isoproylidene chain, propylene chain, tetramethylene chain, 1,2-butylene chain, 1,3-butylene chain, 2,3-butylene chain, isobutylene chain etc.
- Further, a chain being asymmetric in left and right is included in these C1-6 alkylene chains, but in this case, the binding direction is not limited, and both of the binding directions are also included in the “C1-6 alkylene chain”.
- The preferable aspect of the “substituent” in the above-mentioned “C1-6 alkylene chain which may be substituted” includes (i) a hydroxy group, (ii) a halogen atom (for example, fluorine atom, chlorine atom, bromine atom, iodine atom etc.), (iii) nitrile group, (iv) a C1-6alkyl group (for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, tert-butyl group etc.), (v) a C2-6 alkenyl group (for example, vinyl group, allyl group, 1-propenyl group, 2-propenyl group, isopropenyl group, 2-methyl-1-propenyl group, 3-methyl-1-propenyl group, 2-methyl-2-propenyl group etc.), (vi) a C1-6alkoxy group (for example, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, tert-butoxy group etc.), etc.
- Further, when the “substituent” is a c1-6 alkyl group and/or a C2-6 alkenyl group, these substituents can be bound together to form a 5- to 14-membered ring, and in the case of W1 and W2, these substituents can be bonded with the ring B or X to form a 5- to 14-membered ring.
- As the preferable aspect, D1, D2, W1 and W2 are the same as or different from each other and each include (1) a single bond or (2) a methylene chain, ethylene chain, ethylidene chain, trimethylene chain, isopropylidene chain, propylene chain, tetramethylene chain, 1,2-butylene chain, 1,3-butylene chain, 2,3-butylene chain, isobutylene chain etc., which may be substituted respectively with one or more groups selected from hydroxyl group, a halogen atom and nitrile group.
- The respective meanings of E, X, D1, D2, W1 and W2 are described above. Here, the preferable aspect of the partial sturucture -D1-E-D2- includes ethylene chain (—CH2—CH2—), ethylidene chain (—CH(CH3)—), trimethylene chain (—(CH2)3—), isopropylidene chain (—CH(CH3)2—), propylene chain (—CH(CH3)CH2—), tetramethylene chain (—(CH2)4—), 1,2-butylene chain (—CH(C2H5)CH2—), 1,3-butylene chain (—CH(CH3)CH2CH2—), 2,3-butylene chain (—CH(CH3)CH(CH3)—), isobutylene chain (—CH(CH3)2CH2—) etc. The more preferable aspect includes trimethylene chain (—(CH2)3—), isopropylidene chain (—CH(CH3)2—), propylene chain (—CH(CH3)CH2—), tetramethylene chain (—(CH2)4—), 1,2-butylene chain (—CH(C2H5)CH2—) etc., and the further preferable aspect includes tetramethylene chain (—(CH2)3—) etc. Further, the preferable aspect of the partial structure —W1—X—W 2— includes a single bond, a chain represented by the formula —CH2—CH2—O—, —CH2—CH2—NR2—, —(CH2)3—O— or —(CH2 )3—NR2—.
-
- (wherein the respective symbols in the formulae have the same meanings as defined above), a salt thereof or a hydrate of them.
- Compounds obtained in Examples described later are naturally included in the preferable aspects of the compound according to the present invention, and typical compounds are mentioned below.
- 4-[(4-Cyano-5-methyl-4-phenyl)hexyl]-N-(4-fluorophenyl)-N′-(2-methylpropyl)-1(2H)-pyrazinecarboxyimidamide;
- 1-isopropyl-4-[4-(1-isobutyl-1N-benzo[d]imidazol-2-yl)piperazino]-1-phenylbutyl cyanide;
- 1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
- 1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
- 1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[3-(5-cyano-2-thienyl)propyl]piperazine;
- 1-[4-cyano-5-methyl-4-(3-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
- 1-{4-cyano-5-methyl-4-[4-(2-cyano)thienyl]hexyl}-4-[2-(3-cyanophenoxy)ethyl]piperazine;
- 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[(2-benzoxazolyl)amino]piperidine;
- 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3S)-3-[N-(2-cyanoethyl)-N-benzylamino]pyrrolidine;
- 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3R)-3-[N-(2-cyanoethyl)-N-benzylamino]pyrrolidine;
- 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-(benzothiazolyl)piperazine;
- 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[2-(6-methoxy)benzothiazolyl]piperazine;
- 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-(2-benzoxazolyl]piperazine;
- 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-(2-quinolinyl]piperazine;
- 4-[4-(1-methyl-1H-benzo[d]imidazol-2-yl)-1,4-diazepan-1-yl]-1-isopropyl-1-phenylbutyl cyanide;
- 4-[4-(1-ethyl-1H-benzo[d]imidazol-2-yl)-1,4-diazepan-1-yl]-1-isopropyl-1-phenylbutyl cyanide;
- ethyl 4-(4-cyano-5-methyl-4-phenylhexyl)-1-[2-(4-fluorophenoxy)ethyl]-2-piperazinecarboxylate;
- 1-[(2-oxo-1,2-dihydro-3-quinolyl)methyl]-4-[(4-cyano-5-methyl-4-phenyl)hexyl]piperidine;
- 4-[(4-cyano-5-methyl-4-phenyl)hexyl]-1-{[2-methanesulfonylamino]phenyl]methyl}piperazine;
- 4-[(4-cyano-5-methyl-4-phenyl)hexyl]-1-{[2-methanesulfonylamino]phenyl]methyl}piperidine;
- (S)-3-phenyl-2-aminopropanoic acid{1-[4-cyano-5-methyl-5-(2-thionyl)hexyl]piperazinyl}amide;
- 4-[4-(4-phenylpiperidinyl)piperidinyl]-1-isopropyl-1-phenylbutyl cyanide;
- 4-[4-(4-cyano-4-phenylpiperidinyl)piperidinyl]-1-isopropyl-1-phenylbutyl cyanide; and
- 4-[4-(4-benzylpiperidinyl)piperidinyl]-1-isopropyl-1-phenylbutyl cyanide.
- The compound represented by the above formula (I) according to the present invention, a salt thereof or a hydrate of them can be produced by known production processes or processess according to the processes. As the known production processes, for example, a production process described in JP-A 2000-169462 (a production process described in paragraphs “0054” to “0065” in the Publication), and production processes described in JP-A 2000-12207, 2000-12208 and 2000-12209 are listed.
- Further, the raw material compound in the production of the compound (I) may form a salt or a hydrate, and is not specifically limited so far as it does not inhibit the reaction. When the compound (I) according to the present invention is obtained as a free body, it can be converted to a salt which the above compound (I) may form, according to a conventional process. When the compound according to the present invention is prepared as a free body, it can be converted to a salt according to a conventional process. Various isomers (for example, geometrical isomer, optical isomers based on an asymmetric carbon, stereo-isomers, the isomers of tautomers and the like) which are obtained for the compound (I) according to the present invention can be purified and isolated by conventional separation procedures (for example, recrystallization, a diastereomer salt method, an enzyme division method, various chromatography and the like).
- The “salt” in the specification of the present application is not specifically limited so far as it forms a salt with the compound according to the present invention and is pharmacologically accepted, and is preferably a salt of hydrogen halide acid (for example, hydrofluorate, hydrochloride, hydrobromate, hydroiodate and the like), a salt of an inorganic acid (for example, sulfate, nitrate, perchlorate, phosphate, carbonate, bicarbonate and the like), a salt of an organocarboxylic acid (for example, a salt of acetic acid, a salt of trifluoroacetic acid, a salt of oxalic acid, a salt of maleic acid, a salt of tartaric acid, a salt of fumaric acid, a salt of citric acid, and the like), a salt of an organosulfonic acid (for example, methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, camphorsulfonate, and the like), a salt of an amino acid (for example, a salt of aspartic acid, a salt of glutamic acid, and the like), a quaternary ammonium salt, an alkali metal salt (for example, sodium salt, potassium salt and the like), an alkali earth metal salt (for example, magnesium salt, calcium salt and the like), and the like. Hydrochloride, a salt of oxalic acid, a salt of trifluoroacetic acid, and the like are more preferable.
- The compound represented by the fore-mentioned formula (I) or a salt thereof, or a hydrate thereof can be formulated by an ordinary method, and preferable preparations include tablets, powders, granules, parvules, coated tablets, capsules, syrups, troches, inhalants, suppositorium, injections, paste medicines, eye ointments, eye drops, nasal drops, eardrops, poultices, lotions and the like. For preparations, excipients, binders, disintegrants, lubricants, colorants, and flavoring agents which are conventionally used, if necessary, stabilizers, emulsifiers, absorption accelerators, surfactants, pH regulators, antiseptics, antioxidants and the like can be used. Ingredients which are conventionally used for the raw materials of pharmaceutical preparations can be formulated by a normal method. As these ingredients, for example, there are listed animal and vegetable oils such as soy bean flexure, tallow and synthetic glyceride; hydrocarbons such as liquid paraffin, squalane and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenic alcohol; silicone resins; silicone oils; surfactants such as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene-hardened castor oil and polyoxyethylene-polyoxypropylene block copolymer; water-soluble polymers such as hydroxy ethyl cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, poly(vinyl pyrrolidone) and methyl cellulose; lower alcohol such as ethanol and isopropanol; polyvalent alcohols such as glycerin, propylene glycol, dipropylene glycol and sorbitol; sugars such as glucose and dextrose; inorganic powders such as silicic anhydride, aluminum magnesium silicate and aluminum silicate; purified water and the like. Specifically, as excipients used are: lactose, corn starch, white sugar, dextrose, mannitol, sorbit, crystal cellulose, silicon dioxide and the like; as binders used are: polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, gum arabic, gum tragacanth, gelatin, shellac, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, polypropylene glycol-polyoxyethylene block copolymer, meglumine, calcium citrate, dextrin, pectin and the like; as disintegrants used are: starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, carboxymethyl cellulose calcium and the like; as lubricants used are: magnesium stearate, talc, polyethylene glycol, silica, hardened vegetable oil and the like; as colorants used is: any colorant which is approved to be added to pharmaceuticals; as flavoring agents used are: cocoa powder, menthol, aroma powder, peppermint oil, borneol, cinnamon powder and the like; as antioxidants used are: ascorbic acid, a-tocopherol and the like which are approved to be added to pharmaceuticals.
- For example, (1) oral preparations are made as powders, fine granules, granules, tablets, coated tablets, capsules etc. according to a conventional method after adding the compound according to the present invention, a salt thereof or a hydrate of them, fillers, and further, if necessary, binders, disintegrants, lubricants, colorants, flavoring agents etc. (2) In case of tablets and granules, sugar coating and gelatin coating and additionally, if necessary, appropriate coating are allowed to be carried out. (3) In case of syrups, preparations for injection, eye drops and the like, pH regulators, resolving aids, isotonizing agents and the like, and if necessary, dissolution assistants, stabilizers, buffers, suspending agents, antioxidants and the like are added and formulated according to a conventional method. In case of the preparations, a freeze-dry product can be also made, and injections can be administered in vein, subcutis and a muscle. Preferable examples of the suspending agent include methyl cellulose, polysorbate 80, hydroxyethyl cellulose, gum arabic, tragacanth powder, carboxymethyl cellulose sodium, polyoxyethylene sorbitan monolaurate and the like; preferable examples of the resolving aids include polyoxyethylene hardened castor oil, polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate and the like; preferable examples of the stabilizer include sodium sulfite, meta sodium sulfite, diethyl ether and the like; Preferable examples in the preservative include methyl p-oxybenzoate, ethyl p-oxybenzoate, sorbic acid, phenol, cresol, chlorocresol and the like. (4) Further, in the case of external preparations, the preparation process is not specifically limited, and the external preparations can be produced by a conventional method. As the raw material of a base drug used, various raw materials which are conventionally used for pharmaceuticals, quasi drug, cosmetics and the like can be used. For example, raw materials such as animal and vegetable oils, a mineral oil, an ester oil, waxes, higher alcohols, fatty acids, a silicone oil, a surfactant, phosphatides, alcohols, polyvalent alcohols, water-soluble polymers, clay minerals, purified water and the like are listed. According to requirement, a pH regulator, an antioxidant, a chelating agent, antiseptic and fungicide, a coloring agent, flavors and the like can be added. Further, if necessary, ingredients having differential derivation action, blood flow accelerator, antibacterial, antiphlogistine, cell activator, vitamins, amino acids, a humectant, keratolysis medicine and the like can be formulated. The dose of the pharmaceuticals according to the present invention is different depending on the extent of symptom, age, sexuality, body weight, administration form, modality of salt, the difference of sensitiveness for medicine, the specific modality of affection, but in the case of an adult, for oral administration, approximately 30 μg to 1000 mg per day in general, preferably 100 μg to 500 mg, and more preferably 100 μg to 100 mg of the pharmaceutical is administered at one time or several times. For injection administration, approximately 1 to 3000 μg/kg in general, and preferably 3 to 1000 μg/kg of the pharmaceutical is administered at one time or several times.
- The compound represented by the above formula (I) according to the present invention, a salt thereof or a hydrate of them is useful as a calcium antagonist and specifically, a neuron-selective calcium antagonist. The compound according to the present invention has a novel compound having a P/Q-type calcium channel and an N-type calcium channel inhibiting activity, and is useful as an agent for treating or preventing a disease against which a P/Q-type calcium channel inhibitory action and an N-type calcium channel inhibitory action are effective. Further, the compound represented by the above formula (I) according to the present invention, a salt thereof or a hydrate of them has a remarkably low extent of cell affection in comparison with a conventional antagonist, and is a safe calcium antagonist whose toxicity is reduced. Accordingly, the compound according to the present invention, a salt thereof or a hydrate of them is useful as a neural cell death depressor, a cerebral neural cell demulcent, an agent for treating or preventing neural disease and an analgesic. In particular, it is useful as an agent for treating, preventing or improving acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral circulation metabolic affection, cerebral dysfunction, pain, spasm, schizophrenia, migraine, epilepsy, manic-depression, neural degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia, multiple sclerosis etc.
- FIG. 1 shows a HPLC chart in Reference Example 97.
- FIG. 2 shows a HPLC chart in Reference Examples 100 and 101, the spectrum of No. 1 in the drawing shows a spectrum in Reference Example 100 and the spectrum of No. 2 shows a spectrum in Reference Example 101, respectively.
- FIG. 3 shows a HPLC chart in Reference Example 103.
- Examples are shown below as the best modes for carrying out the present invention, but those Reference Examples, Examples (further, a pharmacologically acceptable salt thereof or a hydrate of them, and the pharmaceutical containing thereof) and Test Examples are only illustrative, and the compound according to the present invention is not limited to specific examples below at any case. Those skilled in the art can add various variations to not only Examples shown below, but also the Scope of Claim for Patent in the specification of the present application to carry out the present invention to a maximum extent, and such variations are included in the Scope of Claim for Patent in the specification of the present application.
- Further, the symbol “Z” used in Reference Examples or Examples below means benzyloxycarbonyl group, and “HPLC” means high performance liquid chromatography, respectively.
-
- The title compound was obtained as a pale brown oil in accordance with the method described in Example 15 (15%).
-
-
- 3.00 g (17.9mmol) of 2-naphthylacetonitrile was dissolved in 10 ml of dimethyl sulfoxide, and 2.43 g (19.7 mmol) of 2-bromopropane, 330 mg (0.90 mmol, cat) of tetra-n-butylammonium iodide and 10 ml of 50% potassium hydroxide were successively added thereto. After completion of the reaction, brine was added, and the mixture was extracted with ether. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 150 g of silica gel (ethyl acetate:hexane=1:10), to give 2.42 g (11.6 mnol, 64.6%) of the title compound as a yellow oil.
-
-
- 1.00 g (4.78 mmol) of 3-methyl-2-(2-naphthyl)butyronitrile was dissolved in 20 ml of dimethylformamide, 191 mg (4.78 mmol, 60% by weight) of sodium hydride was added thereto, and the mixture was heated. After 30 minutes, it was cooled to a room temperature, 0.93 ml (4.00 mmol) of (3-bromopropoxy)-tert-butyldimethylsilane was added thereto. After completion of the reaction, brine was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 50 g of silica gel (ethyl acetate:hexane=1:18), to give 1.40 g of a mixture of the objective product, a raw material and an impurity. The mixture was used for the following reaction without purification. Namely, 1.40 g of the abve-mentioned crude 4-cyano-5-methyl-5-(2-naphthyl)hexanoxy-tert-butyldimethylsilane was dissolved in 20 ml of tetrahydrofuran, and 5 ml (5 mmol) of tetraammonium fluoride was added thereto. After completion of the reaction, brine was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with an aqueous saturated ammonium chloride and brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 50 g of silica gel (ethyl acetate:hexane=1:4), to give 590 mg (2.21 mmol, 46.2%, 2 steps) of the title compound as a yellow oil.
-
-
- 2.76 g (8.44 mmol) of 4-cyano-5-methyl-4-phenylhexyl iodide was dissolved in 50.0 ml of acetonitrile, 1.29 ml (9.28 mmol) of triethylamine and 1.88 g (10.1 mmol) of 3-tert-butoxycarbonylaminopyrrolidine were added thereto, and the mixture was heated to 60° C. After completion of the reaction, the mixture was partitioned between ethyl acetate and brine. The organic layer was dried over magnesium sulfate, and then evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate:hexane=2:1), to give 2.97 g (7.76 mmol, 91.3%) of the title compound as a pale yellow syrup.
-
-
- 2.36 g (6.12 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)lhexyl]-3-tert-butoxycarbonylaminopyrrolidine was dissolved in a mixed solution of 5 ml of tetrahydrofuran and 10 ml of methanol, and a 4N hydrogen chloride-ethyl acetate solution was added thereto. After completion of the reaction, the mixture was adjusted to basic with a 2N aqueous sodium hydroxide, and extracted with chloroform. The organic layer was dried over magnesium sulfate, and then evaporated, to give 1.66 g (5.82 mmol, 95.1%, an orange syrup) of a crude product.
-
-
- 700 mg (2.45 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-3-aminopyrrolidine was dissolved in 15 ml of methanol, 0.19 ml (2.85 mmol) of acrylonitrile was added thereto, and the mixture was heated under reflux. After completion of the reaction, the mixture was evaporated, to give a crude product. The crude product was subjected to 20 g of Cromatorex NH silica gel (ethyl acetate 100%), to give 775 mg (2.29 mmol, 93.5%) of the title compound as an orange syrup.
-
-
- 2.00 g (17.8 mmol) of m-fluorophenol was dissolved in 50 ml of dimethylformamide, 785 mg (19.6 mmol, 60% by weight, mineral) of sodium hydride and 3.21 ml (21.3 mmol) of bromoacetaldehydediethylacetal were successively added thereto, and the mixture was heated to 60° C. After completion of the reaction, brine was added thereto and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and then evaporated, to give a crude product. The crude product was subjected to 105 g of Cromatorex NH silica gel (ethyl acetate:hexane=1:40), to give 3.17 g (13.9 mmol, 78.1%) of the title compound as a yellow oil.
-
- 1.68 g (7.38 mmol) of the above acetal was dissolved in 30 ml of acetone and 20 mL of a 2.5N hydrochloric acid, and the mixture was heated. After completion of the reaction, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and then evaporated, to give 800 mg of a crude product which contains the objective compound below. The crude product was subjected to the above-mentioned reaction without purification.
-
- 4.00 g (22.7 mmol) of 1-benzyl-3-aminopyrrolidine was dissolved in 70 ml of methanol, 1.49 ml (22.7 mmol) of acrylonitrile was added thereto, and the mixture was heated to 70° C. After completion of the reaction, the reaction solution was evaporated, and the resulting crude product was subjected to 100 g of Cromatorex NH silica gel (ethyl acetate 100%), to give 4.60 g (20.1 mmol, 88.4%) of the title compound as a yellow oil.
-
-
- 2.03 g (8.87 mmol) of 1-benzyl-3-[(N-(2-cyanoethyl)amino)pyrrolidine was dissolved in 50 ml of dichloroethane, and 1.30 g (8.06 mmol) of 4-cyanophenoxyacetaldehyde separately synthesized, 1.02 ml (17.7 mmol) of acetic acid and 2.56 g (12.1 mmol) of sodium triacetoxyborohydride were successively added thereto. After completion of the reaction, the mixture was adjusted to basic with a 2N aqueous sodium hydroxide, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 250 g of Cromatorex NH silica gel (ethyl acetate:hexane=2:3), to give 2.39 g (6.38 mmol, 79.2%) of the title compound as a yellow syrup.
-
-
- 1-Benzyl-3-[(N-(2-cyanoethyl)-N-{2-(4-cyanophenoxy)ethyl}amino)pyrrolidine was dissolved in dichloroethane, AceCl (0.84 ml, 7.66 mmol) was added thereto, and the mixture was heated under reflux. After about one hour, AceCl (0.12 ml) was added thereto, and the mixture was continued to be heated. After completion of the reaction, the mixture was evaporated. To the residue was added 30 ml of methanol was added thereto, followed by heating under reflux. After one hour, the reaction solution was evaporated. The residue was extracted with 2N hydrochloric acid, washed with ether, and then adjusted to pH 11-12 with a 2N aqueous sodium hydroxide. The mixture was extracted with ethyl acetate, dried over magnesium sulfate evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate:methanol=1:0-3:1), to give 1.12 g (3.93 mmol, 61.6%) of the title compound as a yellow oil.
-
-
- 1.00 g (3.50 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine and 0.54 ml (3.85 mmol) of triethylamine were dissolved in 25 ml of tetrahydrofuran. Under ice-cooling, 0.35 ml (3.85 mmol) of methyl bromoacetate was added drop wise there into. After completion of there action, brine was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate:hexane=1:2), to give 1.22 g (3.41 mmol, 97.5%) of the title compound as an orange oil.
-
-
- To 200 ml of an ethanol solution of 10.0 g (82.6 mmol) of 3-fluorobenzcyanide were added 8.61 g (124 mmol) of hydroxylamine hydrochloride and 22.8 g (165 mmol) of potassium carbonate, followed by heating under ref lux. After completion of the reaction, the mixture evaporated. To the residue was added brine, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 100 g of silica gel (ethyl acetate:hexane=1:2-1:4), to give 8.00 g (51.9 mmol, 62.8%) of the title compound as a yellow solid.
-
-
- 4.70 g (36.4 mmol) of 4-piperidineethanol and 10.0 g (72.8 mmol) of potassium carbonate were dissolved in ether (50 ml) and water (50 ml). Under ice-cooling, ZCl (4.44 ml, 25.0 mmol) was dissolved in 30 ml of ether, and the solution was added dropwise thereinto. The physical property of the resulting title compound is described below. After completion of the reaction, brine was added and the mixture was extracted with ether. The organic layer was washed with brine and an aqueous saturated ammonium chloride, dried over magensium sulfate and evaporated, to give a crude product. The crude product was subjected to 100 g of silica gel (ethyl acetate:hexane=1:2), to give 5.48 g (20.8 mmol, 57.2%) of the title compound as a colorless oil.
-
-
- 2.00g (7.60mmol) of N-Z-4-piperidineethanol, 1.70 g (15.2 mmol) of 4-fluorophenol and 2.39 g (9.12 mmol) of triphenylphosphine were dissolved in 50 ml of tetrahydrofuran, and the mixture was ice-cooled. After 10 minutes, 1.44 ml (9.12 mmol) of diethylazocarboxylate was added dropwise thereinto, and then the mixture was stirred at room temperature. After completion of the reaction, brine was added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 100 g of silica gel (ethyl acetate:hexane=1:3), to give 2.19 g (6.12 mmol, 80.6%) of the title compound as a colorless oil.
-
-
- 2.19 g (6.12 mmol) of 1-benzyloxycarbonyl-4-[2-(4-fluorophenoxy)ethyl]piperidine was dissolved in 40 ml of methanol, 300 mg of 10% palladium-carbon was added, and replacement with hydrogen was carried out. After completion of the reaction, the mixture was filtered, and the filtrate was evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate:hexane=1:3-ethyl acetate:methanol=6:1), to give 1.30 g (5.82 mmol, 95.1%) of the title compound as a yellow oil.
-
-
- 5.00 g (36.4 mmol) of 3-pyridinepropanol was dissolved in 150 ml of acetonitrile, 4.55 ml (38.3 mmol) of benzylbromide was added, and the mixture was heated at 70° C. After 2 hours, heating was stopped, and the mixture was evaporated. Then, the residue was dissolved in 100 ml of methanol, and the mixture was cooled to 0° C. 4.12 g (109 mmol) of sodium borohydride was added thereto. After completion of the reaction, 50 ml of water was added thereto, and the mixture was evaporated. Then, the residue was partitioned between ethyl acetate and brine. After drying the organic layer over magnesium sulfate, the mixture was evaporated, to give a crude product. The crude product was subjected to 150 g of Cromatorex NH silica gel (ethyl acetate:hexane=1:6-1:1), to give 6.48 g (28.0 mmol, 77.0%) of the title compound as a yellow oil.
-
-
- 6.48 g of 1-benzyl-4-hydroxypropyl-1,2,5,6-tetrahydropyridine was dissolved in 60 ml of methanol, 88 mg of PtO2 was added, and atmosphere was replaced with hydrogen. After completion of the reaction, the mixture was filtered, and the filtrate was evaporated, to give 4.50 g (19.3 mmol, 68.9%) of the title compound as a yellow oil.
-
-
- 2.58 g (11.1 mmol) of 1-benzyl-4-hydroxypropylpiperidine and 3.26 ml (23.4 mmol) of triethylamine were dissolved in 50 ml of tetrahydrofuran, and 1.67 ml (21.6 mmol) of methanesulfonyl chloride was added dropwise. After completion of the reaction, the mixture was partitioned between ethyl acetate and brine. The organic layer was dried over magnesium sulfate, and then evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate:hexane=1:1), to give 2.90 g (9.31 mmol, 83.9%) the title compound as a yellow oil. The physico-chemical data of the target compound was as indicated below.
-
-
- 2.43 g (6.49 mmol) of 1-benzyl-4-[(4-cyano-5-methyl-4-phenyl)hexyl]piperidine was dissolved in 30 ml of 1,2-dichloroethane, 0.85 ml (7.79 mmol) of AceCl was added thereto, and the mixture was heated under reflux. After 45 minutes, the mixture was evaporated. Then, 30 ml of methanol was added thereto, and the mixture was heated under reflux again. After completion of the reaction, the mixture was evaporated, extracted with water and washed with ether. The resulting aqueous layer was adjusted to basic, and then the mixture was partitioned between ethyl acetate and brine. The organic layer was dried over magnesium sulfate, and then evaporated, to give 1.62 g (5.69 mmol, 87.7%) a yellow crude product. The physico-chemical data of the title compound was as indicated below.
-
-
- Under a nitrogen atmosphere, sodium borohydride (650 mg) was added in an ice bath to a DMF solution (25 ml) of thiophene-2-acetonitrile (1 g) and (3-bromopropoxy)-tert-butyldimethylsilane (2.06 g). After 20 minutes, the organic layer was separated by adding an aqueous saturated ammonium chloride and ethyl acetate were added thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The resulting residue was dissolved in acetonitrile (20 mL), a 1 M tetrabutylammonium fluoride/tetrahydrofuran solution (9.7 ml) was added thereto, and the mixture was stirred at a room temperature. After 18 hours, the organic layer was separated by adding water and ethyl acetate. The resulting organic layer was rinsed with water and brine, and dried over magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a red oil (637 mg, 43%).
-
-
- Under a nitrogen atmosphere, sodium amide (1.11 g) was added to a tetrahydrofuran solution (25 ml) of phenylacetonitrile (3 g). After 30 minutes, a tetrahydrofuran solution (25 ml) of 2-(2-bromoethyl)-1,3-dioxolane (4.64 g) was added to the reaction solution through a dropping funnel. After stirring 2 hours, an aqueous saturated ammonium chloride and ethyl acetate were added thereto, to separate the organic layer. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound (3.47 g, 62%).
-
-
- Under a nitrogen atmosphere, ethyl trimethylsilylethylacetate (5.19 g) was added at −78° C. to a solution of a lithium diisopropylamide/tetrahydrofuran solution (1.5 M, 21.6 mL) added to tetrahydrofuran solution (100 mL). After 20 minutes, a tetrahydrofuran solution (10 ml) of isobutyrophenone (4.0 g) was added thereto, and the temperature of the mixture was naturally returned to room temperature. After stirring 18 hours, sodium bisulfate monohydrate (0.6 g) was added and the mixture was stirred. Further, after 10 minutes, the organic layer was separated by adding a 0.2N hydrochloric acid solution (250 mL) and ethyl acetate (200 mL) thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. 756 Mg among the resulting crude product (7.9 g) was dissolved in methanol (5 mL), a catalytic amount of 10% palladium carbon (9.5 mg) was added, and the mixture was stirred under hydrogen atmosphere. After 4 hours, the catalyst was filtered off, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a colorless oil (350 mg).
-
-
- Under a nitrogen atmosphere, ethyl 4-methylpentanoate (350 mg) was dissolved in tetrahydrofuran (10 mL) at −78° C., a lithium aluminum hydride/tetrahydrofuran solution (1.0 M, 1.58 mL) was added, and the mixture was stirred. While the temperature of the mixture was naturally returned to room temperature, the mixture was stirred, and after 1.5 hours, water (0.05 mL), a 2N aqueous sodium hydroxide (0.05 mL) and water (0.15 mL) were successively added thereto, and the mixture was stirred. Further, diethyl ether was added thereto, and then the resulting insoluble matters were filtered off and the filtrate was evaporated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a colorless oil (257 mg, 42%: 2 steps).
-
-
- Under a nitrogen atmosphere, sodium hydride (60%, 1.2 g) was added at 0° C. to a tetrahydrofuran solution (30 mL) of tert-butyldiethylphosphonoacetate (4.9 g). After 10 minutes, the temperature of the mixture was naturally returned to room temperature, and the mixture was stirred. After 1 hour, a tetrahydrofuran solution (10 mL) of isobutyrophenone (4.0 g) was added. After stirring for 13 hours, the organic layer was separated by adding water and ethyl acetate thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. 5.48 g among the resulting crude product (6.1 g) was dissolved in methanol (30 mL), a catalytic amount of 10% palladium carbon (250 mg) was added, and the mixture was reacted under pressuring by hydrogen (3.9 kg/cM2). After 1.3 hours, the catalyst was filtered off, and then the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system). The resulting product (3.0 g) was dissolved in acetone (50 mL) and 5N hydrochloric acid (20 mL), and the mixture was stirred for 3 hours under reflux conditions. The solution was evaporated, to give the title compound as a reddish yellow oil (1.96 g, 58%: 3 steps).
-
-
- Under a nitrogen atmosphere, a dimethylformamide solution of diethyl cyanophosphonate (1.97 g) and triethylamine (1.63 mL) was added to a tetrahydrofuran solution (24 mL) of 4-methyl-3-phenyl-pentanoic acid (1.96 g), N,O-dimethylhydroxyamine hydrochloride (1.18 g) and triethylamine (1.63 mL) at 0° C. After 19 hours, the organic layer was separated by adding diethyl ether and an aqueous saturated ammonium chloride thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound (1.13 g, 47%).
-
-
- Under a nitrogen atmosphere, N-methyl-N-methoxy-4-methyl-3-phenyl-pentaneamide (215 mg) was dissolved in tetrahydrofuran (9.1 mL) at −78° C., and a diisobutylaluminum hydride/toluene solution (1.5 M, 1.2 mL) was added. After one hour, methanol (3 mL) was added to the reaction system, the temperature of the mixture was returned to room temperature after termination of foaming, and the mixture was continuously stirred. The organic layer was separated by adding diethyl ether, water and a 1N aqueous hydrochloric acid thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated, to give the title compound as a colorless oil (200 mg). The resulting compound was used for the next reaction without purification.
-
-
- Under a nitrogen atmosphere, a n-butyllithium/tetrahydrofuran solution (1.53 M, 1.2 mL) was added to a tetrahydrofuran solution of (methoxymethyl) triphenylphosphonium chloride (627 mg) at −78° C., and then the temperature of the mixture was raised to 0° C. After 20 minutes, the outer temperature was lowered to −78° C., and then 4-methyl-3-phenyl-pentanal (200 mg) was added thereto together with tetrahydrofuran (4 mL). After 45 minutes, the temperature of the mixture was returned to room temperature, and the mixture was further stirred for 20 minutes. The organic layer was separated by adding diethyl ether and an aqueous saturated ammonium chloride thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated, to give the title compound as a colorless oil (200 mg). The resulting compound was dissolved in isopropanol(2 mL)/water(2 mL), p-toluenesulfonic acid (6 mg) was added thereto, and then the reaction was carried out for 8.5 hours under refluxing. The organic layer was separated by adding diethyl ether and an aqueous saturated ammonium chloride thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The residue was purified by NH silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a colorless oil (103 mg, 59%, 3 steps).
-
-
- The title compound was synthesized in accordance with the method of Example 104 described in JP-A 11-206862.
-
-
- (90%) 4-Bromo-2-thiophenecarboaldehyde (10.0 g) was dissolved in methanol (50 ml), and an ion-exchange resin, Amberlite IR120B (5 g) was added thereto. After heating under reflux for 10 hours, the mixture was cooled as it was to room temperature, and the ion-exchange resin was filtered off. The filtrate was evaporated, and the resulting residue was purified by (NH) silica gel column chromatography (hexane), to give the title compound as a pale yellow oil (8.93 g, 72%).
-
-
- Method 1)
- 4-Bromo-2-thiophenecarboaldehyde dimethylacetal (6.82 g) was dissolved in DMF (50 ml), and copper cyanide (4.29 g) was added thereto. After heating under reflux for 3 hours, the mixture was cooled as it was to room temperature and ethyl acetate was added thereto. The mixture was washed with an aqueous ammonia, water, 0.1N aqueous hydrochloric acid and brine, dried over anhydrous magnesium sulfate and then evaporated, to give an oil. The residue was dissolved in an 80% aqueous acetic acid (100 ml), and the mixture was stirred at 0° C. for one hour. The mixture was washed with brine. After cooling as it was to room temperature, ethyl acetate was added thereto. The mixture was washed with an aqueous saturated sodium bicarbonate and brine, dried over anhydrous magnesium sulfate and then evaporated. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), and then recrystallized from ethyl acetate-hexane, to give the title compound as pale yellowish white crystals (2.44 g, 62%).
- Method 2)
- 4-Bromo-2-thiophenecarboaldehyde (5.00 g) was dissolved in DMF (40 ml), and copper cyanide (3.52 g) was added thereto. After heating under reflux for 3 hours, the mixture was cooled as it was to room temperature and ethyl acetate was added thereto. The mixture was washed with an aqueous ammonia, water, 0.1N aqueous hydrochloric acid and further brine, dried over anhydrous magnesium sulfate and then evaporated. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), and then recrystallized from ethyl acetate-hexane, to give the title compound as pale yellowish white crystals (2.30 g, 71%).
- The physico-chemical data of the title compound was as indicated below.
-
-
- 3-Cyano-5-thiophenecarboaldehyde (2.00 g) was dissolved in anhydrous ether (100 ml) and anhydrous tetrahydrofuran (THF) (20 ml), and an ether solution (10.9 ml) of (2.0 M) isopropylmagnesium chloride was added thereto. After stirring at 0° C. for 2 hours, ethyl acetate was added thereto. The mixture was washed with an aqueous saturated ammonium chloride and further brine, dried over anhydrous magnesium sulfate and then evaporated. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (1.25 g, 47%).
-
-
- Oxalyl chloride (0.70 ml) was dissolved in methylene chloride (10 ml), and then the mixture was cooled to −60 to −50° C. Dimethyl sulfoxide (0.57 ml) was added thereto, and the mixture was stirred for 2 minutes. Further, a methylene chloride solution (6 ml) of 3-cyano-5-(1-hydroxy-2-methylpropyl)thiophene (1.21 g) was added thereto at −60 to −50° C., and the mixture was stirred for 15 minutes. Then, triethylamine (4.65 ml) was added, and the temperature of the mixture was raised to a room temperature. Ethyl acetate was added, and the mixture was washed with water and further brine, dried over anhydrous magnesium sulfate and then evaporated. The resulting residue was recrystallized from ethanol, to give the title compound as pale yellowish white crystals (0.59 g) Further, the filtrate was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound (0.41 g, total yield: 1.00 g, 84%).
-
-
- 3-Cyano-5-(1-oxo-2-methylpropyl)thiophene (0.90 g) was dissolved in THF (50 ml), and a DMF solution (30.1 ml) of (0.5 M) lithium cyanide and (90%) diethylcyanophosphonate (2.29 ml) were added thereto. After stirring at room temperature for 30 minutes, ethyl acetate and hexane were added thereto. The mixture was washed with water and further brine, dried over anhydrous magnesium sulfate and then evaporated. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (1.72 g, quantitatively).
-
-
- [1-Cyano-1-(3-cyano-5-thienyl)-2-methylpropyl]diethylphosphate (45 mg) was dissolved in ethyl acetate (5 ml), (10%) palladium-carbon (20 mg) was added, and hydrogenation was carried out at room temperature and a normal pressure for 2 hours. The catalyst was filtered off, and the filtrate was evaporated. The resulting residue was purified by preparative thin layer silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (22 mg, 88%).
-
-
- Potassium tert-butoxide (35 mg) was suspended in DMF (5 ml), and a DMF solution (5 ml) of 3-cyano-5-(1-cyano-2-methylpropyl]thiophene (0.60 g) was added thereto. After stirring at room temperature for 3.5 hours, ethyl acetate was added. The mixture was washed with an aqueous saturated ammonium chloride and further brine, dried over anhydrous magnesium sulfate and then evaporated. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (0.55 g, 60%).
-
-
- Ethyl 4-cyano-4-(3-cyano-5-thienyl)-5-methylhexanate (0.55 g) was dissolved in THF (10 ml), lithium borohydride (46 mg) was added, and the mixture was heated under reflux for 1.5 hours. After cooling as it was to room temperature, 1N aqueous hydrochloric acid and water were added at 0° C., and the mixture was extracted with ethyl acetate. The mixture was further washed with brine, dried over anhydrous magnesium sulfate and then evaporated. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound pale as a yellow oil (1.25 g, 47%). Further, the catalyst was filtered off, and the filtrate was evaporated. The resulting residue was purified by preparative thin layer silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (0.39 g, 83%).
-
-
- 2.00 g (10.5 mmol) of N-(2-cyanoethyl)-N-(2-hydroxyethyl)aniline was dissolved in 60.0 ml of acetonitrile, and 2.20 ml (15.8 mmol) of triethylamine and 0.90 ml (11.6 mmol) of mesyl chloride were successively added thereto. After completion of the reaction, brine was added thereto, and the objective product was extracted with ether. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was dissolved in acetone, and 12.0 g (80.1 mmol) of sodium iodide was added. After completion of the reaction, brine was added thereto, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to silica gel (eluted with ethyl acetate:hexane=1:3), to give 2.78 g (9.26 mmol, 88.2%) of the title compound as a yellow syrup.
-
-
- 2.78 g (9.26 mmol) of the above-mentioned iodide was dissolved in 50.0 ml of acetonitrile, and 2.5 g (13.4 mmol) of 1-tert-butoxycarbonylpiperazine and 1.29 ml (13.4 mmol) of triethylamine were successively added, and the mixture was heated to 60° C. After completion of the reaction, brine was added thereto, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was dissolved in 40 ml of methanol, and 30 ml of a 4N hydrogen chloride-ethyl acetate solution was added. After completion of the reaction, water and 10 ml of 5N HCl were added, and the mixture was washed with ethyl acetate. Then the aqueous layer was adjusted to pH 11 with a 5N aqueous sodium hydroxide, and then the objective product was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate andthe solventwas evaporated, to give 1.81 g (7.01 mmol, 75.7%) of the title compound as a yellow syrup, as a crude product.
-
-
- 20.3 g (181 mmol) of 3-thiophenealdehyde, 50 ml of ethylene glycol and 2.00 g (7.96 mmol) of PPTS were dissolved in 230 ml of toluene, and dehydration was carried out using Dean-stark. After completion of the reaction, the mixture was extracted with ethyl acetate. The extract was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to silica gel (ethyl acetate:hexane=1:10), to give 12.1 g (77.3 mmol, 86.7%) of the title compound as a yellow oil.
-
-
- 5.00 g (32.0 mmol) of 3-(1,3-dioxolan-2-yl)thiophene was dissolved in 100 ml of THF. 24.5 ml (1.5 mol/l) of n-butyllithium was added dropwise thereinto. After stirring for 0.5 hour, the mixture was cooled to −70° C., 3.10 ml (40.0 mmol) of DMF was added, and then the mixture was transferred to an ice bath. After stirring for about 2 hours, an aqueous saturated ammonium chloride was added, and the mixture was extracted with ethylacetate. The extract waswashed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to silica gel (ethyl acetate:hexane=1:2), to give 3.68 g (20.0 mmol, 62.4%) of the title compound as a yellow oil.
-
-
- 20 ml of a THF solution of 4.49 g (40.0 mmol) of potassium tert-butoxide was cooled to −45 to −30° C., and 20 ml of a THF solution of 3.90 g (20.0 mmol) of TOSmic and 20 ml of a THF solution of 3.68 g (20.0 mmol) of 3-(1,3-dioxolan-2-yl)-2-thiophenecarboaldehyde were successively added thereto. After 40 minutes, 60 ml of methanol was added at −15° C. After heating under reflux for 15 minutes, an aqueous saturated ammonium chloride was added, and the mixture was extracted with ethyl acetate. The extract was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to Cromatorex NH silica gel (ethyl acetate:hexane=1:4), to give 1.43 g (7.32 mmol, 36.6%) of the title compound as a yellow oil.
-
-
- 1.43 g (7.32 mmol) of 3-(1,3-dioxolan-2-yl)-2-thiopheneacetonitrile was dissolved in 2 ml of dimethyl sulfoxide, and 1.08 g (8.78 mmol) of 2-bromopropane, 100 mg (cat) of tetra-n-butylammonium iodide and 3 ml of 50% potassium hydroxide were successively added. After 25 minutes, 300 mg of 2-bromopropane, further after 50 minutes, 1 ml of 50% potassium hydroxide and 2 ml of DMSO were added. After completion of the reaction, brine was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and evaporated, to obtain a crude product. The crude product was subjected to 100 g of silica gel (ethyl acetate:hexane=1:8), to give 853 mg (3.59 mmol, 49.1%) of the title compound as a yellow oil.
-
-
- 2.16 g (9.10 mmol) of 2-[3-(1,3-dioxolan-2-yl)-2-thienyl]-4-methylbutyronitrile was dissolved in 40 ml of acetone, 115 ml of 5N HCl was added, and the mixture was heated at 70° C. for 3 minutes. After completion of the reaction, brine was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 75 g of silica gel (ethyl acetate:hexane=1:2), to give 1.66 g (8.58 mmol, 94.3%) of the title compound as a brown oil.
-
-
- 1.66 g (8.58 mmol) of 2-(3-formyl-2-thienyl)-4-methylbutyronitrile was dissolved in 40 ml of ethanol, 10 ml of an aqueous solution containing 894 mg (12.9 mmol) of hydroxylamine hydrochloride and 1.41 g (17.2 mmol) of sodium acetate was added thereto, and then the mixture was heated at 80° C. After completion of the reaction, brine was added, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude oxime. The oxime was dissolved in 50 ml of dimethylformamide, and 5.56 g (34.3 mmol) of carbodiimidazole was added. Then, the mixture was heated at 60° C., and further after 50 minutes, 2.40 ml (17.2 ml) of triethylamine was added thereto. After completion of the reaction, brine was added under cooling, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to silica gel (eluted with ethyl acetate:hexane=1:9), to give 1.07 mg (5.47 mmol, 63.7%) of the title compound as an orange oil.
-
-
- 1.07 g (5.47 mmol) of 2-(3-cyano-2-thienyl)-4-methylbutyronitrile and 0.71 ml (6.56 mmol) of ethyl acrylate were dissolved in 30 ml of tetrahydrofuran. 123 mg (1.09 mmol, cat.) of potassium tert-butoxide was added little by little to the solution at room temperature. After completion of the reaction, brine, an aqueous saturated ammonium chloride and 2N HCl were successively added, and the objective product was extracted with ethyl acetate. The organic layer was successively washed with brine and brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to silica gel (eluted with ethyl acetate:hexane=1:9), to give 904 mg (3.11 mmol, 56.9%) of the title compound as a yellow oil.
-
-
- 500 mg (1.72 mmol) of ethyl 4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexanolate was dissolved in 10 ml of THF, 37.5 mg (1.72 mmol) of lithium borohydride was added, and the mixture was heated under reflux. After one
hour 20 minutes, heating was stopped, and 2N HCl was added under ice-cooling. The mixture was extracted with ethyl acetate, and the extract was successively washed with brine and water, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to obtain a crude product. The crude product was subjected to silica gel (eluted with ethyl acetate:hexane=35:65), to give 244 mg (0.98 mmol, 57.1%) of the title compound as a colorless oil. -
-
- 244 mg (0.98 mmol) of 4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexanol was dissolved in 10 ml of acetonitrile and 0.16 ml (1.18 mmol) of triethylamine, and 83.6 μl (1.08 mmol) of mesyl chloride was added thereto. After about 5 minutes, 1.47 g (9.80 mmol) of sodium iodide was added. After completion of the reaction, brine and ethyl acetate were added, and the ethyl acetate layer was washed with an aqueous sodium thiosulfate aqueous solution and brine, dried over anhydrous magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to silica gel (eluted at ethyl acetate:hexane=1:10), to give 334 mg (0.93 mmol, 95.1%) of the title compound as a yellow oil.
-
-
- 1.05 g (4.23 mmol) of 4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexanol was dissolved in 40 ml of acetonitrile and 0.80 ml (5.71 mmol) of triethylamine. 0.39 ml (5.07 mmol) of mesyl chloride was added thereto. After about 10 minutes, 6.34 g (42.3 mmol) of sodium iodide was added. After completion of the reaction, brine and ethyl acetate were added. The ethyl acetate layer was washed with an aqueous sodium thiosulfate and brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to silica gel (eluted with ethyl acetate:hexane=1:2), to give 1.39 g (3.88 mmol, 91.7%) of the title compound as a yellow oil.
-
-
- 3.50 g (20.6 mmol) of methyl 3-(2-thienyl)propanonate which was synthesized according to the method described in J. Med. Chem., 1992, 35(21), 3870. was dissolved in 20 ml of DMF, 3.85 g (21.6 mmol) of NBS dissolved in 10 ml of DMF was added thereto, and the mixture was heated at 80° C. After 2 hours, brine was added, and the mixture was extracted with ether. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to silica gel (ethyl acetate:hexane=1:9), to give 4.62 g (18.6 mmol, 90.1%) of the title compound as a pale yellow oil.
-
-
- 4.62 g (18.6 mmol) of methyl 3-(5-bromo-2-thienyl) propanonate, 1.75 g (14.9 mmol) of Zn(CN)2 and 516 mg (0.93 mmol) of DPPF were suspended in a solution of 100 ml of DMF and 1 ml of water, then 341 mg (0.37 mmol) of Pd2dba3 was added, and the mixture was heated at 120° C. After 2 hours, the mixture was cooled as it was and extracted with ether. The organic layer was washed with brine and and 2N HCl, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to silica gel (ethyl acetate:hexane=1:9), to give 2.96 g (18.6 mmol, 100%) of the title compound as a green oil.
-
-
- 1.32 g (7.75 mmol) of methyl 3-(2-thienyl)propanonate was dissolved in 50 ml of THF. After cooling to −20° C., 6.00 ml of LiAlH4 (1.0 M solution) was added. After completion of the reaction, the mixture was quenched using water and 5N NaOH, and filtered through Celite. The filtrate was concentrated, and the resulting crude product was subjected to silica gel (ethyl acetate:hexane=1:1), to give 1.05 g (7.38 mmol, 95.2%) of the title compound as a colorless oil.
-
-
- 2.96 g (18.6 mmol) of methyl 3-(5-cyano-2-thienyl) propanoate was dissolved in 100 ml of THF, 450 mg (18.6 mmol) of lithium borohydride was added, and the mixture was heated under reflux. After one hour, heating was stopped and 2N HCl was added under ice-cooling. The mixture was extracted with ethyl acetate, and the extract was successively washed with brine and water, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to silica gel (eluted at ethyl acetate:hexane=25:75 to 50:50), to give 1.37 g (8.19 mmol, 44.0%) of the title compound as a green oil.
-
-
- 1.05 g (7.38 mmol) of 3-(2-thienyl)propanol was dissolved in 60 ml of acetonitrile, and 2.58 ml (18.5 mmol) of triethylamine and 0.63 ml (8.12 mmol) of mesyl chloride were added to the solution. After 25 minutes, 2.07 g (11.1 mmol) of tert-butyl 1-piperadinecarboxylate, 3.32 g (22.7 mmol) of sodium iodide and 6 ml of water were added, and the mixture was heated to 60° C. After completion of the reaction, brine was added, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried on anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to Cromatorex NH silica gel (eluted at ethyl acetate:hexane=2:8), to give 1.94 g (6.25 mmol, 84.7%) of the title compound as a pale yellow oil.
-
-
- The title compound was synthesized in accordance with the method for producing tert-butyl 4-[3-(2-thienyl)propyl]-1-piperazinecarboxylate in Reference Example 53 (yield: 74.2%).
-
-
- 1.94 g (6.25 mmol) of tert-butyl 4-[3-(2-thienyl) propyl]-1-piperazinecarboxylate was dissolved in 20 ml of methanol, and 15 ml of a 4N hydrogen chloride-ethyl acetate solution was added. After completion of the reaction, the mixture was evaporated. The residue was adjusted to pH 11 with a 2N aqueous sodium hydroxide, then the objective product was extracted with chloroform and dried over anhydrous magnesium sulfate. The solvent was evaporated, to give 1.23 g (5.85 mmol, 93.6%) of the title compound as a yellow oil, as a crude product.
-
-
- The title compound was synthesized in accordance with the method for producing 1-[3-(2-thienyl)propyl]piperazine in Reference Example 55 (yield: 96.0%).
-
- The title compound was produced in accordance with the method described in STNTHETIC COMMUNICATION 19(16) 2921-2924 (1989) (yield: quantitative).
-
-
- 2.00 g (11.9 mmol) of 2-(chloromethyl)benzoxazole was dissolved in 50 ml of acetonitrile, 1.66 ml (11.9 mmol) of triethylamine and 3.15 g (14.3 mmol) of benzyl 1-piprezinecarboxylate were added thereto, and the mixture was stirred at 80° C. After 2 hours, the reaction solution was concentrated, brine was added thereto, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried on anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to Cromatorex NH silica gel (ethyl acetate:hexane=25:75), to give 3.57 g (10.2 mmol, 85.7%) of the title compound as a yellow syrup.
-
-
- 3.57 g (10.2 mmol) of benzyl 4-[(2-benzoxazoyl)methyl]-1-piperazinecarboxylate was dissolved in 50 ml of methanol, and 400 mg of 10% Pd-C was added. After replacing the atmosphere with hydrogen, the mixture was stirred. After completion of the reaction, the reaction solution was filtered and evaporated, to give 2.15 g (9.89 mmol, 97.0%) of the title compound as a yellow oil, as a crude product.
-
-
- The title compound was synthesized in accordance with the method described in STNTHETIC COMMUNICATION 19(16) 2921-2924 (1989) (yield: 79.8%).
-
-
- The title compound was synthesized in accordance with the method for the production of benzyl 4-[(2-benzoxazoyl)methyl]-1-piperazinecarboxylate in Reference Example 58 (yield: 85.6%).
-
-
- The title compound was synthesized in accordance with the method described in Reference Example 59 (yield: 58.0%).
-
-
- 3-Methyl-2-(3-thienyl)butanenitrile (6.23 g) obtained using 3-thienylacetonitrile as a starting material in accordance with the method of Example 114 described in JP-A 11-206862 and ethyl acrylate (4.53 g) were dissolved in dimethylformamide (15 ml), and added at a room temperature to a solution of potassium tert-butoxide (423 mg) in dimethylformamide solution (60 ml). After stirring 5 hours as it was, the organic layer was separated by adding an aqueous saturated ammonium chloride and diethyl ether thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The drying agent was filtered off, and then the filtrate was evaporated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a yellow oil (6.66 g, 67%).
-
-
- A tetrahydrofuran solution (35 ml) in which ethyl 4-cyano-5-methyl-4-(3-thienyl)hexanoate (6.66 g) was dissolved was added dropwise to a tetrahydrofuran solution (50 ml) of lithium aluminum hydride (686 mg). After stirring for 2 hours, 2N aqueous NaOH and water were added to treat the mixture, and the resulting precipitates were filtered. The resulting filtrate was evaporated, and the residue was purified by silica gel column chromatography (ethyl acetate/hexane system), to give the title compound as a yellow oil (5.30 g, 95%).
-
-
- Under nitrogen atmosphere, methanesulfonyl chloride (0.20 ml) was added to an acetonitrile solution (9.0 ml) of 4-cyano-5-methyl-4-(3-thienyl)hexanol (400 mg) and triethylamine (0.75 ml) at a room temperature, and the mixture was stirred. After 2 hours, water and ethyl acetate were added, to separate the organic layer. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The resulting residue was dissolved in acetone (18 ml), sodium iodide (2.68 g) was added, and the mixture was stirred at 40° C. for 2 hours. The organic layer was separated by adding water and ethyl acetate thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated, to give the title compound as a yellow oil (670 mg).
-
-
- Under a nitrogen atmosphere, ethyl 4-cyano-5-methyl-4-(3-thienyl)hexanoate (1.8 g) was dissolved in dimethylformamide (7 mL), a solution of N-bromosuccinimide (1.33 g)/dimethylformamide (7 mL) was added dropwise thereinto at room temperature over 30 minutes. After stirring at 50° C. for 4.5 hours, the organic layer was separated by adding water and diethyl ether thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated, to give ethyl 4-cyano-5-methyl-4-[4-(2-bromo)thienyl]hexanoate (2.42 g) as a yellow oil. The resulting bromo compound (2.42 g) was dissolved in a solution in which zinc cyanide (637 mg) and 1,1′-bis (diphenylphosphino) ferrocene (188 mg) were dissolved in a mixed solution of dimethylformamide (17 mL)/water (0.17 mL) under a nitrogen atmosphere. Palladium-dibenzilideneacetone complex (124 mg) was added thereto. After replacing the atmosphere with nitrogen three times, the mixture was stirred at 120° C. for 5 hours. The organic layer was separated by adding water, diethyl ether and an aqueous ammonia water thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a yellow oil (338 mg, 17%, 2 steps). (Reference literature: P. E. Maligres et al, “Tetrahedron 40(1999) 8193-8195”)
-
-
- The title compound was obtained as a yellow oil in accordance with the above-mentioned LiBH4 reduction method (30%).
-
-
- The title compound was synthesized as a yellow oil in accordance with the methods described in Reference Examples 63, 64 and 65 (91%).
-
-
- Under nitrogen atmosphere, potassium tert-butoxide (869 mg) was added to a tetrahydrofuran solution (10 ml) of benzyl 4-(2-hydroxyethyl)-1-piperazinecarboxylate (1.86 g) in an ice bath. After stirring for one hour, the reaction system was transferred to a dry ice-methanol bath, and after 10 minutes, a 2,5-difluorobenzonitrile (1.09 g)/tetrahydrofuran solution (5 ml) was added thereto. After stirring for 2 hours while the temperature of the reaction system was naturally returned to a room temperature, an aqueous saturated ammonium chloride and diethyl ether were added thereto, to separate the organic layer. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give a colorless oil as an intermediate (1.10 g, 46%). The intermediate (1.10 g) was dissolved in methanol (10 mL), 10% palladium carbon (100 mg) was added, and the mixture was stirred at room temperature under hydrogen atmosphere. After 1.5 hours, the reaction catalyst was filtered through Celite, and the filtrate was evaporated. The resulting title compound (647 mg, 80%) obtained was used for the next reaction as it was.
- Free Body;
-
-
- Under nitrogen atmosphere, 4-cyano-5-methyl-4-(3-thienyl)hexanol (500 mg) was dissolved in dimethylformamide (5 mL), and N-bromosuccinimide (1.0 g) was added thereto at room temperature. After stirring at 100° C. for one hour, water and diethyl ether were added thereto, to separate the organic layer. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate system), to give the title compound as a yellow oil (670 mg, 78%).
-
-
- Under a nitrogen atmosphere, 4-(methylthio) phenol (4.2 g) and bromoethanol (5.6 g) were dissolved in dimethylformamide solution (60 ml), potassium carbonate (12.4 g) was added, and the mixture was heating under stirring at 100° C. After 3 hours, the mixture was cooled to room temperature, then the organic layer was separated by adding diethyl ether and water thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give (4-methylthiophenoxy)ethanol (3.55 g, 64%) as white crystals. The product (1.0 g) was dissolved in dichloromethane (50 ml), the mixture was cooled on a methanol-dry ice bath, methachloroperbenzoic acid (3.6 g) was added, and the mixture was stirred. After cooling naturally to room temperature over 2 hours, a 1N aqueous sodium bicarbonate and 1N Na2S2O3 were added. After stirring, the mixture was extracted with dichloromethane, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The residue was dissolved in acetonitrile (18 ml), triethylamine (2.3 ml) and methanesulfonyl chloride (0.5 ml) were added, and the mixture was stirred at room temperature. After 1.5 hours, sodium iodide (4.9 g) and tert-butyl-1-piperazinecarboxylate (1.2 g) were added, and the mixture was heated under stirring at 60° C. After stirring for 4.5 hours, the organic layer was separated by adding ethyl acetate and water. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering the drying agent, the mixture was evaporated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give tert-butyl-2-(4-methylthiophenoxy)ethyl-1-piperazinecarboxylate (1.15 g) as white crystals. The product (1.15 g) was dissolved in methanol (10 ml), and the solution was added to a 4N hydrochloric acid-ethyl acetate solution (30 ml) in an ice bath. After stirring at room temperature overnight, the resulting white crystals were collected by filtration and washed with diethyl ether. A 1N aqueous sodium hydroxide and dichloromethane were added to the crystals, to separate the organic layer. The resulting organic layer was evaporated, to give the title compound as a yellow oil (820 mg, 53%; 3 steps).
-
-
- Under a nitrogen atmosphere, 3-hydroxyacetophenone (4.1 g) and brominated ethanol (5.6 g) were dissolved in dimethylformamide solution (60 ml), and potassium carbonate (12.4 g) was added, and the mixture was heated under stirring at 100° C. After 3 hours, the mixture was cooled to room temperature, and the organic layer was separated by adding water and diethyl ether thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give (3-acetylphenoxy) ethanol (3.28 g, 61%) as white crystals. The product (977 mg) was dissolved in acetonitrile (18 ml), triethylamine (2.3 ml) and methanesulfonyl chloride (0.5 ml) were added, and the mixture was stirred at room temperature. After 1.5 hours, sodium iodide (4.9 g) and tert-butyl-1-piperazinecarboxylate (1.2 g) were added, and the mixture was heated under stirring at 60° C. After stirring for 4.5 hours, the organic layer was separated by adding water and ethyl acetate thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give tert-butyl-2-(3-acetylphenoxy)ethyl-1-piperazinecarboxylate (1.33 g) as a yellow oil. The product (1.33 g) was dissolved in methanol (10 ml), and the solution was added to a 4N hydrochloric acid-ethyl acetate solution (30 ml). The mixture was stirred at a room temperature overnight, the resulting white crystals were collected by filtration and washed with diethyl ether. The organic layer was separated by adding a 1N aqueous sodium hydroxide and dichloromethane to the crystals. The resulting organic layer was evaporated, to give the title compound (830 mg, 62%; 2 steps) as a yellow oil.
-
-
- tert-Butyl-1-piperazinecarboxylate (540 mg) was added to an acetonitrile solution (11 ml) of 1-iodo-4-cyano-5-methyl-4-(2-thienyl)hexane (744 mg) and triethylamine (0.93 ml) synthesized according to Example 84, and the mixture was stirred at 50° C. for 5 hours under nitrogen atmosphere. The reaction solution was evaporated, and then the resulting crude product was purified by silica gel column chromatography (hexane/ethyl acetate system), to give a colorless oil (705 mg, 81%). The resulting product (705 mg) was dissolved in methanol (5 ml), a 4N hydrochloric acid-ethyl acetate solution (15 ml) was added, and the mixture was stirred for 10 hours. Diethyl ether and ethyl acetate were added, and the mixture was stirred in an ice bath. The resulting hydrochloride of the title compound was collected by filtration (white crystals, 490 mg, 75%). The hydrochloride of the title compound obtained was extracted with dichloromethane and an aqueous saturated sodium bicarbonate, to be converted into a free body, and it was used for the next reaction.
- Hydrochloride:
-
-
- The title compound was synthesized in accordance with the production method of Reference Example 73.
- Free Body:
-
-
- The title compound was synthesized from tert-butyl-1-homopiperazinecarboxylate in accordance with Reference Example 73.
- Free Body:
-
-
-
-
-
-
- Under nitrogen atmosphere, diethyl cyanophosphonate (618 mg) was added to a tetrahydrofuran solution (15 ml) of 3-pyrroline (262 mg) and 4-cyano-4-(2-thienyl)-5-methylhexanoic acid (692 mg) at room temperature, and the mixture was stirred overnight. After the reaction solution was evaporated, the crude product was purified by silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a yellow oil (440 mg).
-
- In the physico-chemical data of the following compounds, the values obtained when NMR was measured for a free body and ESI-MS was measured for a hydrochloride. Further, the hydrochloride was produced in accordance with the method described in JP-A 11-206862.
-
- 867 mg (3.49 mmol) of 4-cyano-4-(5-cyano-2-thienyl)-5-methylhexanol was dissolved in 20 ml of acetonitrile. 0.58 ml (1.20 eq) of triethylamine and 0.30 ml (1.10 eq) of mesyl chloride were added thereto. After 10 minutes, brine was added, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The product was dissolved in 30 ml of acetonitrile, 1.57 g (3.00 eq) of sodium iodine, 0.54 ml (1.10 eq) of triethylamine and 845 mg (4.54 mmol) of (3R)-3-tert-butoxycarbonylaminopyrrolidine were added, and the mixture was heated at 60° C. After completion of the reaction, brine was added, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to 100 g of Cromatorex NH silica gel (ethyl acetate:hexane=25 to 35% of ethyl acetate), to give 1.34 g (3.21 mmol, 92.0%) of the title compound as a yellow oil. The physico-chemical data of the compound was as below.
-
-
- 1-[4-Cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3R)-3-tert-butoxycarbonylaminopyrrolidine (1.34 g=3.21 mmol) obtained in Reference Example 79 was dissolved in 10 ml of methanol, and 10 ml of a 4N hydrochloric acid-ethyl acetate solution was added. After completion of the reaction, the mixture was adjusted to basic with a 5N sodium hydroxide, and extracted with chloroform. The organic layer was dried over magnesium sulfate, and then evaporated, to give 998 mg (3.15 mmol, 99.5%, a red oil) of a crude product. The physico-chemical data of the compound was as below.
-
-
- 998 mg (3.15 mmol) of 1-[4-Cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3R)-3-aminopipyrrolidine obtained in Reference Example 80 was dissolved in 25 ml of methanol, 0.26 ml (3.94 mmol) of acrylonitrile was added, and the reaction solution was heated under reflux. After completion of the reaction, the mixture was evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (100% of ethyl acetate), to give 1.01 g (2.73 mmol, 86.7%) of the title compound as an orange oil. The physico-chemical data of the compound was as below.
-
-
- 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-4-(tert-butoxycarbonyl)piperazine was synthesized from 4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl iodide and tert-butyl 1-piperazinecarboxylate in accordance with the production method of Example 77. The title compound was obtained by carrying out the deprotection of a Boc group in. accordance with the production method of Reference Example 79. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Reference Example 73.
- Free Body:
-
-
- The title compound was synthesized in accordance with Reference Example 73.
- Free Body:
-
-
- The title compound was synthesized in accordance with
- Free Body:
-
-
- The title compound was obtained as a colorless oil in accordance with Reference Example 73.
-
-
- The title compound was obtained as a colorless oil in accordance with Reference Example 73.
-
-
- The title compound was obtained as a colorless oil in accordance with Reference Example 73.
-
-
- Methyl 4-fluorophenylacetate (10.0 g) was dissolved in tetrahydrofuran (150 ml), and 60% sodium hydride (5.95 g) was added under ice-cooling. After stirring for 10 minutes under ice cooling, 1,5-dibromopentane (11.3 ml) was added dropwise thereinto over one hour. After stirring at room temperature overnight, ice-water was added thereto, and the mixture was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and evaporated. The resulting residue was purified by silica gel column chromatography (n-hexane/ethyl acetate system), to give 7.37 g (53%) of an oil.
- The above-mentioned oil (7.37 g) was dissolved in tetrahydrofuran (100 ml), and a diethyl ether solution (18.7 ml) of 1.0 M lithium aluminum hydride was added dropwise thereinto at −50 to −40° C. After stirring at this temperature for 20 minutes, water, a 5N aqueous sodium hydroxide and further water were added under ice-cooling. The insoluble matters were filtered off through Celite, and the filtrate was evaporated. The resulting residue was purified by silica gel column chromatography (n-hexane/ethyl acetate system), to give 3.43 g (53%) of an oil.
- Oxalyl chloride (1.05 ml) was dissolved in methylene chloride (25 ml), and a methylene chloride solution (5 ml) of dimethyl sulfoxide (0.85 ml) was added dropwise at -60 to −50° C. After stirring for 2 minutes, a methylene chloride solution (10 ml) of the above-mentioned oil (2.08 g) was added dropwise therinto within 5 minutes. After stirring for 15 minutes at this temperature, triethylamine (6.96 ml) was added. After stirring for 5 minutes, the temperature was raised to room temperature. The mixture was washed with water and brine, dried over anhydrous magnesium sulfate and evaporated, to give 1.91 g (93%) of an oil.
- 60% Sodium hydride (0.55 g) was suspended in tetrahydrofuran (10 ml), and triethylphosphonoacetate (2.73 ml) in tetrahydrofuran (5 ml) was added dropwise thereinto under ice-cooling. After stirring for 15 minutes under ice-cooling, a tetrahydrofuran solution (15 ml) of the above-mentioned oil (1.89 g) was added dropwise thereinto. After stirring for 15 minutes at this temperature, the mixture was further stirred at room temperature for one hour. An aqueous saturated ammonium chloride was added thereto and the mixture was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and evaporated. The resulting residue was purified by silica gel column chromatography (n-hexane/ethyl acetate system), to give 2.07 g (82%) of an oil.
- The above-mentioned oil (1.02 g) was dissolved in ethanol (20 ml), 10% palladium-carbon (0.2 g) was added, and hydrogenation was carried out at room temperature under a normal pressure for 30 minutes. After filtering off the catalyst, the filtration was evaporated. The resulting residue was purified by silica gel column chromatography (n-hexane/ethyl acetate system), to give 0.97 g (94%) of an oil.
- The above-mentioned oil (9.03 g) was dissolved in ethanol (50 ml), and a 2N aqueous sodium hydroxide (50 ml) was added. After heating under reflux for 2 hours, the mixture was cooled to room temperature, and evaporated. The resulting residue was suspended in ethyl acetate, and the mixture was adjusted to
pH 2 with 5N hydrochloric acid. After drying over anhydrous magnesium sulfate, the mixture was evaporated. The resulting residue was recrystallized from ethyl acetate/n-hexane, to give 6.45 g (79%) of white crystals. - 1-Benzylpiperazine (2.82 g) was dissolved in N,N-dimethylformamide (40 ml), and the above-mentioned crystals (4.00 g) and 1-hydroxybenzotriazole (2.16 g) were added. Under ice-cooling, a N,N-dimethylformamide solution (30 ml) of 1,3-dicyclohexylcarbodiimide (3.63 g) was added dropwise thereinto. After stirring at room temperature overnight, the insoluble matters were filtered off, and the filtrate was extracted with ethyl acetate and 1N hydrochloric acid. The extract was washed with a 2N aqueous sodium hydroxide and brine, dried over anhydrous magnesium sulfate and evaporated. The resulting residue was purified by silica gel column chromatography (n-hexane/ethyl acetate system), to give 6.23 g (95%) of the title compound as an oil.
-
- ESI-Mass; 409 (MH+).
-
- 1-Benzyl-4-[3-[1-(4-fluorophenyl)cyclohexyl]-1-oxopropyl]piperazine (5.90 g) was dissolved in tetrahydrofuran (100 ml), and 80% lithium aluminum hydride (1.03 g) was added thereto under ice-cooling. After heating under reflux for 1.5 hours, the mixture was cooled as it was to room temperature. Under ice-cooling, water, a 1N aqueous sodium hydroxide and further water were added thereto, and the insoluble matters were filtered off. The filtrate was evaporated, and the resulting residue was recrystallized from ethanol, to give 4.48 g (79%) of the title compound as white crystals.
-
- ESI-Mass; 395 (MH+).
-
- 1-Benzyl-4-[3-[1-(4-fluorophenyl)cyclohexyl]propyl]piperazine (4.00 g) was dissolved in methanol (100 ml), and 20% palladium hydroxide-carbon (0.4 g) was added, and hydrogenation was carried out at room temperature under a normal pressure for 6 hours. After filtering off the catalyst, the filtrate was evaporated, to give 3.09 g of the title compound as an oil (quantitative).
-
- ESI-Mass; 305 (MH+).
-
- Ethyl 1-benzyl-4-(4-cyano-5-methyl-4-phenylhexyl)-2-piperazinecarboxylate (857 mg) was dissolved in ethanol (15 ml), and 770 mg of 10% Pd—C was added. After replacing the atmosphere with hydrogen, the mixture was stirred. After completion of the reaction, the solution was evaporated, to give 639 mg (93%) of the title compound as a crude product.
- Free Body:
-
-
- Ethyl 1-benzyl-4-[2-(4-fluorophenoxy)ethyl]-2-piperazinecarboxylate (977 mg) synthesized in accordance with Example 241 described later was dissolved in ethanol (15 ml), and 210 mg of 10% Pd—C was added. After replacing the atmosphere with hydrogen, the mixture was stirred. After completion of the reaction, the solution was evaporated, to give 752 mg (100%) of the title compound as a crude product.
- Free Body:
-
- Among the production intermediates for producing the compound according to the present invention, optically active intermediates can be produced in accordance with known production methods or methods according to them, and additionally, for example, can be produced according to the following methods.
-
- 47.6 g (0.39 mol) of 2-thiopheneacetonitrile and 57.0 g (0.46 mol) of 2-bromopropane were dissolved in 100 ml of DMSO, anda 50% KOH aqueous solution was added dropwise to the solution. After completion of the reaction, water was added, and the mixture was extracted with toluene. After washing with brine and an aqueous saturated ammonium chloride, the mixture was dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to distillation under a reduced pressure (2 to 3 mmHg: 132 to 137 deg), to give 46.4 g (0.28 mol, 72.7%) of the title compound as a colorless oil. The physico-chemical data of the compound was as below.
-
-
- 1.49 g (13.3 mmol, cat.) of potassium tert-butoxide was dissolved in 120 ml of DMF, and a mixed solution of 43.9 g (0.27 mol) of 3-methyl-2-(2-thienyl)butanenitrile and 30.2 ml (0.28 mol) of ethyl acrylate was added little by little to the solution at room temperature. (when a raw material remains, ethyl acrylate and potassium tert-butoxide were additionally added.) It was exothermically continued during the addition. After completion of the reaction, 100 ml of brine and 200 ml of an aqueous saturated ammonium chloride were successively added, and the objective product was extracted with 500 ml of hexane. The organic layer was washed with 400 ml of brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated, to give 67.0 g of a crude product of an ester (ethyl 4-cyano-5-methyl-4-(2-thienyl)hexanolate) as a yellow oil. The physico-chemical data of the compound was as below.
-
-
- 67.0 g of the above-mentioned ester obtained in Example was dissolved in 500 ml of tetrahydrofuran, 200 ml of 5N NaOH and 50 ml of ethanol were added to the solution, and the mixture was stirred. After completion of the reaction, the solution was evaporated. The aqueous layer containing the objective product was washed 4 times with 200 ml of toluene. Then, 320 ml of 5N HCl was added thereto, to adjust pH to 1-2, and the objective product was extracted with 750 ml of toluene. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give 55.6 g (yellow oil) as a crude carboxylic acid. The carboxylic acid was dissolved in 150 ml of toluene, and 22.5 g (0.23 mol) of cyclohexylamine was added. The resulting white crystals were collectedby filtration, to give 55.6 g (0.17 mol) of the title compound. The physico-chemical data of the compound was as below.
-
-
- 55 g (0.16 mol) of cyclohexylamine salt of dl-4-cyano-4-(2-thienyl)-5-methylhexanoic acid was suspended in 100 ml of 5N HCl and 50 ml of water, and the mixture was extracted with 300 ml of toluene. The extract was washed with 2N HCl and brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated, to give 38.7 g crude carboxylic acid. 38.7 g of the crude dl-4-cyano-4-(2-thienyl)-5-methylhexanoic acid was dissolved in 120 ml of toluene. 18.8 g (0.14 mol, 0.85 eq) of (S)-1-(4-methylphenyl) ethylamine/40 ml of toluene was added to the solution containing this carboxylic acid. To the mixture was added the crystals (6 mg) of the title compound previously prepared, and the mixture was cooled as it was. The resulting diastereomer salt (Salt 1) was collected by filtration. The
Salt 1 was dissolved by heating in 250 ml of toluene, and the mixture was cooled as it was to room temperature under stirring. The resulting diastereomer salt (Salt 2: optical purity of 90.5% ee) was collected by filtration, to give 21.3 g (57.2 mmol, 35.1%) (optical purity of 90.5% ee) of the title compound. - dl-4-Cyano-4-(2-thienyl)-5-methylhexanoic acid (96.6 mmol) was converted into a salt in accordance with the above-mentioned dividing method and crystallized, and then recrystallization was repeated twice, to give 14.5 g (38.9 mmol, 40.3%) (optical purity of 95% ee<) of the title compound. The physico-chemical data of the compound was as below. Further, the condition for HPLC analysis was shown below, and the analysis data (HPLC chart) were shown in FIG. 1.
-
- Condition for HPLC Analysis:
- Column: Daicel Chemical Industries, Ltd., CHIRALCEL OJ, 4.6×250 mm
- Mobile phase: 20% (B),
- (A) Mixed solution of n-hexane/trifluoroacetic acid (1000:1)
- (B) Mixed solution of n-hexane/isopropanol/trifluoroacetic acid (500:500:1)
- Flow rate: 0.5 ml/min.
- Detector: UV 231 nm
- Retention time: 15.5 min.
-
- Optically active 4-cyano-4-(2-thienyl)-5-methylhexanoic acid•(S)-1-phenylethylamine salt (107.7 g, 39%) (white crystals, optical purity of 96.9% ee) could be obtained also by using (S)-1-phenylethylamine (67.4 g) and toluene (990 ml) to dl-4-cyano-4-(2-thienyl)-5-methylhexanoic acid (168.8 g) in accordance with the method of Reference Example 97. The physico-chemical data of the compound was as below.
-
- EI-Mass (m/z): 135, 177, 195, 273 (M+)
- Melting point: 136-144° C.
- Condition for HPLC Analysis:
- Column: Daicel Chemical Industries Ltd., (Tokyo) CHIRALCEL OJ,
- Mobile phase: 10% (B),
- (A) n-hexane/trifluoroacetic acid (1000:1)
- (B) n-hexane/2-propanol/trifluoroacetic acid (500:500:1)
- Flow rate: 0.5 ml/min.
- Detector: UV 231 nm
- Retention time: 26.2 min.
-
- The title compound was obtained as white crystals using (R)-1-phenylethylamine and dl-4-cyano-4-(2-thienyl)-5-methylhexanoic acid in accordance with the method of Reference Example 98.
- Melting point: 136-144° C.
- Condition of HPLC Analysis:
- Column: Daicel Chemical Industries Ltd., (Tokyo) CHIRALCEL OJ,
- Mobile phase: 10% (B),
- (A) n-hexane/trifluoroacetic acid (1000:1)
- (B) n-hexane/2-propanol/trifluoroaceticacid (500:500:1)
- Flow rate: 0.5 ml/min.
- Detector: UV 231 nm
- Retention time: 19.9 min.
-
- 5.6 g (optical purity of 86.7% ee) of the title compound was obtained as white crystals from dl-A-cyano-4-(3-thienyl)-5-methylhexanoic acid (11.4 g) and (S)-1-(4-methylphenyl)ethylamine (5.45 g) synthesized in accordance with Reference Examples 96 and 97. The physico-chemical data of the compound was as below. Further, the condition for HPLC analysis was shown below, and the analysis data (HPLC chart) were shown in FIG. 2.
- Free Body: 4-Cyano-4-(3-thienyl)-5-methylhexanoic acid;
-
- Salt: 4-Cyano-4-(3-thienyl)-5-methylhexanoic acid•(S)-1-(4-methylphenyl)ethylamine salt
-
- Condition of HPLC Analysis:
- Column: Daicel Chemical Industries Ltd., (Tokyo) CHIRALCEL OJ,
- Mobile phase: Hexane:IPA:TFA (900:100:1)
- Flow rate: 0.5 ml/min.
- Detector: UV 235 nm
- Retention time: 15.7 min.
-
- The free body of the title compound (3.94 g) was obtained by treating 4-cyano-4-(3-thienyl)-5-methylhexanoic acid•(S)-1-(4-methylphenyl)ethylamine salt (5.6 g) with an aqueous hydrochloric acid, in accordance with the method of Reference Example 97, to produce the title free compound (3.94 g). The physico-chemical data of the compound was as below. Further, the condition of HPLC analysis are shown below, and the analysis data (HPLC chart) are shown in FIG. 2.
-
-
- The title compound (35%, optical purity of 88.5% ee) was obtained as white crystals using (R)-1-(4-methylphenyl) ethylamine and dl-4-cyano-4-(3-thienyl)-5-methylhexanoic acid, in accordance with the production method of Example. Melting point: 140-143° C.
- Condition of HPLC Analysis:
- Column: Daicel Chemical Industries Ltd., (Tokyo) CHIRALCEL OJ,
- Mobile phase: Hexane:IPA:TFA (900:100:1)
- Flow rate: 0.5 ml/min.
- Detector: UV 235 nm
- Retention time: 12.8 min.
-
- The title compound was produced using (R)-1-(4-methylphenyl)ethylamine and dl-4-cyano-4-(2-thienyl)-5-methylhexanoic acid, in accordance with the production method of Reference Example 97. The condition of HPLC analysis are shown below, and the analysis data (HPLC chart) are shown in FIG. 3.
- Condition of HPLC Analysis:
- Column: Daicel Chemical Industries, Ltd., CHIRALCEL OJ, 4.6×250 mm
- Mobile phase: 20% (B),
- (A) Mixed solution of n-hexane/trifluoroacetic acid (1000:1)
- (B) Mixed solution of n-hexane/isopropanol/trifluoroacetic acid (500:500:1)
- Flow rate: 0.5 ml/min.
- Detector: UV 231 nm
- Retention time: 12.8 min.
-
- 4-Cyano-4-(2-thienyl)-5-methylhexanoic acid•(S)-1-(4-methylphenyl)ethylamine salt obtained from Reference Example 97 was returned to its carboxylic acid free form in accordance with Reference Example 97. 8.31 g (35.0 mmol) of this form was dissolved in 140 ml of tetrahydrofuran, 3 drops of N,N-dimethylformamide were added by Pasteur pipette, and the mixture was ice-cooled. To the reaction solution was added dropwise 3.5 ml (40.3 mmol) of oxalyl chloride, followed by warming to room temperature and stirring for 1.5 hours. After evaporating the reaction solvent, 80 ml of tetrahydrofuran was added and the solution was ice-cooled again. 75 ml of methanol and 6.10 ml (43.8 mmol) of triethylamine were added thereto, and the solution was stirred while warming to room temperature. After completion of the reaction, the solution was extracted with ethyl acetate. The extract was washed with an aqueous saturated sodium bicarbonate and brine, and dried over magnesium sulfate. The solvent was evaporated, and the resulting crude product obtained was crudely purified by silica gel column chromatography (hexane/ethyl acetate system), to give 8.00 g (31.8 mmol, 90.9%) of a methyl ester. 8.00 g (31.8 mmol, 90.9%) of the ester was dissolved in 50 ml of tetrahydrofuran. The solution was added dropwise into a THF suspension of 845 mg (22.3 mmol) of lithium aluminum hydride cooled to the outer temperature of −50 to −40° C., followed by heating to the outer temperature of −20° C. over 0.5 hour. After completion of the reaction, the solution was cooled again, 0.9 ml of water, 0.9 ml of 5N NaOH and 2.70 ml of water were successively added, and then filtered through Celite. Then, the filtrate was evaporated, and the resulting crude product was purified by silica gel column chromatography (n-hexane/ethyl acetate system), to give 6.60 g (29.6 mmol, 93.1%) of the title compound as a colorless oil. The physico-chemical data of the compound was as below.
- Carboxylic Acid A:
-
- Methyl Ester Obtained from Carboxylic Acid A:
-
- Alcohol A:
-
-
- Bromination reaction and successively cyanation reaction were carried out using the alcohol A obtained in Reference Example 104, as a starting material in accordance with Example 80. Namely, optically active 4-cyano-4-(5-bromo-2-thienyl)-5-methylhexanol was synthesized by the bromination reaction, and the cyanation reaction was carried out without purifying it, to give the title compound at a yield of 77.9%. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with the method of Example 86-5) described in JP-A 11-206862.
-
- Further, the free body is treated in accordance with the method of Example 20 described in JP-A 11-206862, to give the hydrochloride of the title compound.
- ESI-Mass; 448 (MH+)
-
- In acetonitrile (3 ml) was dissolved 1-benzyl-2-pyrrolidinemethanol (83 mg), followed by adding triethylamine (0.18 ml) andmesyl chloride (0.037 ml). After stirring at room temperature for one hour, an acetonitrile solution (3 ml) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine (124 mg) was added. After heating under reflux for 3 hours, the mixture was left to be cooled to room temperature. Ethyl acetate was added thereto, and the mixture was washed with water and brine. After drying over anhydrous magnesium sulfate, it was evaporated. The resulting residue was purified by (NH) silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (58 mg, 29%). Further, the free body was converted into a hydrochloride in a conventional method, to give the hydrochloride of the title compound.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 459 (MH+)
-
- In 1,2-dichloroethane (6 ml) was dissolved 1-[4-cyano-5-methyl-4-phenyl)hexyl]piperazine (0.19 g), followed by adding benzofuran-2-carboaldehyde (0.11 g), acetic acid (0.095 ml) and sodium triacetoxyborohydride. After stirring for 3 hours at a room temperature, ethyl acetate was added thereto and the mixture was washed with water and further brine. After drying over anhydrous magnesium sulfate, it was evaporated. The resulting residue was purified by (NH) silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as apale yellow oil (0.28 g, quantitatively). Further, the free body was converted into a hydrochloride in a conventional method, to give a hydrochloride of the title compound.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 416 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 3 (86%). Further, the free body was converted into a hydrochloride in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 430 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 3 (76%). Further, the hydrochloride of the title compound was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 415 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 3 (62%). Further, the hydrochloride of the title compound was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 427 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 3 (47%). Further, the hydrochloride of the target compound was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 427 (MH+)
-
- 1-[(4-Cyano-5-methyl-4-phenyl)hexyl]piperazine (150 mg) was dissolved in N,N-dimethylformamide (5 ml). To the mixture were added 1-hydroxybenzotriazole (71 mg) and 1,2,3,4-tetrahydro-2-naphthenoic acid (93 mg), followed by further adding a N,N-dimethylformamide solution (2 ml) of dicyclohexylcarbodiimide (120 mg). After stirring overnight at room temperature, the insoluble matters were filtered off and ethyl acetate was added to the filtrate. A small amount of 1N hydrochloric acid was added and the mixture was stirred. Then, the mixture was washed with an aqueous saturated sodium carbonate and further with brine, dried over anhydrous magnesium sulfate, and then evaporated. The resulting residue was purified by (NH) silica gel column chromatography (n-hexane/ethyl acetate system), to give the title compound as a pale yellow oil (220 mg, 94%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 444 (MH+)
-
- In tetrahydrofuran (5 ml) was dissolved 1-[4-cyano-5-methyl-4-phenyl]hexyl]-4-(1,2,3,4-tetrahydro-2-naphthoyl)piperazine (150 mg), followed by adding 1.0 M borane/tetrahydrofuran complex (1.35 ml) under ice-cooling. After stirring at room temperature for 5 hours, the mixture was evaporated. Methanol (5 ml) and 2N hydrochloric acid (5 ml) were added to the residue, followed by stirring at 80° C. for one hour. After cooling as it was to room temperature, the mixture was evaporated. Ethyl acetate was added thereto, and the mixture was washed with an aqueous saturated sodium carbonate and further brine, dried over anhydrous magnesium sulfate, and then evaporated. The resulting residue was purified by preparative thin layer silica gel column chromatography (methylene chloride/methanol), to give the title compound as a pale yellow oil (72 mg, 50%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 430 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 8 (86%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 448 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 9 (56%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 434 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 8 (82%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 443 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 9 (40%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 429 (MH+)
-
- In methanol (5 ml) was dissolved 2-[(4-cyano-5-methyl-4-phenyl)hexyl]-5-benzyl-2,5-diazabicyclo[2,2,1]heptane (37 mg). To the mixture was added 20% palladium hydroxide-carbon (10 mg), followed by subjecting to hydrogenation at room temperature under normal pressure for 8 hours. After the catalyst was filtered off, the filtrate was evaporated, to give the residue as a pale yellow oil (29 mg). In N,N-dimethylformamide (3 ml) was dissolved the residue, followed by adding a N,N-dimethylformamide solution (2 ml) of triethylamine (0.027 ml) and 2-(4-fluorophenoxy) ethyl bromide (25 mg). After stirring at 50° C. overnight, the solution was left to be cooled to room temperature. Ethyl acetate was added thereto, and the mixture was washed with water and further brine. After drying over anhydrous magnesium sulfate, it was evaporated. The resulting residue was purified by preparative thin layer silica gel column chromatography (methylene chloride/methanol), to give the title compound as a pale yellow oil (20 mg, 48%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 436 (MH+)
-
- In acetonitrile (6 ml) was dissolved 4-cyano-5-methyl-4-phenylhexanol (120 mg), followed by adding triethylamine (0.23 ml) and mesyl chloride (0.051 ml) at room temperature. After stirring at room temperature for one hour, an acetonitrile solution (3 ml) of 1-phenyl-1,3,8-triazaspiro-[4,5]decan-4-one (140 mg) was added thereto. After heating under reflux for 2.5 hours, the solution was left tobe cooled to room temperature. Ethyl acetate was added thereto, and the mixture was washed with water and further brine. After drying over anhydrous magnesium sulfate, it was evaporated. The resulting residue was purified by preparative thin layer silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (61 mg, 26%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 431 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 15 (23%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 417 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 15 (30%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 417 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 15 (52%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 433 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 15 (30%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 447 (MH+)
-
- In N,N-dimethylformamide (3 ml) was dissolved 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[(2-benzothiazolyl)amino]piperidine (50 mg) synthesized in Example 18, followed by adding 60% sodium hydride (7 mg). After stirring at 50° C. for one hour, 2-bromopropane (0.012 ml) was added. After further stirring at 50° C. overnight, 2-bromopropane (0.012 ml) was additionally added. After further stirring at 50° C. for 6 hours, 60% sodium hydride (7 mg) was additionally added. After further stirring at 50° C. overnight, the solution was left to be cooled to room temperature. Ethyl acetate was added, and the mixture was washed with water and further brine. After drying over anhydrous magnesium sulfate, it was evaporated. The resulting residue was purified by (NH) silica gel column chromatography (hexane/ethyl acetate system) to give the title compound as a pale yellow oil (31 mg, 57%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 475 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 15 (12%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 430 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 15 (54%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 458 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 15 (30%). Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 489 (MH+)
-
- The title compound was obtained as a pale yellow oil (21%) in accordance with the method of Example 35 described later. Further, the hydrochloride of the free body (the title compound) was obtained in a conventional method.
-
- Hydrochloride:
- ESI-Mass; 491 (MH+)
-
- In acetonitrile (5 ml) was dissolved 310 mg (1.16 mmol) of 4-cyano-5-methyl-4-(2-naphthyl)hexanol, followed by adding 190 μL (1.36 mmol) of triethylamine and 105 μl (1.36 mmol) of mesyl chloride. After completion of mesylation, 1.11 g (7.38 mmol) of sodium iodide, 255 mg (1.85 mmol) of potassium carbonate, 414 mg (1.85 mmol) of 1-[2-(4-fluorophenoxy)ethyl]piperazine, 5 ml of dimethylformamide and 1 ml of water were added thereto, followed by heating to 60° C. After completion of the reaction, brine was added thereto and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to (NH) silica gel (eluted with ethyl acetate/hexane=2/3), to give 384 mg (0.81 mmol, 69.9%) of the title compound as a yellow syrup.
-
- ESI-Mass; 474 (M+H+)
-
- The title compound was obtained as a colorless oil in accordance with the method of Example 25 (yield: 57.8%).
-
- ESI-Mass; 474 (M+H+)
-
- 4-Cyano-5-methyl-4-(2-pyridyl)hexanol synthesized in accordance with the method of Example 25 was oxidized by SO3-pyridine, which is a conventional method. The resulting crude aldehyde compound was subjected to reductive amination reaction in accordance with the method of Example 42 which is described later, to synthesize the title compound as a colorless oil (yield: 69.1%).
-
- ESI-Mass; 425 (M+H+)
-
- The title compound was obtained as a yellow oil in accordance with the method of Example 25 (yield: 70%).
-
- ESI-Mass; 425 (M+H+)
-
- In acetonitrile (2 ml) was dissolved 100 mg (0.30 mmol) of 4-cyano-5-methyl-5-phenylhexyl iodide. To the mixture were added 55 mg (0.36 mmol) of potassium carbonate and 60 mg (0.36 mmol) of phenylpiperazine, followed by heating to 60° C. After completion of the reaction, the solution was partitioned with ethyl acetate and brine. The organic layer was dried over magnesium sulfate, and then evaporated, to give a crude product. The crude product was subjected to 20 g of Chromatorex NH silica gel (ethyl acetate/hexane=1/5), to give 137 mg (quantitative) of the title compound as a colorless syrup. The physico-chemical data of the title compound was as below.
-
- ESI-Mass; 362 (M+H+)
-
- The title compound was synthesized by using 1-(2-phenylethyl)piperazine in accordance with the method of Example 29 (yield: 100%: a colorless oil).
-
- ESI-Mass; 390 (M+H+)
-
- The title compound was synthesized by using 1-(3-phenylpropyl)piperazine in accordance with the method of Example 29 (yield; 100%: a colorless oil).
-
- ESI-Mass; 404 (M+H+)
-
- In dichloromethane (7 ml) was dissolved 250 mg (0.74 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-3-[N-(2-cyanoethyl)amino]pyrrolidine, followed by successively adding 171 mg (1.11 mmol) of 3-fluorophenoxyacetaldehyde separately synthesized, 0.08 ml (1.48 mmol) of acetic acid and 235 mg (1.11 mmol) of sodium triacetoxyborohydride. After completion of the reaction, the solution was adjusted to basic with a 2N sodium hydroxide, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated, to give a crude product. The crude product was subjected to 25 g of Chromatorex NH silica gel (ethyl acetate/hexane=1/3), to give 290 mg (0.61 mmol, 82.2%) of the title compound as a colorless syrup.
-
- ESI-Mass; 477 (M+H+)
-
- In dichloromethane (7 ml) was dissolved 250 mg (0.74 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-3-[N-(2-cyanoethyl)amino]pyrrolidine, followed by successively adding 179 mg (1.11 mmol) of 3-cyanophenoxyacetaldehyde separately synthesized in the same manner as in the production of 3-fluorophenoxyacetaldehyde, 0.08 ml (1.48 mmol) of acetic acid and 235 mg (1.11 mmol) of sodium triacetoxyborohydride. After completion of the reaction, the solution was adjusted to basic with a 2N sodium hydroxide and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 25 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/3), to give 318 mg (0.66 mmol, 88.9%) of the title compound as a colorless syrup.
-
- ESI-Mass; 484 (M+H+)
-
- In dichloromethane (7 ml) was dissolved 263 mg (0.78 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-3-[N-(2-cyanoethyl)amino]pyrrolidine, followed by successively adding 251 mg (1.56 mmol) of 3-cyanophenoxyacetaldehyde separately synthesized, 0.09 ml (1.56 mmol) of acetic acid and 247 mg (1.17 mmol) of sodium triacetoxyborohydride. After completion of the reaction, the solution was adjusted to basic with a 2N sodium hydroxide, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 25 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/3), to give 311 mg (0.64 mmol, 82.4%) of the title compound as a yellow syrup.
-
- ESI-Mass; 484 (M+H+)
-
- In acetonitrile (5.00 ml) was dissolved 217 mg (1.00 mmol) of 4-cyano-5-methyl-5-phenylhexylhexanol, followed by cooling to 0° C. To the mixture were added 320 μl (2.30 eq) of triethylamine and 85 μl (1.10 eq) of mesyl chloride, followed by heating to room temperature. After 15 minutes, 450 mg (3.00 eq) of sodium iodide and 370 mg (1.30 mmol) of 3-[N-(2-cyanoethyl)-N-{2-(4-cyanophenoxy)ethyl}amino]pyrrolidine were added, and the mixture was heated to 60° C. After completion of the reaction, brine was added and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to 37 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/1), to give 316 mg (0.65 mmol, 65%) of the title compound as a yellow syrup.
-
- ESI-Mass; 484 (M+H+)
-
- The title compound was synthesized by using 4-cyano-5-methyl-5-(2-thienyl)hexanol in accordance with the method of Example 35 (yield: 38%; a pale yellow syrup).
-
- ESI-Mass; 490 (M+H+)
-
- The title compound was synthesized by using 4-cyano-5-methyl-5-(2-thienyl)hexanol and 3-cyanophenoxyacetaldehyde in accordance with the method of Example 35 (yield: 98%; a pale yellow syrup).
-
- ESI-Mass; 490 (M+H+)
-
- (6-Phenylpyridin-3-yl)methanol (185 mg, 1.00 mmol) and triethylamine 0.29 ml were dissolved in 5 ml of acetonitrile, and 85.1 μl (1.10 mmol) of methanesulfonyl chloride was added dropwise thereinto. After confirming the extinction of a raw material by thin layer chromatography, 340 mg (1.19 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine was added to the reaction solution at room temperature, and successively 899 mg of sodium iodide, 5 ml of dimethylformamide and 1 ml of water were added. Then, the mixture was heated to 80° C. After completion of the reaction, brine was added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/2), to give 300 mg (0.66 mmol, 66.3%) of the title compound as a yellow oil.
-
- ESI-Mass; 453 (M+H+)
-
- (5-Phenylisoxazol-3-yl)methanol (61.3 mg, 0.35 mmol) and triethylamine 0.10 ml were dissolved in 3 ml of acetonitrile, followed by adding dropwise 27.1 μl (0.35 mmol) of methanesulfonyl chloride thereinto. After confirming the extinction of a raw material by thin layer chromatography, 100 mg (0.35 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine was added to the reaction solution at room temperature, and successively 262 mg of sodium iodide and 2 ml of dimethylformamide were added. Then, the mixture was heated to 70° C. After completion of the reaction, brine was added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 15 g of Cromatorex NH silica gel (ethyl acetate/hexane=2/3), to give 45 mg (0.10 mmol, 29.0%) of the title compound as a yellow syrup.
-
- ESI-Mass; 443 (M+H+)
-
- (2-Phenylthiazol-4-yl)methanol (66.9 mg, 0.35 mmol) and 0.10 ml of triethylamine were dissolved in 3 ml of acetonitrile, and 27.1 μl (0.35 mmol) of methanesulfonyl chloride was added dropwise thereinto. After confirming the extinction of a raw material by thin layer chromatography, 100 mg (0.35 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine was added to the reaction solution at room temperature. Further, 262 mg of sodium iodide, 2 ml of dimethylformamide and 2 ml of acetonitrile were added thereto, followed by heating to 70° C. After completion of the reaction, brine was added thereto and the mixture was extracted with ethylacetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 15 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/2), to give 63 mg (0.14 mmol, 40.0%) of the title compound as a colorless syrup.
-
- ESI-Mass; 459 (M+H+)
-
- (2-Phenyloxazol-4-yl) methanol (61.3 mg, 0.35 mmol) and 0.10 ml of triethylamine were dissolved in 3 ml of acetonitrile, and 27.1 μl (0.35 mmol) of methanesulfonyl chloride was added dropwise thereinto. After confirming the extinction of a raw material by thin layer chromatography, 100 mg (0.35 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine was added to the reaction solution at room temperature. Further, 262 mg of sodium iodide and 2 ml of dimethylformamide were added thereto, followed by heating to 70° C. After completion of the reaction, brine was added thereto and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 15 g of Cromatorex NH silica gel (ethyl acetate/hexane=2/3), to give 41 mg (0.09 mmol, 26.5%) of the title compound as a colorless syrup.
-
- ESI-Mass; 443 (M+H+)
- Further, in the above-mentioned Examples, (6-phenylpyridin-3-yl)methanol and (5-phenylisoxazol-3-yl)methanol are synthesized in accordance with the method described in Med.Chem.1998, 41, 2390-2410, (2-phenyloxazol-4-yl)methanol was synthesized in accordance with the method described in Org.Chem.1996, 61, 6496-6497, and (2-phenylthiazol-4-yl)methanol was synthesized in accordance with the method described in Bull. Chem. Soc. Jpn. 71, 1391-1396 (1998).
-
- 5 ml of 2-(4-phenyl-2-oxo-3-oxazolidinyl)acetaldehyde dimethylacetal was dissolved in 5 ml of acetone and 6 mL of 2.5N hydrochloric acid, and the mixture was heated. After completion of the reaction, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give 300 mg of a crude product of 2-(4-phenyl-2-oxo-3-oxazolidinyl)acetaldehyde. The crude product was used for the following reaction without purification. Namely, 2-(4-phenyl-2-oxo-3-oxazolidinyl)acetaldehyde was dissolved in 5 ml of dichloroethane, and 300 mg (1.46 mmol) of the above-mentioned 2-(4-phenyl-2-oxo-3-oxazolidinyl)acetaldehyde, 0.11 ml (2.00 mmol) of acetic acid and 318 mg (1.50 mmol) of sodium triacetoxyborohydride were successively added. After completion of the reaction, the solution was adjusted to basic with a 2N sodium hydroxide, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/1), to give 477 mg (0.94 mmol, 94.2%) of the title compound as a colorless syrup.
-
- ESI-Mass; 475 (M+H+)
-
- 5-(Hydroxymethyl)-3-phenyl-2-oxooxazolidine was synthesized in accordance with the method described in J. Med. Chem. 989 673-1681. The 5-(hydroxymethyl)-3-phenyl-2-oxooxazolidine (193 mg, 1.00 mmol) and 0.29 ml of triethylamine were dissolved in 5 ml of acetonitrile, followed by adding dropwise 85.1 μl (1.10 mmol) of methanesulfonyl chloride thereinto. After confirming the extinction of a raw material by thin layer chromatography, 340 mg (1.19 mmol) of 1-[(4-cyano-5-methyl-4-phenyl) hexyl]piperazine was added to the reaction solution at a room temperature, and successively 899 mg of sodium iodide, 5 ml of dimethylformamide and 1 ml of water were added. Then, the mixture was heated to 60° C. After completion of the reaction, brine was added and the mixture was extracted with ethylacetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 50 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/1), to give 110 mg (0.24 mmol, 23.9%) of the title compound as a yellow oil.
-
- ESI-Mass; 461 (M+H+)
-
- In tetrahydrofuran (3 ml) were dissolved 95.3 Mg (0.70 mmol) of benzamidoxime and molecular sieve 4A (400 mg). To the mixture were added 32 mg (0.8 mmol) of sodium hydride and further 20 mg were added, followed by heating to 60° C. After 10 minutes, 3 ml of tetrahydrofuran solution of 500 mg (1.40 mmol) of 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[(methoxycarbonyl)methyl]piperazine was added thereto, followed by heating under reflux. After completion of the reaction, brine was added and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to preparative chromatography (ethyl acetate: 10%) and further subjected to 25 g of Cromatorex NH silica gel (ethyl acetate/hexane=3:5), to give 127 mg (0.29 mmol, 40.9%) of the title compound as a colorless oil.
-
- ESI-MS; 444 (M+H+)
-
- The title compound was synthesized by using 3-fluorobenzamidoxime in accordance with the method for producing 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]piperazine in Example 44 (yield; 26%: a pale yellow syrup).
-
- ESI-MS; 462 (M+H+)
-
- In acetonitrile (2 ml) was dissolved 100 mg (0.30 mmol) of 4-cyano-5-methyl-4-phenylhexyl iodide. To the mixture were added 55 mg (0.36 mmol) of sodium carbonate and 80 mg (0.36 mmol) of 4-[(2-(4-fluorophenoxy)ethyl)piperidine, followed by heating to 60° C. After completion of the reaction, the mixture was partitioned between ethyl acetate and brine. The organic layer was dried over magnesium sulfate and then evaporated, to give a crude product. The crude product was subjected to 40 g of Cromatorex NH silica gel (ethyl acetate/hexane=1:5), to give 120 mg (0.28 mmol, 94.7%) of the title compound as a colorless syrup. The physico-chemical data of the title compound was as below.
-
- ESI-MS; 423 (M+H+)
-
- In DMF (70 ml) was dissolved 2.39 g (15.0 mmol) of 3-methyl-2-phenylpentanenitrile. To the mixture was added 600 mg (60% by weight, 15.0 mmol) of sodium hydride, followed by heating to 60° C. After 30 minutes, the reaction solution was returned to room temperature, 2.90 g (9.31 mmol) of 1-benzyl-4-methanesulfonyloxypropylpiperidine dissolved in 10 ml of DMF was added, and the mixture was heated again. After completion of the reaction, the mixture was partitioned between ethyl acetate and brine. The organic layer was dried over magnesium sulfate, and then evaporated, to give a crude product. The crude product was subjected to 100 g of silica gel (ethyl acetate/hexane=1/100 to 1/0), to give 2.57 g (6.86 mmol, 73.7%) of the title compound as a yellow oil.
-
-
- In acetonitrile (5 ml) was dissolved 200 mg (0.70 mmol) of 4-[(4-cyano-5-methyl-4-phenyl)hexyl]piperidine. To the mixture were added 69 mg (0.50 mmol) of potassium carbonate and 110 mg (0.50 mmol) of 4-fluorophenoxyethyl bromide, followed by heating to 60° C. After completion of the reaction, the mixture was partitioned between ethyl acetate and brine. The organic layer was dried over magnesium sulfate, and then evaporated, to give a crude product. The crude product was subjected to 40 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/7), to give 160 mg (0.38 mmol, 76.0%) of the title compound as a colorless syrup. The physico-chemical data of the compound was as below.
-
- ESI-MS; 423 (M+H+)
-
- The free body of the title compound was obtained as a yellow oil from 3-cyano-3-(2-thienyl)propanol (114 mg) and 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine(90 mg) (refer to Formula 86 shown in JP-A 10-280103) (63 mg, 22%).
- Free Body:
-
- Further, 63 mg of the above-mentioned free body (the title compound) was treated in a conventional method, to give 60 mg of the hydrochloride.
- Hydrochloride:
- ESI-Mass; 449 (MH+)
-
- 2-[(3-Cyano-3-phenyl)propyl}-1,3-dioxolane (1.77 g) was dissolved in a solution of 2N HCl (15 mL) and tetrahydrofuran (15 mL). After stirring at room temperature for 13 hours, 2N NaOH (15 mL) and ethyl acetate were added thereto, to separate the organic layer. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. 99 mg among the residue obtained (5-oxo-2-phenylpropanenitrile), 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine (99 mg) and acetic acid (0.1 mL) were dissolved in dichloromethane (3.5 mL), and sodium triacetoxyborohydride (147 mg) was added. After stirring at room temperature for 18 hours 30 minutes, the mixture was neutralized by adding an aqueous saturated sodium bicarbonate thereto, and then extracted with dichloromethane. The resulting organic layer was dried over anhydrous magnesium sulfate. After filtering off the drying agent, the mixture was evaporated. The resulting residue was purified by NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound (136 mg, 88%: yield was calculated based on 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine).
-
- Further, 136 mg of the above-mentioned free body (the title compound) was treated according to a conventional method, to give 141 mg of the hydrochloride.
- Hydrochloride:
- ESI-Mass; 461 (MH+)
-
- An acetonitrile solution (10 mL) in which 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine (100 mg), 4-chloro-4′-fluorobutyrophenone (91 mg) and triethylamine (0.1 mL) were dissolved was stirred under a reflux condition. After 6 hours, the reaction solution was cooled to a room temperature, the organic layer was seprated by adding water and ethyl acetate. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The resulting residue was purified with silica gel column chromatography (methanol/ethyl acetate system), to give 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[4-(4-fluorophenyl)butane-1-on]piperazine as a precursor (56 mg). 27 mg among the product was dissolved in ethanol (2 mL), and hydroxyammonium chloride (8.3 mg) and sodium acetate (9.8 mg) were added, and the mixture was stirred under a reflux condition. After 2 hours, the solution was cooled to a room temperature, and the organic layer was separated by adding water and ethyl acetate. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The resulting residue was purified by silica gel column chromatography (methanol/ethyl acetate system), to give the title compound as a colorless oil (17 mg).
-
- Further, 17 mg of the above-mentioned free body (the title compound) was treated in a conventional method, to give 14 mg the hydrochloride.
- Hydrochloride:
- ESI-Mass; 465 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 49 (85 mg, 60%).
- Free Body:
-
- Further, the hydrochloride (80 mg) of the title compound was obtained by treating the free body in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 446 (MH+)
-
- The title compound was obtained in accordance with the method of Example 1 described in JP-A 11-206862 (150 mg, yield: 94%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 460 (MH+)
-
- The title compound was obtained as a pale yellow oil (183 mg, 38%) in accordance with the method of Example 104 described in JP-A 11-206862.
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 450 (MH+)
-
- The title compound was obtained as a colorless oil (67 mg, 62%) in accordance with the method of Example 104 described in JP-A 11-206862.
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 494 (MH+)
-
- In hydrogen atmosphere, 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[3-arloxy-2-(4-fluorophenoxy)propyl]piperazine (85 mg) was dissolved in ethanol (3.5 mL) at room temperature. To the mixture was added 10% palladium-carbon (10 mg), followed by stirring. After 3
hours 20 minutes, palladium-carbon was separated by filtration, and then the filtrate was evaporated. The resulting residue was purified by NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound (34 mg, 40%). - Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 496 (MH+)
-
- In tetrahydrofuran (5 ml) was dissolved 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[3-allyloxy-2-(4-fluorophenoxy)propyl]piperazine (125 mg), followed by adding sodium borohydride (14.4 mg) and then iodine(64 mg)/tetrahydrofuran (2 mL). After stirring for one hour, the organic layer was separated by adding ethyl acetate and water. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The residue was purified by NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (70 mg, 61%). The hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 436 (MH+)
-
- The title compound was obtained from 1,2,3,4-tetrahydroquinoline in accordance with the method of Example 89 described in JP-A 11-206862 (34%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 445 (MH+)
-
- Under a nitrogen atmosphere, to a solution of 1-(fluorophenyl)-3-isobutylurea (300 mg), triphenylphosphine (561 mg) and triethylamine (0.3 mL) added in dichloromethane (10 ml) were added a solution of carbon tetrabromide (948 mg) dissolved in dichloromethane (4 ml). After 45 minutes, the reaction solution was cooled to room temperature, and the organic layer was separated by adding water and dichloromethane thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated. The resulting residue was immediately purified by NH silica gel column chromatography (hexane/ethyl acetate system), to give a colorless oily carbodiimide as an intermediate. The carbodiimide and 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine (100 mg) were dissolved in 2-propanol (10 mL), followed by stirring under a reflux condition. After 2 hours, the solvent was evaporated, and the resulting residue was purified by NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a colorless solid (174 mg, 25%, 2 steps).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 478 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the method of Example 59 (62%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 492 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the method of Example 59 (62%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 492 (MH+)
-
- In nitrogen atmosphere, N-cyano-N′-ethyl(4-fluorophenoxy)-O-phenylisourea (168 mg) and 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine (100 mg) were dissolved in 2-propanol (5 mL), followed by stirring under reflux. After 24 hours, the solvent was evaporated, and the resulting residue was purified by NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a colorless solid (98 mg, 71%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 491 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the method of Example 62 (62%).
- Free Body:
-
- The hydrochloride of the title compound was obtained by treating the free body in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 345 (MH+)
-
- 2-Chloro-1-isobutyl-1H-benzo[d]imidazole (4 g) and 1-[(4-cyano-5-methyl-4-hexyl]piperazine (5 g) were dissolved in tetrahydrofuran (10 mL), followed by stirring on an oil bath at 150° C. for 6 hours in an open system. The reaction product was purified by NH silica gel (ethyl acetate/hexane system), to give the title compound as a brown oil (6.8 g, 85%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a similar method as in Example 1.
- Hydrochloride:
- ESI-Mass; 458 (MH+)
-
- In nitrogen atmosphere, thionyl chloride (4 mL) was added to (4-cyano-5-methyl-4-phenyl)hexanol (2.33 g) under ice cooling, followed by heating under stirring under reflux condition. After 2 hours, the mixture was evaporated. Then, the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate system), to give (4-cyano-5-methyl-4-phenyl)hexyl chloride (2.35 g, 93%) as a yellow oil. The resulting chloride (454 mg), [(4-cyano-5-methyl-4-phenyl)hexyl]piperazine (166 mg) and sodium iodide (289 mg) were dissolved in acetonitrile (5 mL), followed by stirring under a reflux condition. After 2 hours, the mixture was cooled to a room temperature, and the organic layer was separated by adding ethyl acetate and water thereto. The resulting organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After the drying agent was filtered off, the mixture was evaporated. The residue was purified by NH silica gel column chromatography (hexane/ethyl acetate), to give the title compound as a pale yellow oil (213 mg, 23%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in the same manner as in Example 1.
- Hydrochloride:
- ESI-Mass; 485 (MH+)
-
- The title compound was obtained as a pale yellow oil in accordance with the method of Example 65 (yield: 52%).
-
- Further, the hydrochloride of the title compound was obtained by treating the free body (the title compound) in the same manner as in Example 1.
- Hydrochloride:
- ESI-Mass; 471 (MH+)
-
- The title compound was obtained in accordance with the method of Example 49 (yield: 51%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in the same method as in Example 1.
- Hydrochloride:
- ESI-Mass; 433 (MH+)
-
- In acetonitrile (5 ml) was dissolved 4-cyano-4-(3-cyano-5-thienyl)-5-methylhexanol (0.13 g). To the mixture were added triethylamine (0.21 ml) and mesyl chloride (0.048 ml), followed by stirring at room temperature for one hour. Water was added thereto, and the mixture was extracted with ethyl acetate and further washed with brine. After drying over anhydrous magnesium sulfate, the mixture was evaporated, to give a pale yellow oil. The resulting oil was dissolved in DMF (2 ml), followed by adding a DMF solution (4 ml) of 1-[2-(4-cyanophenoxy)ethyl]piperazine (0.14 g), triethylamine (0.21 ml) and sodium iodide (0.15 g). After stirring at 60° C. overnight, ethyl acetate was added thereto, and the mixture was washed with water and further brine. After drying over anhydrous magnesium sulfate, the solvent was evaporated, and the resulting residue was purified by NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a pale yellow oil (0.09 g, 33%).
- Free Body:
-
- Further, the hydrochloride was obtained by treating the above free body (the title compound) in a conventional method.
- Hydrochloride:
- ESI-Mass; 462 (MH+)
-
- The title compound was obtained as a pale yellow oil (0.15 g, 58%) from 4-cyano-4-(3-cyano-5-thienyl)-5-methylhexanol and 1-[2-(3-cyanophenoxy)ethyl]piperazine in the same manner as in Example 68.
- Free Body:
-
- Further, the hydrochloride was obtained by treating the free body (the title compound) in a conventional method.
- Hydrochloride:
- ESI-Mass; 462 (MH+)
-
- In acetonitrile (10.0 ml) was dissolved 400 mg (1.61 mmol) of 4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexanol, followed by cooling to 0° C. To the mixture were added 0.26 ml (1.85 mmol) of triethylamine and 0.14 ml (1.77 mmol) of mesyl chloride, followed by heating to room temperature. After 20 minutes, ether and brine were added thereto. The ether layer was washed with an aqueous saturated sodium bicarbonate and dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The half amount (ca. 0.1 mmol) of the crude mesyl compound was dissolved in 8.00 ml of dimethylformamide. To the mixture were added 724 mg (4.83 mmol) of sodium iodide, 111 mg (0.81 mmol) of potassium carbonate and 243 mg (1.05 mmol) of 1-[2-(3-cyanophenoxy)ethyl]piperazine, followed by heating to 60° C. After completion of the reaction, brine was added thereto, and the objective product was extracted with ethyl acetate. The organic layer was washed with brine, and then dried over anhydrous magnesium sulfate. The solvent was evaporated, to give a crude product. The crude product was subjected to Cromatorex NH silica gel (eluted with ethyl acetate/hexane=1/1), to give 289 mg (0.63 mmol, 77.3%) of the title compound as a yellow syrup.
-
- ESI-Mass; 462 (MH+)
-
- The title compound was synthesized using [2-{N-(2-cyanoethyl)anilino}ethyl]piperazine in accordance with the method for producing 1-[(4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine in Example 70 (yield; 90.1%: a pale yellow oil).
-
- ESI-MS; 489 (M+H+)
-
- In 1.5 ml of acetonitrile was dissolved 111 mg (0.31 mmol) of 4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl iodide. To the mixture were added 56.2 μl (0.40 mmol) of triethylamine and 109 mg (0.47 mmol) of 1-(3-cyanophenoxyethyl)piperazine, followed by stirring for 3 days. The organic layer separated by adding ethyl acetate and brine to the reaction solution was dried over magnesium sulfate, and then evaporated, to give a crude product. The crude product was subjected to 12.5 g of Cromatorex NH silica gel (ethyl acetate/hexane=1/2), to give 144 mg (quantitative) of the title compound as a yellow syrup.
-
- ESI-Mass; 462 (MH+)
-
- The title compound was synthesized in accordance with the method of Example 72 (yield: 82.3%).
-
-
- The title compound was synthesized in accordance with the method of Example 72 (yield: 70.2%).
-
-
- The title compound was synthesized using 4-cyano-5-methyl-4-(2-thienyl)hexyl iodide in accordance with the method of Example 72 (yield: 94.7%).
-
-
- The title compound was synthesized using 4-cyano-5-methyl-4-(2-thienyl)hexyl iodide in accordance with the method of Example 72 (yield: 40.9%).
-
- ESI-MS; 437 (M+H+)
-
- In acetonitrile (3 ml) was dissolved 200 mg (0.56 mmol) of 4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl iodide. To the mixture were added 78.0 μl (0.56 mmol) of triethylamine and 178 mg (0.76 mmol) of 1-[3-(5-cyano-2-thieny)propyl]piperazine, followed by stirring at 55° C. After 5 hours, the reaction solution was concentrated, and the residue was subjected to Cromatorex NH silica gel (ethyl acetate/hexane=1/2), to give 243 mg (0.52 mmol, 92.8%) of the title compound as a yellow syrup.
-
- ESI-Mass; 466 (M+H+)
-
- The title compound was synthesized in accordance with the production method described in Example 77 (yield: 96.4%).
-
- ESI-MS; 441 (M+H+)
-
- The title compound was synthesized using 4-cyano-5-methyl-4-(2-thienyl)hexyl iodide in accordance with the production method described in Example 77 (yield: 96.4%).
-
- ESI-MS; 441 (M+H+)
-
- The title compound was produced in the synthesis condition of tert-butyl 4-[3-(2-thienyl)propyl]-1-piperazinecrboxylate which is described below (yield: 23.6%), by using 4-cyano-5-methyl-4-(4-cyano-2-thienyl)hexanol and 1-[3-(2-thienyl)propyl]piperazine synthesized according to the method of Example 69.
-
- ESI-MS; 441 (M+H+)
-
- In acetonitrile (5 ml) was dissolved 230 mg (0.82 mmol) of 1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]piperazine synthesized in a similar manner as the above-mentioned 1-[3-(5-cyano-2-thienyl)propyl]piperazine. To the mixture were added 120 mg (0.72 mmol) of 2-(chloromethyl)benzoxazole and 0.10 ml (0.72 mmol) of triethylamine, followed by heating to 50° C. After 5 hours, the reaction solution was concentrated, and the residue was subjected to Cromatorex NH silica gel (ethyl acetate/hexane=1/2), to give 244 mg (0.58 mmol, 80.5%) of the title compound as a yellow syrup.
-
- ESI-Mass; 423 (M+H+)
-
- In acetonitrile (3 ml) was dissolved 200 mg (0.56 mmol) of 4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl iodide. To the mixture were added 78.0 μl (0.56 mmol) of triethylamine and 146 mg (0.67 mmol) of 1-[(2-benzoxazoyl)methyl]piperazine, followed by stirring at 55° C. After 14 hours, the reaction solution was concentrated, and the residue was subjected to Cromatorex NH silica gel (ethyl acetate/hexane=1/2), to give 237 mg (0.53 mmol, 94.6%) of the title compound as a yellow syrup.
-
- ESI-Mass; 448 (M+H+)
-
- The title compound was synthesized in accordance with the production method described in Example 82 (yield: 89.3%).
-
- ESI-MS; 448 (M+H+)
-
- In nitrogen atmosphere, 1-[2-(4-fluorophenoxy)ethyl]piperazine (50 mg) synthesized in accordance with the method described in Production Example 1 in JP-A 11-206862 was added to an acetonitrile solution (3 ml) of 1-iodo-4-cyano-5-methyl-4-(3-thienyl)hexane (50 mg) and triethylamine (0.06 ml) at room temperature. After stirring at 50° C. for 4 hours, the solvent was evaporated, and the resulting residue was purified by Cromatorex NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a yellow oil (62 mg, 96%).
- Free Body:
-
- Further, 62 mg of the above-mentioned free body (the title compound) was dissolved in methanol, followed by adding an excessive 4N hydrochloric acid/ethyl acetate solution thereto. After stirring, the mixture was evaporated. After water was added to the resulting residue, the aqueous solution was frozen by being immersed in a dry ice-methanol bath. The solvent was removed by freeze-dry process over day and night, to give the hydrochloride of the title compound (white amorphous, 62 mg).
- Hydrochloride:
- ESI-Mass; 430 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (85%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- Hydrochloride:
- ESI-Mass; 437 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (76%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 455 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (78%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 462 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (72%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 455 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (72%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 455 (MH+)
-
- The title compound was obtained as a colorless oil in a similar method as in Example 84 (64%), by using 2-(4-cyano-2-fluorophenoxy)ethyl]piperazine synthesized in the same manner as in Reference Example 69 as a raw material.
- Free Body:
-
- The hydrochloride of the target compound was obtained by treating the free body in the similar manner as in Example 84.
- ESI-Mass; 455 (MH+)
-
- The title compound was obtained as a colorless oil according to a similar method as in Example 84 (64%), by using 2-(4-cyano-2-fluorophenoxy)ethylpiperazine synthesized in accordance with Reference Example 69 as a raw material,
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 455 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (78%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 593, 595, 597 (MH+)
-
- In a nitrogen atmosphere, 1-{4-cyano-5-methyl-4-[(2,5-dibromo)-3-thienyl]hexyl}-4-[2-(3-cyanophenoxy)ethyl]piperazine (145 mg) was dissolved in a mixed solvent of dimethylformamide (10 mL)/water (0.1 mL) of zinc cyanide (57.3 mg) and 1,1′-bis(diphenylphosphino)ferrocene (13.5 mg). Palladium-dibenzylidene acetone complex (8.9 mg) was added thereto, the atmosphere of the mixture was replaced 3 times with nitrogen, and then the solution was stirred at 120° C. for 4 hours. Water, diethyl ether and an aqueous ammonia were added thereto, to separate the organic layer. The resulting organic layer was washed with water and brine, dried over anhydrous magnesium sulfate. After filtering off the drying agent, the filtrate was evaporated, and the residue was purified by LC-MS (ODS column; acetonitrile/water system), to give the title compound as a yellow oil (8 mg, 6.7%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 540, 542 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with Example 45 described in JP-A 11-206862 (64%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 456 (MH+)
-
- The title compound was obatined as a colorless oil in accordance with the production method described in Example 84 (85%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 490 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (72%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 454 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (60%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 454 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (55%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 437 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with Example 45 described in JP-A 11-206862 (59%).
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 456 (MH+)
-
- The title compound was obtatined as a colorless oil in accordance with the production method described in Example 84 (56%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 490 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (87%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 490, 492 (MH+)
-
- The title compound was obtained as a colorless oil in accordance with the production method described in Example 84 (97%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 412 (MH+)
-
- By using [4-cyano-5-methyl-4-(2-bromo-5-thienyl)hexyloxy]-tert-butyldimethylsilane (700 mg) which was obtained in Example 114-5) described in JP-A 11-206862, 4-cyano-5-methyl-4-(2-bromo-5-thienyl)hexanol (371 mg, 80%) was synthesized as a yellow oil in accordance with Example 114-8) described in JP-A 11-206862. From 105 mg of the resulting compound and 96 mg of 2-(3-cyanophenoxy)ethylpiperazine, the title compound was synthesized as a colorless oil in accordance with the production method described in Example 84 (138 mg, 62%).
- Free Body:
-
- Further, the hydrochloride of the free body (the title compound) was obtained in accordance with the method described in Example 84.
- ESI-Mass; 515, 517 (MH+)
-
- From 4-cyano-4-(3-cyano-5-thienyl)-5-methylhexanol and 1-[2-(4-methylsulfonylphenoxy)ethyl]piperazine, the title compound was synthesized as a pale yellow oil in accordance with the method of Example 68 (39%). Further, the hydrochloride was obtained by treating the free body (the title compound) in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 515 (MH+)
-
- From 4-cyano-4-(3-cyano-5-thienyl)-5-methylhexanol and 1-[2-(3-acetylphenoxy)ethyl]piperazine, the title compound was obtained as a pale yellow oil in accordance with the method of Example 68 (yield: 38%). Further, the hydrochloride was obtained by treating the free body (the title compound) in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-Mass; 479 (MH+)
-
- By using 1-[{2-(5-cyanobenzofuranyl)}methyl]piperazine, the title compound was synthesized in accordance with the method of Example 75 (yield: 100%).
-
- ESI-MS; 447 (M+H)+
-
- By using 1-[2-phenoxyethyl]piperazine, the target compound was synthesized in accordance with the method of Example 77 (yield: 96.5%). The physico-chemical data of the title compound was as indicated below.
-
- ESI-MS; 437 (M+H)+
-
- By using 1-[2-(3-bromophenoxy)ethyl]piperazine, the title compound was synthesized in accordance with the method of Example 77 (yield: 83.5%). The physico-chemical data of the title compound was as indicated below.
-
- The compounds of Examples 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 were synthesized in accordance with the method of Example 1, 89 or 99 described in JP-A 11-206862, or according to the methods.
-
- The title compoud was obtained as a pale brown oil in accordance with Example 1 described in JP-A 11-206862.
- Hydrochloride:
- ESI-MS (m/e); 515, 517 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 471 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 563 (M+H)
-
- Hydrochloride:
- ESI-MS (m/e); 478 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 450 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 423 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 416 (M+H)
-
- Trifluoroacetate:
- ESI-MS (m/e); 388 (M+H)
-
- Free Body:
- Rf=0.5 (developing solvent; ethyl acetate:hexane=2:1, Fuji Silysia Chemical Ltd., NH TLC)
- Hydrochloride:
- ESI-MS (m/e); 444 (M+H)
-
- Free Body:
- Rf=0.4 (developing solvent; ethyl acetate:hexane=2:1, Fuji Silysia Chemical Ltd., NH TLC)
- Hydrochloride:
- ESI-MS (m/e); 469 (M+H)
-
- Free Body:
- Rf=0.5 (developing solvent; ethyl acetate:hexane=2:1, Fuji Silysia Chemical Ltd., NH TLC)
- Hydrochloride:
- ESI-MS (m/e); 458 (M+H)
-
- The title compound was synthesized in accordance with the method of Example 63 or 67 described in JP-A 11-206862, or according to those methods.
- Trifluoroacetate:
- ESI-MS (m/e); 515 (M+H)
-
- The title compound was synthesized in accordance with the method of Example 63 or 67 described in JP-A 11-206862, or according to the methods.
- Trifluoroacetate:
- ESI-MS (m/e); 501 (M+H)
-
- The title compound was synthesized in accordance with the method of Example 63 or 67 described in JP-A 11-206862, or according to the methods.
- Hydrochloride:
- ESI-MS (m/e); 467 (M+H)
-
- 3-Methyl-2-(2-oxoethyl)-2-phenylbutanenitrile (100 mg) and anhydrous piperazine (22 mg) were dissolved in methylene chloride (5 ml) To the mixture were added acetic acid (0.085 ml) and sodium triacetoxyborohydride (158 mg), followed by stirring overnight at room temperature. The organic layer was separated by adding an aqueous saturated sodium bicarbonate and methylene chloride, and it was washed with water, dried over anhydrous magnesium sulfate and evaporated. The resulting residue was purified by Chromatorex NH silica gel column chromatography (hexane/ethyl acetate system), to give the title compound as a colorless oil (81 mg, 71%). The hydrochloride (89 mg) of the title compound was obtained by treating the free body in a conventional method.
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 457 (M+H)
- The title compounds of Examples 124 to 126 were synthesized in accordance with the method of Example 123.
-
- Hydrochloride:
- ESI-MS (m/e); 471 (M+H)
-
- Hydrochloride:
- ESI-MS (m/e); 499 (M+H)
-
- Hydrochloride:
- ESI-MS (m/e); 469 (M+H)
-
- After dissolving 1-[(4-cyano-5-methyl-4-phenyl)hexyl]piperazine (14 mg) and N-(tert-butoxycarbonyl)-1-phenylalanine (10 mg) in methylene chloride (0.5 ml), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (10 mg) and triethylamine (0.015 ml) were added thereto, and the mixture was stirred overnight at room temperature. After the solution was purified by silica gel column chromatography (diethyl ether), the solvent was removed by blowing of nitrogen. After dissolving the resulting residue in methylene chloride (0.4 ml), trifluoroacetic acid (0.2 ml) was added thereto and the mixture was stirred at room temperature for 9 hours. The reaction solvent was removed by standing the mixture as it was at 35° C. by blowing of nitrogen overnight, to give the hydrochloride (21 mg, 91%) of the title compound.
- Hydrochloride:
- ESI-MS (m/e); 433 (M+H)
- The title compounds of Examples 128 and 129 were synthesized in accordance with the method of Example 127.
-
- Hydrochloride:
- ESI-MS (m/e); 439 (M+H)
-
- Hydrochloride:
- ESI-MS (m/e); 425 (M+H)
-
- Under a nitrogen atmosphere, 5-(2,5-dihydro-1H-1-pyrrolyl]-2-isopropyl-5-oxo-2-(2-thienyl)pentanenitrile (260 mg) was dissolved in a mixed solvent of dimethyl sulfoxide (2 ml) and water (0.1 ml) at room temperature. To the mixture was added N-bromosuccinimide (177 mg), followed by stirring overnight. The reaction solution was partitioned between ethyl acetate and water, and the resulting organic layer was dried over anhydrous magnesium sulfate and then evaporated. The residue was purified by silica gel column chromatography (ethyl acetate/hexane system), to give a colorless oily intermediate (140 mg). The intermediate (20 mg) was dissolved in tetrahydrofuran (0.05 ml), a 1N aqueous sodium hydroxide (0.06 ml) was added, and the mixture was stirred at room temperature. After stirring for 45 minutes, a benzylamine (11 mg)/tetrahydrofuran solution (0.05 ml) was added thereto, and the mixture was stirred at 70° C. overnight. The reaction solution was cooled to room temperature and partitioned between ethyl acetate and water. The resulting organic layer was dried over anhydrous magnesium sulfate and then evaporated. The residue was purified by Cromatorex NH silica gel column chromatography (ethyl acetate/hexane system), to give the title compound as a colorless oil (20 mg).
- Hydrochloride:
- ESI-MS (m/e); 412 (M+H)
- The title compounds of Examples 131 to 136 were synthesized in accordance with the method of Example 130.
-
- Hydrochloride:
- ESI-MS (m/e); 426 (M+H)
-
- Hydrochloride:
- ESI-MS (m/e); 432 (M+H)
-
- Trifluoroacetate:
- ESI-MS (m/e); 467 (M+H)
-
- Trifluoroacetate:
- ESI-MS (m/e); 507 (M+H)
-
- Trifluoroacetate:
- ESI-MS (m/e); 427 (M+H)
-
- Trifluoroacetate:
- ESI-MS (m/e); 505 (M+H)
- The title compounds of Examples 137 to 172 were synthesized in accordance with the method of the above-mentioned Example 64.
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 449 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 419 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e) ; 403 (M+H)
-
- Free Body:
- Rf=0.6 (developing solvent; diethyl ether, Merck silica gel 60F254 TLC)
- Hydrochloride:
- ESI-MS (m/e); 413 (M+H)
-
- Free Body:
- Rf=0.45 (developing solvent; diethyl ether, Merck silica gel 60F254 TLC)
- Hydrochloric acid salt:
- ESI-MS (m/e); 413 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 472 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 506 (M[34Cl]+H), 508 (M[36Cl]+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 402 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 416 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 430 (M+H)
-
- Free Body:
- Rf=0.35 (developing solvent; ethyl acetate:hexane=1:1, Fuji Silysia Chemical Ltd., NH TLC)
- Hydrochloride:
- ESI-MS (m/e); 436 (M+H)
-
- Free Body:
- Rf=0.4 (evolution solvent; ethyl acetate:hexane=1:1, Fuji Silysia Chemical Ltd., NH TLC)
- Hydrochloride:
- ESI-MS (m/e); 464 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 444 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 416 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 430 (M+H)
-
- Free Body:
- 1H NMR (400 MHz, CDCl3) δ 0.77 (d, J=6.8 Hz, 3H), 1.05-1.17 (m, 1H), 1.19 (d, J=6.6 Hz, 3H), 1.40 (t, J=7.2 Hz, 3H), 1.47-1.62 (m, 1H), 1.76-2.23 (m, 5H), 2.40-2.50 (m, 2H), 2.60-2.67 (m, 2H), 2.68-2.76 (m, 2H), 3.51-3.63 (m, 4H), 4.02 (d, J=7.2 Hz, 3H), 7.06-7.54 (m, 9H).
- Hydrochloride:
- ESI-MS (m/e); 444 (M+H)
-
- Free Body:
-
-
- Free Body:
-
-
- Free Body:
-
-
- Free Body:
-
-
- Free Body:
-
-
- Free Body:
-
-
- Free Body:
-
-
- Free Body:
-
-
- Free Body:
-
-
- Oxalate:
-
-
- Oxalate:
-
-
- Oxalate:
-
-
- Oxalate:
-
-
- Oxalate:
-
-
- Oxalate:
-
-
- Oxalate:
-
-
- Oxalate:
-
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 444 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 506 (M+H)
-
- Free Body:
-
- Hydrochloride:
- ESI-MS (m/e); 472 (M+H)
-
- In dichloromethane (8 ml) was dissolved 300 mg (0.81 mmol) of 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3R)-3-[N-(2-cyanoethyl)amino]pyrrolidine obtained in Reference Example 81, followed by successively adding 98.9 mg (0.93 mmol) of benzaldehyde, 0.09 ml (1.62 mmol) of acetic acid and 258 mg (1.22 mmol) of sodium triacetoxyborohydride. After completion of the reaction, the reaction solution was adjusted to basic with a 5N sodium hydroxide and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated, to give a crude product. The crude product was subjected to 25 g of Cromatorex NH silica gel (ethyl acetate:hexane=25% of ethyl acetate), to give 220 mg (0.48 mmol, 59.1%) of the title compound as a colorless syrup. The physico-chemical data of the compound was as below.
-
- Further, the diastereomer of the title compound of Example 173 is synthesized in accordance with the production method of the above-mentioned Example 173 from 4-cyano-4-(5-cyano-2-thienyl) -5-methylhexanol (hereinafter, referred to as “alcohol b”) synthesized in accordance with Reference Examples 104 and 105 from 4-cyano-4-(2-thienyl) -5-methylhexanoic acid obtained from Reference Example 103, and (3R)-3-tert-butoxycarbonylaminopyrrolidine. Similarly, the mirror isomer of the title compound of Example 173 is synthesized in accordance with the production method of the above-mentioned Example 173 from the alcohol b and (3S)-3-tert-butoxycarbonylaminopyrrolidine.
-
- The title compound was synthesized in accordance with the production method of Example 173 from 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3R)-3-[N-(2-cyanoethyl)amino]pyrrolidine obtained from Reference Example 81 and 2-thiophenecarboxyaldehyde. The physico-chemical data of the compound was as below.
- Yield: 46.7%
-
-
- The title compound could be synthesized in accordance with the following two methods (synthetic methods A and B).
- Synthetic Method A
-
- (3S)-3-[N-(2-Cyanoethyl)-N-benzylamino]-1-(tert-butoxycarbonyl)pyrrolidine was synthesized in accordance with the production methods of Reference Example 81 and Example 173 from (3S)-3-amino-1-(tert-butoxycarbonyl)pyrrolidine. The title compound was obtained by de-protecting the Boc group in accordance with Reference Example 80 (yield; 78.2%, (3 steps)). The physico-chemical data of the compound was as below. The physico-chemical data of (3S)-3-[N-(2-cyanoethyl)-N-benzylamino]-1-(tert-butoxycarbonyl)pyrrolidine
-
- The Physico-Chemical Data of (3S)-3-[N-(2-cyanoethyl)-N-benzylamino)pyrrolidine
-
- (2) 1-[4-Cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]-(3S)-3-[N-(2-cyanoethyl)-N-benzylamino]pyrrolidine
- Optically active body, 4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl iodide (iodide C (optically active body)) was synthesized from the alcohol B in accordance with Example 77 (1). The title compound was synthesized in accordance with Example 77(2) from the iodide C and (3S)-3-[N-(2-cyanoethyl)-N-benzylamino]pyrrolidine which was obtained in (1). The physico-chemical data of the compound was as below.
- Yield; 90.6%.
- ESI-MS; 460 (M+H)+
-
- Synthetic Method B
- The title compound was synthesized in accordance with the production of Example 173 from the above-mentioned iodide C (or the alcohol B) and (3S)-3-tert-butoxycarbonylaminopyrrolidine.
-
- Optically active body, 4-cyano-4-(2-thienyl)-5-methylhexyl iodide (iodide D (optically active body)) was synthesized from the alcohol A in accordance with Example 77(1). The title compound was synthesized in accordance with Example 75 from the iodide D and (3S)-3-[N-(2-cyanoethyl)-N-benzylamino]pyrrolidine of “Synthetic method A” (1) (1) of Example 175. The physico-chemical data of the title compound was as below.
- Yield; 97%.
-
-
- The title compound was synthesized in accordance with Example 75 from the iodide D and (3S)-3-[N-(2-cyanoethyl)-N-(3-cyanobenzyl)amino]pyrrolidine synthesized in accordance with the production method of “Synthetic method A” (1) of Example 175. The physico-chemical data of the compound was as below.
- Yield; 82%.
-
-
- The title compound was synthesized in accordance with Example 75 from the iodide D and 1-[{3-methoxy-(2R)-2-(2-pyridyloxy)}propyl]piperazine. The physico-chemical data of the target compound obtained is indicated below. The values of the physical properties of the title compound obtained are indeicated below.
-
-
- The title compound was synthesized in accordance with Example 75 from the iodide C (optically active compound) and (3R)-3-{N-[4-cyano-4-(2-thienyl)-5-methylhexyl]amino}pyrrolidine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 77 from 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]piperazine and 2-chloromethyl-5-chlorobenzoxazole synthesized in accordance with Example 83. The physico-chemical data of the compound was as below.
-
-
- According to Example 180, from 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]piperazine and 2-chloromethyl-5-methylbenzoxazole synthesized in accordance with Example 83, the title compound was synthesized in accordance with Example 77. The physico-chemical data of the compound was as below.
-
-
- According to Example 180, the title compound was synthesized in accordance with Example 77 from 1-[4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl]piperazine in accordance with Example 180 and 2-chloromethylbenzothiazole which was synthesized in accordance with Example 83. The physico-chemical data of the compound was as below.
-
-
- The target compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl]iodide and 1-[2-(5-trifluoromethyl-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 77 from 4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl iodide and 1-[2-(5-trifluoromethyl-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(5-chloro-3-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 77 from 4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl iodide and 1-[2-(5-chloro-3-pyridyloxy)ethyl)piperazine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 4-[2-(5-chloro-3-pyridyloxy)ethyl]piperidine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 4-(3-pyridylamino)piperidine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-{N-isopropyl-N-(2-pyridyl)amino}ethyl]piperazine. The physico-chemical data of the compound was as below.
-
-
- The titile compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(6-methoxymethyl-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
- ESI-MS; 457 (M+H)+
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(6-fluoromethyl-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
- The values of the physical properties of the target compound obtained are indicated below.
- ESI-MS; 445 (M+H)+
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(6-bromo-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(6-fluoro-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
- ESI-MS; 431 (M+H)+
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
- ESI-MS; 413 (M+H)+
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(6-methyl-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
-
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(2-thienyl)-5-methylhexyl iodide and 1-[2-(6-cyano-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
- ESI-MS; 438 (M+H)+
-
- The title compound was synthesized in accordance with Example 75 from 4-cyano-4-(5-cyano-2-thienyl)-5-methylhexyl iodide and 1-[2-(6-cyano-2-pyridyloxy)ethyl]piperazine. The physico-chemical data of the compound was as below.
- ESI-MS; 463 (M+H)+
-
- The title compound was synthesized in accordance with the production method of Example 35.
- Hydrochloride: ESI-Mass; 491 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 3.
- Hydrochloride: ESI-Mass; 406 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 70 by using the above-mentioned 4-[3-[1-(4-fluorophenyl)cyclohexyl]propyl]piperazine.
- Hydrochloride: ESI-Mass; 510 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 70.
- Hydrochloride: ESI-Mass; 487 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 70.
- Hydrochloride: ESI-Mass; 432 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 3.
- Hydrochloride: ESI-Mass; 457 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 3.
- Hydrochloride: ESI-Mass; 438 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 3.
- Hydrochloride: ESI-Mass; 463 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 3.
- Hydrochloride: ESI-Mass; 447 (MH+)
-
- The title compound was obtained-in accordance with the production method of Example 70.
- Oxalate: ESI-Mass; 434 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 35.
- Hydrochloride: ESI-Mass; 522 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 35.
- Hydrochloride: ESI-Mass; 497 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 17.
- Hydrochloride: ESI-Mass; 423 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 17.
- Hydrochloride: ESI-Mass; 448 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 70.
- Hydrochloride: ESI-Mass; 421 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 17.
- Oxalate: ESI-Mass; 407 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 35.
- Hydrochloride: ESI-Mass; 476 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 35.
- Oxalate: ESI-Mass; 460 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 70.
- Hydrochloride: ESI-Mass; 363 (MH+)
-
- The title compound was obtained in accordance with the production method of Example 70.
- Hydrochloride: ESI-Mass; 369 (MH+)
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 3.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 3.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 3.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 3.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 3.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 3.
- Oxalate:
-
-
- The title compound was obtained as a colorless oil in accordance with Example 3.
-
-
- The title compound was obtained as a colorless oil in accordance with Example 3.
-
-
- The oxalate of the. title compound was obtained as a colorless solid in accordance with Example 48.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 48.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 48.
- Oxalate:
-
-
- The title compound was obtained as a pale brown oil in accordance with Example 15.
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 15.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 15.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 3.
- Oxalate:
-
-
- The oxalate of the title compound was obtained as a pale brown solid in accordance with Example 15.
- Oxalate:
-
-
- The title compound was obtained as yellow amorphous in accordance with Example 15.
-
-
- The title compound was obtained as pale brown amorphous in accordance with Example 3.
-
-
- The oxalate of the title compound was obtained as a colorless solid in accordance with Example 48.
- Oxalate:
-
-
- The title compound was obtained as a pale yellow oil in accordance with Example 3.
-
-
- The title compound was synthesized by using 1-benzyl-2-(ethoxycarbonyl)piperazine (Synthesis 318, 1991) in accordance with Example 15.
- Free Body:
-
-
- The title compound was synthesized by using ethyl 4-(4-cyano-5-methyl-4-phenylhexyl)-2-piperazinecarboxylate in accordance with Example 48.
- Free Body:
-
-
- Into a diethyl ether solution (5.0 ml) of lithium aluminum hydride (20 mg) was added dropwise a diethyl ether solution (3.0 ml) of 213 mg of ethyl 4-(4-cyano-5-methyl-4-phenylhexyl)-1-[2-(4-fluorophenoxy)ethyl]-2-piperazinecarboxylate under ice-cooling. After stirring under ice-cooling for one hour, water (0.1 ml), a 1N aqueous sodium hydroxide (0.1 ml) and water (0.2 ml) were successively added to the reaction solution. Anhydrous magnesium sulfate was added to the reaction solution, and the unnecessary product was filtered. The solvent was evaporated, to give the title compound (194 mg).
- Free Body:
-
-
- The title compound was synthesized by using 1-benzyl-2-(ethoxycarbonyl)piperazine (Synthesis 318, 1991) in accordance with Example 48.
- Free Body:
-
-
- The title compound was synthesized by using ethyl 4-[2-(4-fluorophenoxy)ethyl]-2-piperazinecarboxylate in accordance with Example 15.
- Free Body:
- ESI-MS (m/e); 496 (M+H)
-
- was obtained as a crude product (752 mg, 100%) by dissolving ethyl 1-benzyl-4-[2-(4-fluorophenoxy)ethyl]-2-piperazinecarboxylate (977 mg) synthesized in accordance with Example 241 in ethanol (15 ml), adding 210 mg of 10% Pd—C thereto, replacing the atmosphere of the reaction solution with hydrogen, stirring it, and evaporating it after completion of the reaction.
- Free Body:
-
-
- By using ethyl 1-(4-cyano-5-methyl-4-phenylhexyl)-4-[2-(4-fluorophenoxy)ethyl]-2-piperazinecarboxylate, the title compound was synthesized in accordance with Example 240.
- Free Body:
-
- The calcium inhibitory action (Test Example 1) in vitro was evaluated for the compound according to the present invention, and the shrinking action of infarction nidus (Test Example 2) in rat middle cerebral artery emphraxis model in vivo and the analgesic action (Test Example 3) in a formalin test using a mouse were evaluated. The respective test methods and results are as described below.
- The most importance is attached to a “glutamic acid-Ca assumption” as the mechanism of brain infarction (neural cell death by ischemia). Namely, when cerebral blood flow is lowered, anaerobic glycolysis is carried out, and the ATP of brain tissue is exhausted. Ion concentration gradient in the inside and outside of the cell is not kept by this energy exhaustion, and depolarization occurs. The potential dependent calcium channel is activated by depolarization in pre synapse, and the excess release of glutamic acid is induced. In post synapse, the potential dependent calcium channel is activated by depolarization to increase the Ca2+ concentration in the cell, and glutamic acid which was excessively released stimulates a glutamic acid receptor and increases the Ca2+ concentration in the cell. As a result of these, various kinds of enzymes, such as carpaine and phospholipase, depending on the Ca2+ concentration are activated, and induce neural cell death. The present experiment system can evaluate the Ca2+ influx in the pre synapse among these flow charts.
- Further, it is known that 10 μM of nifedipine being an L-type inhibitor, 1 μM of n-conotoxin GVIA being an N-type inhibitor and 1 μM of w-Agatoxin-IVA being a P/Q type inhibitor exhibit inhibitions of 16%, 18% and 64% against the Ca2+ influx, respectively (refer to the following reference literature). Accordingly, it is considered that the system is suitable for evaluating the N-type and P/Q type inhibitions.
- Reference Literature:
- D. Bowman, S. Alexander and D. Lodge, Pharmacological characterization of the calcium channels coupled to the plateau phase of KCl-induced intracellular free Ca2+ elevation in chicken and rat synaptosomes, Neuropharmacology, 32 (11) 1195-1202 (1993)
- (1) Preparation of Cerebral Cortex Synaptosome:
- Cerebral cortex synaptosome was prepared as described below in accordance with the method described in “Neuropharmacology, 32(11), 1195-1202, 1993”. Namely, cerebral cortex was taken out from a rat decapitated brain, and crushed with scissor scoarsely. It was charged in a homogenizer, homogenized in 3 M sucrose, and centrifuged (1,500 g×10 min.) at 4° C. The supernatant obtained was further centrifuged (10,000 g×20 min.) at 4° C. 0.3 M of sucrose was added to the precipitate obtained and the mixture was suspended. The suspension was stratified in 0.8 M sucrose, and centrifuged (10,000 g×30 min.). The precipitate obtained was suspended in a “solution A” (118 mM-NaCl, 4.6 mM-KCl, 1 mM-CaCl2, 1 mM-MgCl2, 1.2 mM-Na2HPO4, 10 mM-D-glucose, 20 mM-HEPES-NaOH, pH 7.4, 0.1%-BSA), to prepare cerebral cortex synaptosome.
- (2) Calcium Channel Inhibiting Action:
- 4 mM-fura2/AM (Doujin) was suspended in the fore-mentioned solution A to prepare a solution for loading. The solution for loading in an equal amount was added to the synaptosome solution prepared according to the method described above, and the mixture was incubated for 40 minutes at a room temperature. After completion of the incubation, the solution for loading was removed by centrifuge, and further washed 2 times with the solution A. The solution A containing the present compound was added to this solution, and the mixture was incubated for 10 minutes at a room temperature. The calcium channel was stimulated by adding 1/10 volume of a “solution B” (122.6mM-KCl, 1 mM-CaCl2, 1 mM-MgCl2, 1.2 mM-Na2HPO4, 10 mM-D-glucose, 20 mM-HEPES-NaOH, pH 7.4, 0.1%-BSA) to this solution. The calcium ion concentration in the cell was measured according to specific measurement by two wave lengths of 340 nm and 380 nm with ARUGUS-FDSS (HAMAMATSU PHOTONICS Co.), and IC50 values of the respective test compounds were determined. Further, verapamil hydrochloride was used as a control compound for comparison.
- Result:
TABLE 1 Ex. No. IC50 (μM) 1 8.4 3 5.4 5 7.6 6 9 7 5.8 8 6.8 9 4.5 11 5.1 12 8.2 13 6.6 14 6.5 17 8 18 5.6 22 8.7 24 3 25 4.9 26 5.2 30 7.7 31 4.5 32 5.1 33 2.6 34 4.4 37 8.3 38 5.8 39 6.2 40 3.5 45 7.4 46 4.9 48 3.5 49 5.9 50 4.8 51 5.2 52 5.1 53 2.8 55 3.5 56 3.7 57 5.5 58 5.6 59 8.2 60 7.4 61 7.7 62 5.3 64 6.2 65 2.7 66 4.4 67 7.1 70 13 75 9 76 13 78 8.9 85 10 92 3.1 93 6.9 94 0.7 95 < 96 1.9 97 2.1 98 < 99 0.8 100 < 101 0.8 102 1.9 104 < 105 < 106 1.3 107 1.6 108 0.6 109 0.5 110 5.6 112 5.9 113 4.2 114 10 115 8.2 116 9.4 117 11 118 12 119 5.4 121 14 123 8.5 124 3.6 125 5.0 126 8.4 127 11 128 5.2 136 19 137 19 138 19 139 32< 140 11 141 15 142 8.9 143 9.8 144 12 145 15 146 7.4 147 13 148 14 149 10 150 11 151 9 152 6.1 153 7.4 154 9.8 155 7.9 156 10 157 9.9 158 14 159 12 160 8.0 161 12 162 20 163 14 164 21 165 24 166 16 167 13 168 20 169 15 170 10 171 12 172 10 173 7.2 174 9.3 175 3.9 176 2.8 177 3.4 178 5.2 179 19 180 9.3 181 8.6 182 7.8 183 5.5 184 5.4 185 13 186 18 187 6.9 189 5.8 190 11 191 6.4 193 11 195 10 196 12 197 9.8 200 3.7 201 8.1 202 7.2 203 9.2 204 14 205 11 206 14 207 16 208 6.3 209 5.2 210 4.6 211 7.8 212 7.3 213 17 214 11 215 13 218 18 219 9.8 220 32< 221 16 222 16 223 19 224 10 225 16 226 9.4 227 10 228 9.3 229 14 230 14 232 18 233 15 234 12 236 8.7 237 6.6 238 20 239 11 240 9.0 242 12 243 9.9 Control >16 — — - A calcium ion in the cell plays an important role in the expression of various cell functions. But when the calcium ion concentration in the cell rises excessively, cell affection is induced (refer to literatures 1) and 2), hereinafter, the same as this.). For example, neural cell affection induced by excitatory amino-acid occurring in the case of cerebral ischemia provokes excessive rise of the calcium ion concentration in the cell (3) and 4)). The maintenance mechanism of membrane potential fails by excitatory amino-acid which rose in the case of local cerebral ischemia (3)), the depolarization of membrane is induced (5)), and the influx of the calcium ion into the cell through the potential dependent calcium channel is increased (6) and 7)). In light of these fact, it is suggested that an assumption that neural cell death is based on excitation toxicity by excitatory amino-acid is correlated with an assumption that neural cell death is based on the rise of the calcium ion concentration in the cell, and that the activation of potential dependent calcium channel contributes to the induction of neural cell death (8)). The potential dependent calcium channels existing in the neural cell are classified in 6 kinds of sub-types based on the electro-physiological and pharmacological investigation (T, L, N, P, Q and R types) (9)). Among these, N, P and Q types play an important role in the liberation of glutamic acid from rat cerebral cortex synaptosome (10) and 11)). Therefore, the protection effect for neural cell affection induced after local cerebral ischemia and possessed by the typical examples of the present compound in rat middle cerebral artery emphraxis model was evaluated.
- (1) Preparation of Specimen
- The compound represented by the above formula (I) according to the present invention was dissolved in a physiological saline, and appropriately prepared so as to be in doses of 1.5, 5 and 15 mg/kg/h. The concentration of the specimen was calculated based on the average body weight of an animal. Further, the average body weight was calculated by measuring the body weight of all animals which are intended to be used for experiment. For example, in the case of 5 mg/kg/h, it was calculated as: concentration of specimen=5 mg×average body weight (kg)/administration volume (0.616 ml) per hour.
- (2) Manufacture of Nylon Embolus
- The embolus made from nylon stitch (Ethicon, Inc., Somerville, N.J., USA) of 4-0 monofilament was used for emphraxis of middle cerebral artery. As the nylon embolus, that prepared by previously rounding its tip with flame, fragmenting it in a length of 25 mm, and marking at a position of 17 mm from the tip with an oily felt pen was used.
- (3) Implantation of Catheter for Intravenous Administration
- The implantation of catheter for intravenous administration (Atom Vein Catheter 3Fr, manufactured by ATOM MEDICAL Co., Ltd., Tokyo) was carried out under 70% laughing gas-2% halothane anaesthesia. Catheter which was filled up with a physiological saline solution was inserted from the femoral vein of left foot.
- (4) Emphraxis of Middle Cerebral Artery
- The emphraxis of middle cerebral artery was carried out in accordance with the method of Longa et al (12)). The operation was carried out under 70% laughing gas-2% halothane anaesthesia just after implanting the catheter. A rat was laid in facing upward under the stereoscopic microscope for operation, the neck was cut open, and the portion where the whole carotid arteries of the right side are diverged to the external carotid artery and the internal carotid artery was confirmed. The external carotid artery was cut off at the periphery side, and the nylon embolus was inserted from the terminal of the external carotid artery which was cut off into the internal carotid artery. The embolus was inserted up to the position where the position of 17 mm from the tip of the embolus is duplicated with a branch point of the external carotid artery and the internal carotid artery, and was fixed. The nylon embolus was pulled back after 2 hours from the emphraxis of middle cerebral artery, in order to restart blood flow.
- (5) Selection of Animals which Exhibit Ischemia Symptom
- The rat was caught and lifted with the cauda after 30 minutes from the emphraxis of middle cerebral artery, an indivisual which expresses clearly the one side paralysis of a fore-leg (the paralysis of a fore-leg of the opponent side which loaded infarct) was provided for experiment as an example in which middle cerebral artery was occluded and was able to make an ischemia condition.
- (6) Administration of Medium and Specimen
- A rat which expressed the one side paralysis after 30 minutes from middle cerebral artery emphraxis was put in a cage of a body temperature control apparatus, and a probe for monitoring a body temperature was fixed in the rectum. Then, a syringe in which a medium or a specimen was charged was put in the catheter for intravenous administration, and the intravenous administration of the half amount (0.34 ml) of the dose which would be infused for 1 hour was carried out for one minute. Then, administration was carried out at a rate of 0.682 ml/h for 24 hours using a syringe pump for infusion (Razel Scientific Instruments, Inc., Stamford, Conn., USA). During the administration and for 2 hours after the administration, the temperature of the rectal was controlled in a range of from 37.0° C. to 38.5° C. under the body temperature control system.
- (7) Measurement of Infarction Nidus Size (TTC Staining of Vrain Slice)
- After 24 hours from the emphraxis of middle cerebral artery, the rat was decapitated, the brain was taken out, and the blood attached was rinsed with physiological saline solution which was ice-cooled. Using the brain from which olfactory bulb was removed, it was sliced at an interval of 2 mm from the tip (6 slices in total), and they were immersed in a 2%-TTC solution so that the rear face of the brain is faced upward. The TTC was appropriately dissolved in physiological saline solution. After being left as it was at room temperature for one hour or more in the TTC solution, it was used for area determination of infarction nidus.
- (8) Calculation of Infarction Nidus Volume
- The top of each slice (the rear face of brain) was used for calculation of infarction nidus area. As for the brain slices, images were taken in a computer (PM7500/100, Apple Japan, Tokyo) using an image taking device (CCD Color Camera, SANKEI Inc., Tokyo). The areas of infarction nidus of brain cortex in the images were measured using an image analysis software (NIH image ver.1.60, National Institutes of Health, USA). The volume of the infarction nidus of one individual was calculated as the total sum (unit=mm3) of 6 slices by multiplying the area (unit=mm2) of the infarction nidus of the respective slices measured, by 2 (unit=mm) which is the thickness of the slice.
- (9) Data Analysis Method
- The volume (unit=mm3) of the infarction nidus of brain cortex was indicated by average value ± standard error. Statistical significance between the medium control group and the respective specimen groups was analyzed by multiplex comparative assay of Dunnett, and the level of significance was defined as 5% of both sides. Dose reactivity was analyzed by regression analysis, and the level of significance was defined as 5% of one side.
- (10) Result:
- After the middle cerebral artery was occluded by the nylon embolus for 2 hours, blood flow was restarted by removing the nylon embolus, and the volume of the infarction nidus was measured after 24 hours from the emphraxis of middle cerebral artery. As a result, the compound according to the present invention significantly suppressed the volume of the infarction nidus of cerebral cortex, and the dose dependency was confirmed in the shrinking effect of the infarction nidus by the compound according to the present invention as a result of regression analysis. For example, the compound of Example 70 reduced the volume of the infarction nidus of cerebral cortex by 4% (128.9±12.5 mm3, n=16), 20% (108.0±14.9 mm3, n=15) and 44% (75.7±11.2 mm3, n=12: p<0.01), respectively, by carrying out intravenous administration in doses of 1.5, 5 and 15 mg/kg/h after 30 minutes from the emphraxis of middle cerebral artery, as compared with the volume of the infarction nidus of cerebral cortex of 134.3±12.3 mm3 (n=19) for a control group. Further, the compound of Example 75 reduced the volume of the infarction nidus of cerebral cortex by 26% (119.9±12.6 mm3, n=16), 37% (102.01±14.1 mm3, n=14: p<0.01) and 49% (83.7±21.3 mm3, n=11: p<0.001), respectively, by carrying out intravenous administration in doses of 1.5, 5and 15 mg/kg/h after 30 minutes from the emphraxis of middle cerebral artery, as compared with the volume of the infarction nidus of cerebral cortex of 162.9±8.4 mm3 (n=15) for control group.
- Namely, the compound according to the present invention inhibits the calcium ion influx into rat cerebral cortex synaptosome which is induced by high concentration of KCl, and inhibits the disengagement of glutamic acid from rat cerebral cortex slice. Further, the present compound has a protecting action for neural cell affection caused by local cerebral ischemia in the present experiment, and exhibits a significant shrinking effect of the infarction nidus by administration carried after 30 minutes from ischemia development. Accordingly, the compound according to the present invention can exhibit the effectiveness by post administration even in apoplectic ictus of human.
- Further, these results are supported by reports in which SNX-111 (CAS Registration No. 107452-89-1) being an N-type calcium channel inhibiting peptide protected the liberation of glutamic acid from cerebral cortex and subsequent neural cell affection in rat local cerebral ischemia model (13) and 14)), and also a report in which ω-agatoxin IVA being P/Q type channel inhibiting peptide exhibited a protective action for neural cell in rat local cerebral ischemia model (15)).
- Reference Literature:
- 1) -Schanne, F. A. X., Kane, A. B., Young, E. E., Farber, J. L. Calcium dependence of toxic cell death: a final common pathway. Science 206: 700-702 (1979).
- 2) Kristian, T., Siesjo, B. K. Calcium in ischemic cell death. Stroke 29: 705-718 (1998).
- 3) Graham, S. H., Shiraisi, K., Panter, S. S., Simon, R. P., Faden, A. I. Changes in extracellular amino acid neurotransmitters produced by focal cerebral ischemia. Neurosci. Lett. 110: 124-130 (1990).
- 4) Rothman, S. M., Olney, J. W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19: 105-111(1986).
- 5) Siesjo, B. K., Bengtsson, F. Calcium influxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: A unifying hypothesis. J. Cereb. Blood Flow Metab. 9: 127-140 (1989).
- 6) Mayer, M. L., Miller, R. J. Excitatory amino acid receptors, second messengers and regulation of intracellular Ca2+ in mammalian neurons. Trends Pharmacol. Sci. 11: 254-260 (1990).
- 7) Osuga, H., Hakim, A. M. Relationship between extracellular glutamate concentration and voltage-sensitive calcium channel function in focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 16: 629-636 (1996).
- 8) Choi, D. W. Calcium-mediatedneurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11: 465-469 (1988).
- 9) Randall, A. D., Tsien, R. W. Pharmacological dessection of multiple types of Ca2+ channel currents in rat cerebellar granule neurons. J. Neurosci. 15: 2995-3012 (1995).
- 10) Turner, T. J., Dunlap, K. Pharmacological characterization of presynaptic calcium channels using subsecond biochemical measurements of synaptosomal neurosecretion. Neuropharmacology 34: 1469-1478 (1995).
- 11) Maubecin, V. A., Sanchez, V. N., RosatoSiri, M. D., Cherksey, B. D., Sugimori, K., Llinas, R., Uchitel, O. D. Pharmacological characterization of the voltage-dependent Ca2+ channels present in synaptosomes from rat and chicken central nervous system. J. Neurochem. 64: 2544-2551 (1995).
- 12) Longa, E. Z., Weinstein, P. R., Carlson, S., Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91 (1989).
- 13) Bowersox, S. S., Singh, T., Luther, R. R. Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal ischemia in rats, Brain Res. 747: 343-347 (1997).
- 14) Takizawa, S., Matsushima, K., Fujita, H., Nanri, K., Ogawa, S., Shinohara, Y. A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia. J. Cereb. Blood flow Metab. 15: 611-618 (1995).
- 15) Asakura, K., Matsuo, Y., Kanemasa, T., Ninomiya, M. P/Q-type Ca2+ channel blocker ω-agatoxin IVA protect against brain injury after focal ischemia in rats. Brain Res. 7760: 140-145 (1997).
- N-type calcium channel which is one of neuron specific calcium channels is selectively inhibited by SNX-111 of a low molecular polypeptide. Further, it is reported that SNX-111 exhibits an analgesic action by administration in spinal cord, in the formalin test which is one of analgesic tests (1) and 2)). Therefore, the analgesic effect obtained in the case where the intravenous administration of the present compound was carried out was studied in the formalin test (3)) using a mouse.
- (1) Experimental Animal
- Ddy mice (male, 4 to 7 weeks age) purchased from Japan SLC Co. were used for experiment. Preliminary feeding of 4 days or more was carried out for mice (breeding condition: a room temperature 23±1° C., air humidity 55±5%, lighting cycle of every 12 hours). The mice were accommodated by a group of approximately 20 in a cage made of polycarbonate for 20 mice in which floor cloth (White Flake, Charles River Co., Ltd., Tokyo) was spread, and were bred. At the morning of the day tested, they were moved to a laboratory. They were freely fed MF (Oriental Yeast Co., Tokyo) as a feed. Further, they drunk city water freely.
- (2) Test Compound
- Examples 7, 20, 47, 49, 58, 63, 64, 198, 199, 209, 189, 123, 124, 219 and 221 were used as test compounds. Further, as known analgesics, the morphine which is a narcotic strong analgesic and an indomethacin which is an antiphlogistic analgesic were used, and these were used as control drugs.
- (3) Preparation of Test Compound
- The compound according to the present invention was dissolved in 5.28% Mannitol so as to be 1 mg/ml (10 mg/kg). The test compounds were weighed on the experimental day to be prepared. On the other hand, morphine was dissolved in physiological saline so as to be 3 mg/ml (30 mg/kg), and the indomethacin was suspended in 0.5% methyl cellulose so as to be 1 mg/ml (10 mg/kg). The test compounds were weighed on the experimental day to be prepared.
- (4) Preparation of Reagent
- 30 μL of a commercially available 35.0-38.0% formaldehyde solution was sampled and added to 970 μa physiological saline. This was used as 3% formalin. Further, formalin is a 37% formaldehyde solution, and since the purity of the formaldehyde solution used is indicated as 35.0-38.0%, the 3% formalin which is prepared for the experiment to be used is accurately 2.84-3.08% formalin.
- (5) Dose, Administration Route, Number of Examples
- 10 mg/kg of the present compound was intravenously administered (0.1 ml of 1 mg/ml solution was administered per a body weight of 10 g). 30 mg/kg of morphine was orally administered (0.1 ml of 3 mg/ml solution was administered per a body weight of 10 g). 10 mg/kg of indomethacin was orally administered (0.1 ml of 1 mg/ml suspension solution was administered per a body weight of 10 g). 0.1 ml of the respective solvents were intravenously or orally administered per a body weight of 10 g as controls. Five examples for every group were tested.
- (6) Test Method
- 10 mg/kg of the present compound was intravenously administered via tail vein, 30 mg/kg of morphine was orally administered and 10 mg/kg of indomethacin was orally administered. After 5, 30 and 90 minutes of the respective administrations, 20 μL of 3% formalin was subcutaneously administered to the planta of the mouse left hind leg, and the mouse was stored in an observation cage made of a transparent plastic. Just after the administration of formalin, the licking time of an action in which a mouse licked his left hind leg was measured for 5 minutes, and it was made as an index of pain. The respective solvents were similarly administered as the control. Setting the licking time of the control as 100%, the suppression rate (%) of the present compound was calculated by the following calculation formula.
- Formula:
- Depression rate (%)=(licking time of control-licking time of test compound)/(licking time of control)×100
- (7) Result:
- The compound according to the present invention statistically and significantly suppressed the licking time as compared with the control group, and the suppression rate was within a range of 33 to 88%. In particular, Example 189 showed the analgesic action by a suppression rate of 59%. On the other hand, the morphine showed the analgesic action by a suppression rate of 54%, and the suppression rate of indomethacin was −38% and no analgesic action was confirmed.
- Namely, as a neuron specific calcium channel inhibitor, the compound according to the present invention exhibits the analgesic action similar as SNX-111 which is an N-type calcium channel inhibitor, exhibits the similar analgesic action as the morphine which is a narcotic strong analgesic even in comparison with known analgesics, and further exhibits more superior analgesic action to indomethacin which is an antiphlogistic analgesic. Accordingly, the compound according to the present invention is extremely useful for therapy and amelioration of a pain.
- Reference literature:
- 1) Annika B. Malmberg, and Tony L. Yaksh (1994) Voltage-Sensitive Calcium Channels in Spinal Nociceptive Processing: Blockade of N- and P-Type Channels Inhibits Formalin-Induced Nociception. The Journal of Neuroscience 14(8): 4882-4890.
- 2) S. Scott Bowersox, Theresa Gadbois, Tejinder Singh, Mark Pettus, Yong-Xiang Wang and Robert R. Luther (1996) Selective N-type Neuronal Voltage-Sensitive Calcium Channel Blocker, SNX-111, Produces Spinal Antinociception in Rat Models of Acute, Persistent and Neuropathic Pain. The Journal of pharmacology and Experimental Therapeutics 279(3): 1243-1249.
- 3) Hunskaar S, Fasmer O B and Hole K (1985) Formalin test in mice, a useful technique for evaluating mild analgesics. Journal of Neuroscience Methods 14(1): 69-76.
Claims (17)
1. A method for treating stroke, inhibiting neural cell death or protecting cerebral neurons, wherein said method comprises:
applying an effective amount of a pharmaceutical composition to a patient in need thereof;
2. The method of claim 1 , wherein said compound, salt thereof or hydrate of them in the pharmaceutical composition is selected from the group consisting of:
1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; and
1-[4-cyano-4-(3-cyano-5-thienyl)-5-methylhexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine.
3. A method for treating or improving a neural disease or condition, wherein said method comprises:
applying an effective amount of a pharmaceutical composition to a patient in need thereof;
4. The method of claim 3 , wherein the neural disease or condition is at least one selected from the group consisting of
wherein said disease is acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, cerebral circulation metabolic affection, cerebral dysfunction, spasm, schizophrenia, migraine, epilepsy, manic-depression, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy, cerebral vascular dementia, and multiple sclerosis.
5. The method according to claim 3 , wherein the neural disease or condition is at least one selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and neural degenerative diseases.
6. The method according to claim 3 , wherein the neural disease or condition is multiple sclerosis.
7. The method of claim 3 , wherein said compound, salt thereof or hydrate of them in the pharmaceutical composition is selected from the group consisting of:
1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; and
1-[4-cyano-4-(3-cyano-5-thienyl)-5-methylhexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine.
8. A method for treating stroke, inhibiting neural cell death or protecting cerebral neurons, said method comprising:
administering a pharmacologically effective amount of a compound, a salt thereof or a hydrate of them to a patient in need thereof;
wherein said compound is represented by the following formula (I):
wherein R is a hydrogen atom or a nitrile.
9. The method of claim 8 , wherein said compound, salt thereof or hydrate of them is selected from the group consisting of:
1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; and
1-[4-cyano-4-(3-cyano-5-thienyl)-5-methylhexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine.
10. A method for suppressing a neural cell death or protecting a cerebral neural cell, said method comprising:
administering a pharmacologically effective amount of a compound, a salt thereof or a hydrate of them to a patient in need thereof;
wherein said compound is represented by the following formula (I):
wherein R is a hydrogen atom or a nitrile.
11. The method of claim 10 , wherein said compound, salt thereof or hydrate of them in the pharmaceutical composition is selected from the group consisting of:
1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; and
1-[4-cyano-4-(3-cyano-5-thienyl)-5-methylhexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine.
12. A method for treating or improving a neural disease or condition, said method comprising:
administering a pharmacologically effective amount of a compound, a salt thereof or a hydrate of them to a patient in need thereof;
wherein said compound is represented by the following formula (I):
wherein R is a hydrogen atom or a nitrile;
wherein said disease or condition is at least one selected from the group consisting of acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral neural cell death, cerebral circulation metabolic affection, cerebral dysfunction, spasm, schizophrenia, migraine, epilepsy, manic-depression, AIDS dementia complications, edema, anxiety disorder, diabetic neuropathy and cerebral vascular dementia.
13. The method of claim 12 , wherein said compound, salt thereof or hydrate of them in the pharmaceutical composition is selected from the group consisting of:
1-(4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; and
1-[4-cyano-4-(3-cyano-5-thienyl)-5-methylhexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine.
14. A method for treating a disease, wherein said method comprises:
applying a pharmacologically effective amount of a compound, a salt thereof or a hydrate of them to a patient in need thereof;
wherein said compound is represented by the following formula (I):
wherein R is a hydrogen atom or a nitrile; and
the neural disease is selected from the group consisting of acute ischemic stroke, cerebral apoplexy, head trauma, migraine, epilepsy and diabetic neuropathy.
15. The method of claim 14 , wherein said compound, salt thereof or hydrate of them in the pharmaceutical composition is selected from the group consisting of:
1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; and
1-[4-cyano-4-(3-cyano-5-thienyl)-5-methylhexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine.
16. A method for treating multiple sclerosis, wherein said method comprises:
administering a pharmacologically effective amount of a compound, a salt thereof or a hydrate of them to a patient in need thereof;
wherein said compound is represented by the following formula (I):
wherein R is a hydrogen atom or a nitrile.
17. The method of claim 16 , wherein said compound, salt thereof or hydrate of them in the pharmaceutical composition is selected from the group consisting of:
1-[4-cyano-5-methyl-4-(5-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine;
1-[4-cyano-5-methyl-4-(3-cyano-2-thienyl)hexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine; and
1-[4-cyano-4-(3-cyano-5-thienyl)-5-methylhexyl]-4-[2-(3-cyanophenoxy)ethyl]piperazine.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/855,357 US20040220193A1 (en) | 2000-01-20 | 2004-05-28 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
US11/229,768 US20060084658A1 (en) | 2000-01-20 | 2005-09-20 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-12176 | 2000-01-20 | ||
JP2000012176 | 2000-01-20 | ||
US10/169,837 US6906072B1 (en) | 2000-01-20 | 2001-01-18 | Piperazine compound and pharmaceutical composition containing the compound |
US10/855,357 US20040220193A1 (en) | 2000-01-20 | 2004-05-28 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/000288 Division WO2001053258A1 (en) | 2000-01-20 | 2001-01-18 | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same |
US10/169,837 Division US6906072B1 (en) | 2000-01-20 | 2001-01-18 | Piperazine compound and pharmaceutical composition containing the compound |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/229,768 Division US20060084658A1 (en) | 2000-01-20 | 2005-09-20 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040220193A1 true US20040220193A1 (en) | 2004-11-04 |
Family
ID=18539929
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/169,837 Expired - Fee Related US6906072B1 (en) | 2000-01-20 | 2001-01-18 | Piperazine compound and pharmaceutical composition containing the compound |
US10/855,357 Abandoned US20040220193A1 (en) | 2000-01-20 | 2004-05-28 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
US11/229,768 Abandoned US20060084658A1 (en) | 2000-01-20 | 2005-09-20 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/169,837 Expired - Fee Related US6906072B1 (en) | 2000-01-20 | 2001-01-18 | Piperazine compound and pharmaceutical composition containing the compound |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/229,768 Abandoned US20060084658A1 (en) | 2000-01-20 | 2005-09-20 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound |
Country Status (18)
Country | Link |
---|---|
US (3) | US6906072B1 (en) |
EP (2) | EP1254895B1 (en) |
KR (1) | KR20020069362A (en) |
CN (1) | CN1205185C (en) |
AT (1) | ATE362926T1 (en) |
AU (1) | AU779870B2 (en) |
BR (1) | BR0107733A (en) |
CA (1) | CA2398409A1 (en) |
DE (1) | DE60128542T2 (en) |
HK (1) | HK1049004A1 (en) |
HU (1) | HUP0204071A3 (en) |
IL (1) | IL150651A0 (en) |
MX (1) | MXPA02007035A (en) |
NO (1) | NO20023456L (en) |
NZ (1) | NZ519981A (en) |
RU (1) | RU2230060C2 (en) |
WO (1) | WO2001053258A1 (en) |
ZA (1) | ZA200205322B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060172994A1 (en) * | 2004-12-29 | 2006-08-03 | Carson Kenneth G | Compounds useful as chemokine receptor antagonists |
US20060189628A1 (en) * | 2004-12-29 | 2006-08-24 | Gerard Rosse | Compounds useful as chemokine receptor antagonists |
FR2890391A1 (en) * | 2005-09-05 | 2007-03-09 | Oreal | Use of piperazine derivatives as agents to induce and/or stimulate the growth of human keratinous fibers, to slow down their degradation and/or to increase their density |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
PE20030445A1 (en) * | 2001-09-25 | 2003-07-26 | Otsuka Pharma Co Ltd | ARIPIPRAZOLE MEDICINAL SUBSTANCE OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME |
US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
ES2298782T3 (en) * | 2003-06-11 | 2008-05-16 | Eli Lilly And Company | 3-AMINOPIRROLIDINAS AS INHIBITORS OF MONOAMINE REABSORTION. |
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
MX2010003113A (en) * | 2007-09-25 | 2010-04-01 | Abbott Lab | Octahydropentalene compounds as chemokine receptor antagonists. |
US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
WO2013149376A1 (en) | 2012-04-02 | 2013-10-10 | Abbott Laboratories | Chemokine receptor antagonists |
KR20150075091A (en) * | 2012-10-29 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
CN108883103A (en) * | 2015-12-02 | 2018-11-23 | 阿斯特来亚治疗有限责任公司 | Piperidyl nociceptin acceptor compound |
US11773449B2 (en) | 2017-09-01 | 2023-10-03 | The Hospital For Sick Children | Profiling and treatment of hypermutant cancer |
RU2676701C1 (en) * | 2017-12-01 | 2019-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Agent for repression of death of neurons in ischemic stroke of brain and method of cell-mediated gene therapy for ischemic stroke of brain by repression of death of neurons in ischemic stroke of brain |
KR20200136895A (en) | 2018-03-30 | 2020-12-08 | 도레이 카부시키가이샤 | Inhibitors of increasing calcium concentration in nerve cells |
IT201800007580A1 (en) * | 2018-07-27 | 2020-01-27 | Maria Cecilia Hospital Spa | 1,3,8-triazaspiro compounds and their use as medicaments |
RU2676100C1 (en) * | 2018-10-05 | 2018-12-26 | федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") | Application of the piperazin derivatives for treatment of the alzheimer's disease and the alzheimer's type dementia with disturbed ventricular calcium signaling |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994460A (en) * | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
US5231105A (en) * | 1987-06-02 | 1993-07-27 | Ajinomoto Co., Inc. | Ethylamine derivatives and antihypertensives containing the same |
US5281601A (en) * | 1989-12-12 | 1994-01-25 | Pfizer Inc. | Muscarinic receptor antagonists |
US5420131A (en) * | 1993-03-23 | 1995-05-30 | J. Uriach & Cia, S.A. | Cyanomethylpyridine derivatives |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1305458A (en) * | 1969-02-26 | 1973-01-31 | ||
JPS62286980A (en) * | 1986-06-05 | 1987-12-12 | Hokuriku Seiyaku Co Ltd | Phenylpiperazine derivative |
US4886809A (en) * | 1986-07-31 | 1989-12-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof |
JPH0696555B2 (en) * | 1986-07-31 | 1994-11-30 | 大塚製薬株式会社 | Carbostyril derivative |
JPH0745493B2 (en) * | 1987-06-24 | 1995-05-17 | 大塚製薬株式会社 | Carbostyril derivative |
JP2544939B2 (en) * | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | Benzoheterocycle derivative |
JPH0283375A (en) * | 1988-09-21 | 1990-03-23 | Dainippon Pharmaceut Co Ltd | 2-substituted piperazinyl-2-(1,2-benzisoxazol-3-yl)acetic acid derivative |
CA2014520C (en) * | 1989-04-17 | 1996-07-16 | Fumio Suzuki | Hexitol derivatives |
GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
US4966472A (en) * | 1989-07-17 | 1990-10-30 | Link Larry R | Roller bushing |
EP0441226A1 (en) * | 1990-01-29 | 1991-08-14 | J. URIACH & CIA. S.A. | (cyanomethyl)pyridines useful as PAF antagonists |
US5215987A (en) * | 1990-04-23 | 1993-06-01 | Ortho Pharmaceutical Corporation | Substituted benzhydryl 2-hydroxypropyl piperazine derivatives |
ATE113947T1 (en) * | 1990-06-01 | 1994-11-15 | Pfizer | 3-AMINO-2-ARYLQUINUCLIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. |
FR2676225B1 (en) * | 1991-05-03 | 1993-08-27 | Sanofi Elf | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF DIALKYLENEPIPERIDINO COMPOUNDS. |
JPH0597673A (en) * | 1991-10-08 | 1993-04-20 | Ajinomoto Co Inc | Antiarrhythmic agent |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
GB9526558D0 (en) | 1995-12-27 | 1996-02-28 | Fujisawa Pharmaceutical Co | Heterobicyclic derivatives |
PT876366E (en) * | 1996-01-15 | 2002-01-30 | Janssen Pharmaceutica Nv | ANGIOGENESE INHIBITOR PYRIDAZINAMINS |
IT1293804B1 (en) | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | DIARYLALKYL PIPERAZINS ACTIVE ON LOW URINARY TRACT |
JP4153574B2 (en) * | 1997-09-10 | 2008-09-24 | トーアエイヨー株式会社 | NOVEL PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND CARDIOLOGICAL AGENT CONTAINING THE SAME |
TWI250152B (en) * | 1998-07-21 | 2006-03-01 | Eisai Co Ltd | N,N-substituted cyclic amine compounds used as calcium antagonizer |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
-
2001
- 2001-01-18 CA CA002398409A patent/CA2398409A1/en not_active Abandoned
- 2001-01-18 DE DE60128542T patent/DE60128542T2/en not_active Expired - Lifetime
- 2001-01-18 US US10/169,837 patent/US6906072B1/en not_active Expired - Fee Related
- 2001-01-18 NZ NZ519981A patent/NZ519981A/en unknown
- 2001-01-18 HU HU0204071A patent/HUP0204071A3/en unknown
- 2001-01-18 MX MXPA02007035A patent/MXPA02007035A/en active IP Right Grant
- 2001-01-18 WO PCT/JP2001/000288 patent/WO2001053258A1/en active IP Right Grant
- 2001-01-18 RU RU2002122335/04A patent/RU2230060C2/en not_active IP Right Cessation
- 2001-01-18 CN CNB01803988XA patent/CN1205185C/en not_active Expired - Fee Related
- 2001-01-18 AT AT01901413T patent/ATE362926T1/en not_active IP Right Cessation
- 2001-01-18 AU AU27059/01A patent/AU779870B2/en not_active Ceased
- 2001-01-18 KR KR1020027009235A patent/KR20020069362A/en active IP Right Grant
- 2001-01-18 EP EP01901413A patent/EP1254895B1/en not_active Expired - Lifetime
- 2001-01-18 BR BR0107733-3A patent/BR0107733A/en not_active IP Right Cessation
- 2001-01-18 IL IL15065101A patent/IL150651A0/en unknown
- 2001-01-18 EP EP06016525A patent/EP1818326A1/en not_active Withdrawn
-
2002
- 2002-07-03 ZA ZA200205322A patent/ZA200205322B/en unknown
- 2002-07-18 NO NO20023456A patent/NO20023456L/en not_active Application Discontinuation
-
2003
- 2003-02-19 HK HK03101263.5A patent/HK1049004A1/en unknown
-
2004
- 2004-05-28 US US10/855,357 patent/US20040220193A1/en not_active Abandoned
-
2005
- 2005-09-20 US US11/229,768 patent/US20060084658A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231105A (en) * | 1987-06-02 | 1993-07-27 | Ajinomoto Co., Inc. | Ethylamine derivatives and antihypertensives containing the same |
US4994460A (en) * | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
US5281601A (en) * | 1989-12-12 | 1994-01-25 | Pfizer Inc. | Muscarinic receptor antagonists |
US5420131A (en) * | 1993-03-23 | 1995-05-30 | J. Uriach & Cia, S.A. | Cyanomethylpyridine derivatives |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US20060172994A1 (en) * | 2004-12-29 | 2006-08-03 | Carson Kenneth G | Compounds useful as chemokine receptor antagonists |
US20100234356A1 (en) * | 2004-12-29 | 2010-09-16 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
US20110237601A1 (en) * | 2004-12-29 | 2011-09-29 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
US8168788B2 (en) | 2004-12-29 | 2012-05-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
US8399455B2 (en) | 2004-12-29 | 2013-03-19 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US8648197B2 (en) | 2004-12-29 | 2014-02-11 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
US20060189628A1 (en) * | 2004-12-29 | 2006-08-24 | Gerard Rosse | Compounds useful as chemokine receptor antagonists |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
FR2890391A1 (en) * | 2005-09-05 | 2007-03-09 | Oreal | Use of piperazine derivatives as agents to induce and/or stimulate the growth of human keratinous fibers, to slow down their degradation and/or to increase their density |
Also Published As
Publication number | Publication date |
---|---|
WO2001053258A1 (en) | 2001-07-26 |
CN1205185C (en) | 2005-06-08 |
US20060084658A1 (en) | 2006-04-20 |
AU779870B2 (en) | 2005-02-17 |
EP1254895A4 (en) | 2003-01-22 |
IL150651A0 (en) | 2003-02-12 |
HUP0204071A2 (en) | 2003-03-28 |
EP1254895B1 (en) | 2007-05-23 |
DE60128542D1 (en) | 2007-07-05 |
NO20023456D0 (en) | 2002-07-18 |
HK1049004A1 (en) | 2003-04-25 |
NZ519981A (en) | 2005-02-25 |
ATE362926T1 (en) | 2007-06-15 |
MXPA02007035A (en) | 2002-12-13 |
CN1395562A (en) | 2003-02-05 |
RU2230060C2 (en) | 2004-06-10 |
KR20020069362A (en) | 2002-08-30 |
EP1254895A1 (en) | 2002-11-06 |
ZA200205322B (en) | 2003-08-18 |
HUP0204071A3 (en) | 2003-07-28 |
DE60128542T2 (en) | 2008-01-31 |
RU2002122335A (en) | 2004-01-10 |
US6906072B1 (en) | 2005-06-14 |
EP1818326A1 (en) | 2007-08-15 |
AU2705901A (en) | 2001-07-31 |
NO20023456L (en) | 2002-09-20 |
BR0107733A (en) | 2003-03-11 |
CA2398409A1 (en) | 2001-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6906072B1 (en) | Piperazine compound and pharmaceutical composition containing the compound | |
JP6915003B2 (en) | Human plasma kallikrein inhibitor | |
KR101799010B1 (en) | 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same | |
AU675786B2 (en) | Azacyclic compounds | |
JP6392888B2 (en) | Novel compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing the same | |
CN102573471B (en) | Novel pyrrolidine derived beta 3 adrenergic receptor agonists | |
CN106928127B (en) | Substituted piperidine amide derivative, preparation method and pharmaceutical application thereof | |
EA009903B1 (en) | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | |
EP3828174A1 (en) | Pyridazinone derivative | |
JP2022502370A (en) | Substituted pyridinyl compounds and their use | |
EP1847535A1 (en) | 1-(piperidin-4-yl)-1h-indole derivative | |
JP3966693B2 (en) | Nitrogen-containing ring compounds and pharmaceutical compositions comprising them | |
KR100364340B1 (en) | Imidazolidinone derivatives, acid addition salts and old age dementia | |
KR20210066848A (en) | Isoxazole carboxamide compounds and uses thereof | |
CN114456150A (en) | NR2B receptor antagonist or pharmaceutically acceptable salt thereof, preparation method and application | |
JP2009523747A (en) | Modulator of α7 nicotinic acetylcholine receptor and therapeutic use thereof | |
AU2005201992A1 (en) | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same | |
KR20070015639A (en) | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same | |
KR101152657B1 (en) | New diphenylpropanoyl compounds having activity for T-type calcium channel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: EISAI R&D MANAGEMENT CO., LTD.,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EISAI CO., LTD.;REEL/FRAME:019500/0673 Effective date: 20061228 Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EISAI CO., LTD.;REEL/FRAME:019500/0673 Effective date: 20061228 |